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Abstract 
This study focussed on two areas in the field of cancer susceptibility. The initial area 
was the genetic analysis of a recently mapped breast cancer susceptibility locus, 
BRCAl, in a number of breast and breast-ovarian cancer families. In the largest of the 
ICRF families studied (BOV3), linkage to the long arm of chromosome 17 was 
confirmed and a number of recombinants were identified. One such cross-over event 
enabled the reduction of the interval harbouring BRCAI to a region estimated to be 
between 1-1.5 Mh. During the course of this study, a second gene for breast/ovarian 
cancer predisposition, BRCA2, had been assigned to a 6 cM region at 13q12-13. 
Towards the identification of this gene, a YAC contig was constructed spanning the 
published minimal genetic interval for BRCA2. This contig provided a framework for 
the identification of BRCA2. Allele loss studies were also performed and indicated that 
BRCA1 acts as a tumour suppressor. Analysis of familial and sporadic infiltrating 
ductal grade 3 breast carcinomas revealed a pattern of combined loss or retention of 
BRCAI and BRCA2. This supports a role for both genes in the development of this 
tumour type. The other area of study was the genetic analysis of a group of autosomal 
dominant skin diseases, termed the non-epidermolytic palmoplantar keratodermas. 
This study demonstrated genetic heterogeneity between three forms of NEPPK: 
diffuse, punctate and focal. Genetic heterogeneity was also established between 
families presenting with clinically similar forms of focal NEPPK. Mutations in the 
type I keratin on 17q12-21, KRT16, were identified as the genetic basis of focal 
NEPPK in a pedigree without associated susceptibility to oesophageal cancer. In the 
pedigrees with a striking association between focal NEPPK and oesophageal cancer 
susceptibility, the region harbouring this disease locus (TOC) was refined to a lcM 
region on 17q24-25. 
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CHAPTER 1: INTRODUCTION 
This thesis describes the genetic analysis of families in which a susceptibility to certain 
forms of malignancy appears to be segregating. Initial studies were directed towards 
the genetic analysis of breast and breast -ovarian cancer families. 
t.t.Breast Cancer 
The most frequently occuring malignancy in women, excluding skin cancer, is breast 
cancer (CRC Cancer Surveys). In the United Kingdom, 25,000-30,000 new cases are 
diagnosed each year. To date, the most effective treatment of the disease is surgery 
followed by local radiotherapy or whole body chemotherapy. Survival is greatly 
diminished if the cancer has metastasised. Therefore, early detection of the disease is a 
priority for improved survival rates. 
1.2. Risk Factors 
A number of factors have been shown to be associated with increased risk of 
developing breast cancer (Table 1.1), some of which are discussed. 
Table t.t. Factors associated with breast cancer risk (adapted from Petrakis et al, 
1..2ru 
Increased risk Decreased risk 
over age 40 years racial origin, Asian 
high socio-economic status oophorectomy before age 40 
early age of menarche pregnancy before age 21 
family history 
first pregnancy over age 30 
early exposure to x-irradiation 
high fat diet 
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1.20) a2e 
The risk of developing the disease increases dramatically with age; the majority of 
breast cancer cases occur in women around 70 years of age (CRC Cancer Surveys). 
This is probably related to longtime exposure to environmentallhormonal risk factors 
and the time required for a breast cell to progress to the cancerous state. 
1.2(ii) reproductive behaviour 
Breast cancer risk appears to be associated with prolonged exposure to the hormone 
oestrogen. For example, women who have an early menarche and late menopause are 
at greater risk of breast cancer (Kampert et at, 1988). Also, oophorectomy has a 
protective effect as does an early age of full term pregnancy. In the normal breast, 
oestrogen induces the epithelial stem cells to divide but only in combination with other 
endocrine products such as insulin, thyroxine, progesterone, prolactin and growth 
hormone. Therefore, a correct balance of these complex hormonal interactions is 
required for normal breast epithelial growth. 
Due to the association of oestrogen with breast cancer risk, clinical trials are in 
progress with the anti- oestrogen, tamoxifen, in an attempt to counteract the growth 
stimulatory activity of the hormone. However, altering the levels of oestrogen can 
perturb the balance of hormones that it interacts with and may have a disadvantageous 
effect in some women. For example, there is a small increased risk of endometrial and 
uterine cancer associated with tamoxifen treatment (Seoud et ai, 1993). 
l.2fiiil obesity 
The risk of developing breast cancer has been associated with a high fat intake! or high 
body mass, in particular, abdominal obesity in postmenopausal women (reviewed in 
Stoll, 1994). This may be related to high levels of oestrogen exposure derived from the 
aromatisation of androgen from the fat deposits (Kampert et ai, 1988). No increased 
risk has been found in obese premenopausal women (Albanes, 1987). The lower 
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breast cancer incidence observed in vegetarian women would support a role for obesity 
in breast cancer risk as, generally, this population are slightly less obese and have a 
reduced fat intake than omnivorous women (Phillips, 1975). 
Predisposition to abdominal fat deposition may be genetically linked to breast cancer 
susceptibility (Sellers et aZ, 1992; 1993). Women usually deposit fat on their hips 
whereas women who deposit fat in the abdominal region may be genetically 
predisposed to do so, though a fat-rich diet clearly is an important factor (Sims, 1990). 
Alternatively, the hormonal changes that occur with abdominal obesity may elevate 
breast cancer development in genetically susceptible women. 
1.2 (i v) country of birth/residence 
The continent which shows the lowest incidence of breast cancer is Asia (Petrakis et 
aI, 1982; Aaltomaa et aI, 1992). This, in part, may be related to the population having 
a lower fat diet and poorer socio-economic climate than Western Europe and the US. 
Environmental factors clearly have a role as demonstrated by migrant studies. Women 
born in low breast cancer risk countries, but brought up in a high risk one, show an 
increased rate of breast cancer incidence. For example, the female Japanese 
population, who emigrated to Hawaii 2-3 generations ago, have a similar risk of 
developing breast cancer as that of the indigenous female Hawaiian population 
(Aaltomaa et aZ, 1992). 
1.2(v) family history 
The clearest risk factor for breast cancer development is having a family history of the 
disease. Although, approximately 95 % of breast cancer cases are thought to be 
sporadic, that is, they occur without a highly penetrant genetic component, a small 
proportion of cases arise from the inheritance of a mutation in genes which confer an 
extremely high risk of disease development. There have been numerous 
epidemiological studies in which a number of breast cancer cases have been shown to 
occur in families. This can be explained either as chance clustering of sporadic disease 
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or due to an inherited susceptibility (Bishop et ai, 1988; Claus et ai, 1991; Slattery and 
Kerber, 1993). In a proportion of these families, there is clear evidence of a dominant 
autosomally inherited susceptibility gene segregating through the generations with the 
highest proportion of genetic cases occurring at a young age, often with bilateral 
disease. 
Numerous studies of familial risks of breast cancer have been conducted to estimate 
the risks to female relatives of affected individuals, particularly those diagnosed at an 
early age, of developing the disease (for example, Slattery and Kerber, 1993). The 
most extensive study was the Cancer and Steroid study (CASH) which was performed 
on 4730 cases of breast cancer diagnosed between the ages 20 and 54 by comparing 
family history to a large population of matched controls (Claus et ai, 1990). This, and 
other studies demonstrated a familial affect on breast cancer risk to relatives of affected 
individuals. From the CASH study, the age of onset of breast cancer in patients 
dramatically affected the relative risk of female family members developing the 
disease. The relative risk to first degree female relatives was increased less than 
twofold if the disease was diagnosed over age 50, but increased to fivefold with cases 
diagnosed below age 40. The risk of breast cancer in women also increased if they had 
two or more first or second degree affected relatives. A further indication of a genetic 
component in a proportion of breast cancer cases was demonstrated by the observation 
that relatives of individuals with bilateral disease were at greater risk than relatives of 
unilateral cases (Bernstein et ai, 1992). 
Epidemiological studies in relatives of breast cancer cases which are likely to have a 
genetic component have demonstrated increased risks of the development of other 
cancers. One genetic association is that of breast cancer with ovarian cancer. A 
moderate increase in risk of ovarian cancer in relatives of women with breast cancer 
and vice versa has been observed (Schidkraut et ai, 1989). A number of families in 
which breast and ovarian cancer segregates through consecutive generations have been 
reported suggesting the existence of a gene(s) which confers susceptibility to both 
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diseases (Lynch et ai, 1978). A second familial association is that of early onset breast 
cancer with childhood bone and soft tissue sarcoma, termed the Li Fraumeni cancer 
syndrome (reviewed Birch, 1990). Another cancer syndrome in which breast cancer is 
a component is Cowden (or multiple hamartoma) disease in which thyroid cancer, 
digestive tract carcinomas and breast cancer may occur at a relatively early age 
(reviewed Hanssen and Fryns, 1995). Other reports, derived either from population 
studies or extensive cancer families, have implied possible genetic associations of 
breast cancer with prostate cancer (Cannon et ai, 1982; Tulinius et ai, 1992; Arason et 
ai, 1993) and colorectal cancer (Phipps and Perry, 1989). 
Breast cancer risk is increased in relatives of individuals affected with the autosomal 
recessive progressive neurological disorder, ataxia telangiectasia (AT) (Swift et ai, 
1992). These presumed AT heterozygotes are also at increased risk of developing 
other cancers, for example, stomach cancer and leukemia. Estimates suggest the 
contribution of AT heterozygotes to breast cancer incidence could vary from a minimal 
to a significant proportion (Easton et ai, 1993a). The recent cloning of the AT gene, 
A TM, will allow the molecular identification of AT heterozygotes and a greater 
understanding of its role in breast cancer predisposition (Savitsky et ai, 1995). 
1.3. Se2re2ation Analysis 
Segregation analyses have tested a number of genetic models to support the existence 
of inherited predisposition for breast cancer. Using this analysis, it is possible to fit the 
best single locus genetic model to the susceptibility gene by varying parameters such 
as population allele frequency, penetrance (the probability that an individual with or 
without the gene defect will develop the disease by a given age) and mode of 
transmission. Using the CASH data set, the most likely model to explain familial 
breast cancer is that susceptibility is conferred by an autosomal dominant gene with a 
population frequency of 0.0033 (Claus et ai, 1991). For disease gene carriers, the 
cumulative risk or penetrance of breast cancer was estimated to be 38% by age 50 and 
67% by age 70. For non-gene carriers, the cumulative risk was estimated to be 1.5% 
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by age 50 and 5% by age 70. Using this model, about 35 % of breast cancer cases 
diagnosed below age 30 were estimated to be due to a defect in this gene, compared 
with about 1% of cases diagnosed over age 80 (Claus et ai, 1991). Similar models 
have been found for other data (Bishop et ai, 1988; Newman et ai, 1988; Iselius et ai, 
1991). This gene(s) is unlikely to account for the majority of breast cancer cases which 
will occur sporadically, although it is also possible that there are lower penetrance 
genes in the population which "modify" the risk of breast cancer. These "modifying" 
genes may have a role in a much larger number of cases. 
1.4. Linkaee Analysis 
Segregation studies support the presence of one (or more) major susceptibility gene(s) 
in familial breast cancer. Using the families which have a number of affected cases and 
show evidence of autosomal dominant inheritance, genetic linkage studies can be 
performed. These studies aid in the identification of disease gene(s) by pinpointing the 
position in the genome to which it is localised. Linkage analysis is an extremely 
powerful tool and has been used successfully to map numerous disease genes of either 
dominant or recessive inheritance with complete or variable penetrance. This strategy 
has enabled the identification of genes for heritable traits and diseases for which only 
the phenotype was known and not the protein product (reviewed Ballabio, 1993). 
1.4.1. Concept of Genetic Linkaee 
The concept of genetic linkage is based on various observations regarding features of 
heredity and the extensive genetic variability found in humans (for a review see 
Strachan and Read, 1996). Key observations include: 
(i) two traits are more likely to be coinherited if their corresponding genes are close 
together on the same chromosome, termed non- independent segregation. 
(ii) if two traits map to different chromosomes, they segregate independently of each 
other because of the independent segregation of the chromosomes in meiosis 
(iii) the more distant two traits map from each other, the more likely that they show 
independence of segregation. This is due to the process of genetic exchange which 
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occurs at meiosis between paired chromosome homologues. The greater the distance 
between two loci, the greater the likelihood that recombination occurs between them. 
The position and frequency of these cross-overs differ from one meiosis to the next, 
with on average one or two exchanges per chromosome per meiosis. 
1.4.2. Basic mathematics of linka~e analysis (see Ott, 1992) 
The basic requirements for a linkage study are an understanding of the mode of 
inheritance of the trait or disease under investigation in families and the availability of 
genetic markers (see section 1.5). Additionally, the sample size has to be large enough 
that the statistical evidence of linkage can be found. Problems encountered with certain 
modes of inheritance for specific traits are discussed in the next section. The 
development of genetic markers and their integration into a genetic linkage map is 
discussed in section 1.5. 
Even for two adjacent loci, genetic linkage is not complete as there is always a 
possibility of recombination between the two 'linked' alleles at each locus during 
meiosis, though the frequency is much less than that between two distant loci. The 
probability that a cross- over occurs between two loci is referred to as the 
recombination fraction, represented by theta (9), and is calculated from the proportion 
of recombinants generated as a fraction of the combined number of meioses. The 
recombination fraction is thus an indication of genetic distance between two loci. For 
two unlinked loci, that is, when alleles of the two loci segregate independently of each 
other, the value for e is close to 0.5 and would indicate the two loci are far apart on the 
chromosome or on different chromosomes. For two loci mapping very close to each 
other on the chromosome, the theta value would be nearer to zero as there would be 
fewer recombination events observed between alleles at the two loci. Genetic distance 
between loci is measured in centiMorgan s (eM): a Morgan is the genetic distance in 
which exactly one recombination event occurs. On average over the whole genome, 
one cM approximates to the physical length of one Mh. However, there is not an exact 
relationship between the two measures of distance as there are differences in 
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recombination frequencies between chromosomal regions and the sexes for specific 
chromosomes. 
In human linkage studies, the LOD score method is used to investigate linkage 
(Morton, 1955). It measures the relative likelihood of observing a given distribution of 
a trait/disease and a genetic marker segregating within a family for a range of 
recombination fractions. The relative odds of the trait/disease locus and the marker 
locus being linked against no linkage are expressed as the 10glO of the odds ratio or the 
'LOD score' for each possible recombination fraction. The maximum value of the LOD 
score (over different recombination fractions) can be incorporated into a statistical test 
for linkage. Satisfactory evidence for two loci being genetically linked is generally 
accepted as a LOD score of 3.0 or greater. A LOD score of 3.0 at a recombination 
fraction of 10 % indicates that the segregation of alleles for a trait with a genetic marker 
is one thousand times more likely to have occurred if the two loci are genetically linked 
(that is, recombination between the two loci occurred only once in ten meioses) than if 
they were genetically distant. For any two randomly chosen loci, the odds for those 
two loci being linked is estimated to be 1: 50 (Elston and Lange, 1975). The posterior 
odds for linkage between two loci when a LOD score of 3 is attained is calculated from 
multiplying the odds from the data, 1000: 1, with the prior odds of linkage, 1: 50 
which is 20: 1. This equates to p= 0.05, the conventional threshold for statistical 
significance. Thus the posterior probability of the two loci being linked is 95 %, and 
that of a false positive result being 5 %. The greater the LOD score, the lower the 
probability of a false positive, for example, a LOD score of 5 will be misleading, on 
average, one time in 2,000. 
A LOD score of - 2 is a strong indicator of exclusion of linkage between two loci 
(Morton, 1955). Those scores between -2 and +3 are generally regarded as 
inconclusive. Though in some circumstances, lower LOD scores than 3 could be 
suggestive of linkage when there is prior evidence of a disease locus mapping to the 
region. 
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1.4.3. Problems encountered in a Iinka2e study 
The LOD score method can be implemented to cope with the complexities of mapping 
traits! diseases including problems encountered with untyped individuals, potential 
phenocopies and variable penetrance. The majority of these variables can be combined 
in the analysis by the use of computer algorithms (for example, Lathrop and Lalouel, 
1984). Some of the problem areas, particularly those related to breast cancer 
inheritance, are discussed below : 
1.4.3(0 Genetic hetero2eneity 
As the probability of linkage is measured logarithmically, LOD scores for two or more 
families with the same trait can be added together to increase the power of detecting 
linkage of the trait with a genetic marker. Therefore analysis of small families (rather 
than one extensive pedigree) can be used in linkage mapping. However, genetic 
heterogeneity of a disorder can create difficulties in the interpretation of data when 
combining LOD scores, for example, if mutations in two or more distinct gene loci 
predispose individuals to apparently identical disease phenotypes. Two ways of 
limiting this problem are : 
(a) analyse families from isolated geographic communities for a disease which is 
sufficiently rare enough that mutations in two distinct gene loci are unlikely to be 
segregating through the population 
and/or 
(b) analyse a few extended pedigrees when available. However, if the disease 
mutations are relatively common in the population, it is possible that distinct mutations 
may be segregating in different branches of the family. 
1.4.3(ji) incomplete penetrance 
Even though an individual may have inherited a mutation in a susceptibility locus, 
other factors may affect the clinical presentation of the disease such as environmental 
effects, chance and/or modifying gene loci. This is of particular relevance to inherited 
breast cancer. All three factors may have a role in determining whether a woman 
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carrying a mutation in a breast cancer susceptibility gene develops the disease early in 
life or, indeed, at all. 
1. 4.3 (ii il Phenocopies 
This occurs when individuals present with the disease though they are not carrying a 
susceptibility mutation. This "sporadic" disease may be explained by a non-inheritable 
occurence or by a distinct mutation in the same or different gene to that inherited by the 
majority of affected cases in the family. As long as the proportion of phenocopies to 
gene carriers in a family is low enough, linkage analysis models can cope with this 
problem. The same problem as sporadic disease can occur because of misdiagnosis. 
The affected status of each individual must be clinically confirmed. 
1.5. Genetic Markers 
In order to localise a disease gene by linkage analysis, chromosomal homologues must 
be 'tagged' as they segregate through pedigrees to see if a particular chromosome 
region follows the inheritance pattern of the disease. This can be achieved by using the 
extensive genetic variation found in humans visualised in the form of genetic 
polymorphic markers. A genetic marker must show variation in the form of alleles and 
each of these morphs must be relatively easy to detect. The degree of polymorphism is 
indicated by the number and frequency of alleles at each marker locus in the 
population. An individual is more likely to be heterozygous at a locus if that locus 
displays a wide range of alleles of equal frequency. It is important that these alleles are 
relatively stable in the population as the appearance of 'new' alleles can affect the 
tracing of the marker through a pedigree. Theoretical examples of how variation at a 
locus can affect the 'tagging' of chromosomes are demonstrated in Figure 1.1. 
Initial studies in human genetics were hampered by the impossibility of controlled 
matings in humans compared to other organisms, such as Drosophila and mice, and 
the lack of genetic polymorphisms which could make existing human matings for 
specific traits informative for linkage analysis. Therefore, to fully utilise the family 
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material available to study human inheritance, a comprehensive linkage map of the 
human genome was required. Work over the last ten to fifteen years has made the 
prospect of a complete linkage map of the human genome a reality. For example, a 
genetic map has been constructed which spans a sex-averaged distance of 3, 699 eM 
(Dib et ai, 1996). This means that there are sufficient genetic marker loci across every 
chromosome to potentially identify linkage to any gene of interest. The map has 
developed to the degree that once linkage to a marker has been identified, the 
chromosomal location is immediately known. The size of the region may be reduced 
further by screening with close flanking markers to aid in the physical identification of 
the gene (discussed in section 1.11). However, this is dependent on the presence of 
informative recombinants in families. 
1.5.1. Development of the Human Genetic Linka2e Map 
Morgan (1910) and colleagues introduced the concept of genetic linkage maps for 
ordering genes along a chromosome from studies on the fruitfly, Drosophila 
melanogaster (reviewed in Strachan and Read, 1996). One of the first polymorphic 
systems used in humans were protein polymorphisms, for example, blood group 
antigens, but there were few available, and they covered only small intervals of the 
genome (reviewed White and Lalouel, 1988). The breakthrough came in the late 
1970's with the detection of variation in DNA sequences. These first DNA marker 
systems were polymorphisms generated by a single base change or deletion which 
affected a restriction site. The majority of these marker loci have two alleles; one with 
the restriction site and the other without. DNA extracted from individuals is 
enzymatically digested with the specific restriction endonuclease that recognises the 
restriction site. The digested DNA is resolved by electrophoresis through agarose gels 
and transferred to a nitrocellulose or nylon membrane (Southern, 1975). A DNA 
probe spanning the present! absent restriction site is then hybridised to the genomic 
DNA and the allelic sequence variation visualised. Such polymorphisms are referred to 
as restriction fragment length polymorphisms (RFLPs) (Botstein et ai, 1980). This 
DNA variation was found to be sufficiently common in the human genome to suggest 
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that a complete linkage map was possible (Willard et ai, 1985). Genetic maps were 
constructed using these RFLP markers which consisted of linkage groups on all 
chromosomes (Donis-Keller et ai, 1987). A set of three generation families collected 
by the Centre d'Etude du Polymorphisme Humain (CEPH) were used to order these 
markers by multipoint linkage analysis. This analysis computes LOD scores for the 
most likely location of the marker locus based on its segregation in families in relation 
to other marker loci, for example, using the LINKAGE program (Lathrop et aI, 1986; 
Lathrop and Lalouel, 1988). DNA samples from the CEPH families are screened by 
groups wishing to integrate new genetic markers into the map. RFLP markers enabled 
the chromosomal localisation of a number of disease genes, for example, the 
Huntington's disease locus (Gusella et aI, 1983). 
The majority of the RFLP DNA markers are relatively uninformative exhibiting a low 
level of polymorphism (maximum heterozygosity 50%) and, as a consequence, are 
often uninformative for genetic linkage analysis in most families (Figure 1.1.(i) and 
(ii}). However, a small number of DNA marker loci were cloned which exhibited a far 
higher degree of allelic variation with heterozygosity levels approaching 90% for some 
loci. This high level of polymorphism was found to be due to short DNA sequencies 
(11 to 60 bp) being tandemly repeated; such loci are referred to as "minisatellites" or 
variable number of tandem repeats (VNTRs: Jeffreys et aI, 1985). These multiallelic 
systems are ideally suited to linkage studies as individuals are likely to be informative 
or heterozygous at the locus (Nakamura et aI, 1987; Figure 1.1. (iii)). The application 
of the polymerase chain reaction (peR: Saiki et aI, 1988) increased the speed of DNA 
marker analysis plus reduced the quantity and quality of DNA required. Short 
oligonucleotide primers are designed in unique DNA sequence either side of the 
repetitive sequence and are used to amplify the DNA sequence in between using a 
thermostable Taq polymerase. The PCR amplification products are resolved by gel 
electrophoresis to detect the length variation. However, many minisatellite alleles are 
beyond the effective limits for PCR (> 1 0 Kb in length). 
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(i) two allele marker system: one common allele 
1 1 1 1 
1 1 1 1 
(iii) multi allelic marker system: equal allele frequency 
2 1 3 4 
2 3 2 4 
Oi) two allele marker system: approximate equal allele frequency 
2 1 2 1 
2 1 1 1 
Fi~ure 1.1. The affect of allele number and frequency in linka~e analysis 
Circle indicates female and square indicates male; if blackened, indicates 
affected individual. Genotype of each individual for each marker system 
shown directly under the individual. 
(i) As both parents are homozygous for the same allele, it is impossible to 
determine from which parent, the affected daughter inherited each allele 
from. 
(ii) As both parents are heterozygous for the same two alleles, it is 
impossible to determine from which parent, the affected daughter inherited 
each allele from. However, the unaffected daughter clearly has inherited 
allele 1 from each parent, inferring that the disease locus segregates with 
allele 2. 
(iii) Marker is fully informative as parents are heterozygous for different 
alleles. Affected daughter has clearly inherited allele 3 from her affected 
mother, whilst her unaffected sib inherited the maternal allele 4. 
A major disadvantage of VNTR markers for linkage analysis is that the majority are 
clustered towards the telomeres of the chromosomes (Royle et ai, 1988). Thus a 
genetic map of the genome could not be based on this marker system alone. Another 
class of tandemly repeated DNA sequences are found in the genome. These are in great 
abundance and it is estimated that a repeat block is present every 30-60 kb with a 
relatively even distribution throughout the genome (Hamada et ai, 1984). This 
repetitive DNA family consists of short dinucleotide repeats such as (dC-dA)n. (dG-
dT)n, which are designated "CA" repeat microsatellites. They are reported to have 
arisen due to "slippage" in DNA replication and are often highly polymorphic with 
multiple alleles due to length variation of the "CA" blocks (Hearne et ai, 1992). Weber 
and May (1989) demonstrated the usefulness of these microsatellites as an abundant 
source of genetic markers. Generally, the longer the run of repeats, the greater the 
number of alleles at that locus (Weber, 1990). The properties that have made this 
marker system so useful for linkage studies are as follows: 
(i) frequent distribution in the genome 
(ii) high polymorphic multi-allelic systems 
(iii) rapid and easy detection by PCR 
(iv) ability to PCR amplify DNA from archival pathological material, for example, to 
increase the informativeness of families for linkage analysis. 
Other classes of polymorphic markers have been developed, for example, the 
polydeoxyadenylate tract found in Aiu repetitive elements (Economou et aI, 1990), but 
the majority of marker loci which form the basis of current genetic linkage maps are 
the microsatellites. 
Vast numbers of microsatellite marker loci have been isolated across the genome and 
integrated into high resolution genetic maps (NIWCEPH Collaborative Mapping 
Group, 1992; Weissenbach et al,1992; Gyapay et ai, 1994, Dib et ai, 1996). The 
application of fluorescence-based technology has improved methods of detection of 
these marker loci (Ziegle et ai, 1992; Mansfield et ai, 1994). Sets of microsatellite 
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marker loci tagged with either one of three fluorescent dyes and with different allele 
size ranges are available which span each chromosome (for example, Reed et ai, 
1994). The resulting PCR products are pooled and run on the same gel to increase the 
speed and accuracy of a genomic search in a disease gene linkage mapping study. 
1.5.2. Intea:rated Genetic and Physical map of the human a:enome 
The generation of a comprehensive genetic linkage map of the genome will increase the 
potential power of disease gene localisation by linkage analysis. However, the actual 
identification of the gene requires the physical positioning of transcribed sequences in 
relation to the flanking genetic markers. Such candidate transcribed sequences can then 
be characterised and mutation analysis performed to identify the disease gene. This 
approach has been termed "positional cloning" (reviewed Ballabio, 1993). One of the 
first successes using this approach was the identification of the Cystic Fibrosis gene 
(Riordan et ai, 1989). 
Numerous methods of identifying transcribed sequences have been used including 
CpG island mapping (Cross and Bird, 1995), exon trapping (Buckler et ai, 1991) and 
the sequencing of randomly selected cDNAs ( Adams et ai, 1991; 1995). Transcribed 
sequences can be rapidly assigned to chromosomes and physically ordered using, for 
example, human rodent somatic cell hybrid mapping panels (reviewed Spurr et ai, 
1996), in situ hybridisation (FISH: Buckle and Craig, 1986) and 'fingerprint' contig 
construction using yeast artificial chromosomes (YACs) (Bellanne-Chantelot et ai, 
1991; Cohen et ai, 1993). A Y AC is a vector in which large fragments of human DNA 
(up to 1000 kb or greater) can be cloned (Burke et ai, 1987; Anand et ai, 1989). The 
development of Y AC contigs has proved the most successful method towards the 
integration of the physical and genetic maps (reviewed Schlessinger, 1990). Large 
regions of every chromosome have been covered in Y AC contigs facilitating the 
ordering of any transcribed sequence or any DNA landmark in relation to genetic 
marker loci (Chumakov et ai, 1995). 
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CANCER GENETICS 
1.6. Cancer is a multi-step 2enetic disease 
There is strong evidence that a cancer arises from a single cell as a result of clonal 
expansion (Nowell, 1976; Ponder and Wilkinson, 1986). A focus for molecular 
biology has been the identification of the genetic changes occurring in that cell which 
disrupt the controlling mechanisms that prevent every cell becoming cancerous. The 
model that fits best is that of multistep carcinogenesis (Foulds, 1957; Nowell, 1976). 
This is explained by the acquisition of changes in genes which control proliferation 
and cell-cell interactions. Accumulation of these specific gene mutations will allow the 
"cancer cell" to progress along the tumorigenic pathway enabling the it to "escape" the 
confines of nonnal cell regulation and metastasise. The hypothesis that these genetic 
changes are ordered in the multi-step process is clearly demonstrated in the colon 
cancer pathway (Fearon and Vogel stein, 1990) shown in Figure 1.2; and is supported 
by the following observations: 
1.6(i) Histopatholo2ical 
From looking at specific tumours, there is evidence for clear histopathological 
differences in the development of tumours (Foulds, 1957). One of the best examples is 
the progression of a nonnal colon epithelial cell to that of a metastasising carcinoma; 
whereby the cell passes through a hyperproliferative stage, via various classes of 
adenoma to that of a carcinoma (Sugarbaker et ai, 1985; Vogel stein and Kinzler, 
1993). This pathway is shown in Figure 1.2. 
1.600 Epidemiolo2Y 
In cancer syndromes, every cell has inherited a mutation in the germline, but not all 
these cells become cancerous. Therefore, other mutational events are required (Hansen 
and Cavenee, 1987). Each "growth-advantageous" mutation will allow that cell to 
divide more freely thus increasing the relative proportion of cells carrying that 
mutation. This increases the probability that one of these mutated cells will aquire 
subsequent growth selective genetic alterations. 
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Figure 1.2. Multistep model for colorectal tumourigenesis (adapted from Fearon and Vogelstein, 1990) 
Model showing some of the identified gene tic changes occurring during the progression of a colon epitheli al cell 
to a me tasti sing cancer cell . 
1.6(iii) Non-random eenetic aberrations 
Cancer cells have abnormal chromosomes. These karotypic changes are often 
unevenly distributed throughout the genome (Mitelman and Levan, 1981; Cavenee and 
White, 1995). Some are common in particular tumour types, for example the 
Philadelphia chromosome in chronic myeloid leukaemia (CML), a chromosome 9 and 
22 translocation t(9;22) (q34;ql1) (Prakash and Yunis, 1984). These are termed 
primary chromosome aberrations. Others are secondary karyotypic aberrations which 
occur frequently in different tumours of the same cellular origin and are implicated in 
the progression of that tumour type. The most recurrent karyotypic abnormality 
observed in breast tumours involves chromosome 1, though other specific 
chromosomal abnormalities are also observed (Rodgers et ai, 1984). 
The key somatic genetic changes that occur in the multistep process are as a result of 
mutations (reviewed Loeb, 1991), possibly as a consequence of an inherited defect, 
for example, defective mismatch repair genes resulting in an elevated mutation rate 
(Bodmer et ai, 1994; Lindahl, 1994; MacPhee, 1995) and/or environmental damage. 
1.7. Cancer Genes 
A number of genes have been implicated in carcinogenesis. They have been identified 
as having an important inherited component and/or are somatically altered during 
tumour formation. These genes fall into broadly two classes which have contrasting 
mechanisms: tumour suppressor genes and oncogenes. Both have roles in the 
regulation of cellular growth, differentiation and/ or cell-cell interactions. 
1.8. Tumour Suppressor Genes 
The loss of specific chromosomal regions is a common event in the majority of 
tumours (Cavenee and White, 1995). These deletions may result in loss of function of 
a gene or genes which are involved in the etiology of the cancer. These genes are 
called tumour suppressor genes, and inactivation of the gene removes its inhibitory 
role in the regulation of cell growth and differentiation (Friend et ai, 1986). Hybrid 
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fusion of tumorigenic and non-tumorigenic cells demonstrated that recessive genetic 
changes were required for tumour formation. These hybrid cells did not give rise to a 
malignant phenotype unless specific chromosomes were deleted from the non-
tumorigenic parent cells (Weissmann and Stanbridge, 1983). 
1.8.1. Paradi2m of Retinoblastoma 
Epidemiological studies on families with the rare childhood cancer, retinoblastoma, led 
Knudson (1971) to propose the "two-hit" hypothesis for the action of tumour 
suppressor genes III inherited cancer. Retinoblastomas are malignant tumours that 
develop in the retina. From the observation that bilateral cases were often diagnosed at 
an earlier age and had a family history, Knudson suggested that the cancer resulted 
from two mutational events; one in each allele of the same gene. These bilateral cases 
were likely to be carrying a germline mutation in the susceptibility gene but required a 
second somatic mutational event in the normal allele of a retinal cell before the cancer 
manifested. This hypothesis could also explain sporadic retinoblastoma which was 
more likely to occur in unilateral cases and at a later age. The same gene was likely to 
be involved but two somatic mutation events in that gene in the same cell were 
required. As two hits are required in the tumour suppressor gene, the inherited 
susceptibility allele is actually recessive at the cellular level. An example of this 
mechanism is shown in Figure 1.3. The apparent dominant inheritance of cancer can 
still be explained if the susceptibility allele is recessive at the cellular level as a second 
hit is highly likely to occur in at least one retinal cell carrying a germline mutation. 
Studies leading up to and after the cloning of the retinoblastoma susceptibility (RB) 
gene on chromosome 13q 14 supported this mechanism. These include: 
(i) interstitial deletion at 13ql4 in germline cells of retinoblastoma cases (Knudson, 
1976) 
(ii) cytogenetic deletion of 13q 14 in a proportion of retinoblastoma tumours (Benedict 
et ai, 1983) 
(iii) linkage analysis of the susceptibility gene in retinoblastoma families to this region 
(Sparkes et ai, 1983) 
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Fi2ure 1.3. Knudson's two hit model for retinoblastoma 
(a) Familial retinoblastoma (b) Sporadic retinoblastoma 
Germline 
one "hit" 
c..., 
.~ 
Somatic second "hit" 
second "hit" one "hit" 
! 
Cancer progression Cancer progression 
(iv) detection of mutations in the retained allele of the RB gene in familial and sporadic 
tumours (Friend et ai, 1986). 
Using the model of inactivation of tumour suppressor genes, it is possible to identify 
candidate regions which may harbour these genes in specific familial and sporadic 
cancers, for example, to target linkage studies. The identification of specific 
chromosomal abnormalities associated with familial and!or sporadic cancer may be 
detected cytogenetically and! or by allele loss studies. 
1.8.2. Allele loss 
For inherited cancer, the first mutation in the tumour suppressor gene is passed to all 
cells through the germline. This mutation is often a small DNA sequence change which 
disrupts the function of the protein translated from that allele, such as an amino acid 
change causing premature truncation of the protein. Following Knudson's hypothesis 
a second somatic mutation is required to 'knock-out' the normal allele. This second 
event is often a deletion of the whole gene, either through loss of the whole 
chromosome or due to a smaller interstitial deletion. Using polymorphic genetic 
markers, it is possible to detect this deletion in the tumour (Figure 1.4). If the genetic 
marker maps within the deleted region and is heterozygous in normal cells from the 
individual, then only one allele will be present in the tumour. This is termed "loss of 
heterozygosity" (LOH) or allele loss (Lasko et ai, 1991). This loss of an allele, if seen 
frequently in a number of tumours, may indicate the presence of a tumour suppressor 
gene in the common region of deletion. This method of analysis has been successfully 
reported for a number of tumour suppressor genes associated with familial cancer. for 
example, Retinoblastoma, RB 1 (Cave nee et ai, 1983), TP53 (Li-Fraumeni syndrome: 
Hollstein et ai, 1991; Donehower and Bradley. 1993), von Hippel-Lindau (VHL) 
disease (Latif et ai, 1993) and adenomatous polyposis coli (APC) (Sasaki et al. 1989). 
Using the high density genetic maps available. it is possible to produce LOH patterns 
or allelotypes for all familial and sporadic tumours (Vogelstein et ai, 1989). These 
allelotypes reveal numerous regions of the genome which may harbour tumour 
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FiJ:u re 1.4. Allele loss to detect tumour suppressor J:ene 
Thi fi gure demon trate the detection of allele 10 toward the identificati on of a 
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inter titial deletion. Both event delete one copy of the T gene. 
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suppressor genes. These deletion maps have also aided in the identification of tumour 
suppressor genes which apparently are not involved in familial cancer but have a role 
in later stages of the cancer pathway, for example, the Deleted in Colon Carcinoma 
(OCC) gene in colon cancer (Fearon et ai, 1990). 
The majority of familial tumour suppressor genes appear to be inactivated at the first 
step in the cancer pathway. One possible exception may be in familial adenomatous 
polyposis coli, for which the second inactivating mutation at the APC gene locus may 
occur after polyp formation (Solomon et ai, 1987). This means the inherited mutant 
APC allele has a slight phenotypic effect on some of the colonic epithelial cells and 
therefore, is not completely recessive. The APC protein appears to have multi-
functional domains (Groden et ai, 1991). One central domain associates with catenins 
which, in conjunction with E-cadherin, among other proteins, form an important 
component in cell-cell adhesion and communication (Rubinfield et ai, 1993; Su et ai, 
1993). This may explain the proposed dosage effect with polyp formation. A slight 
reduction in the APClcatenin contact inhibition signal may induce colonic epithelial 
cells to grow and result in abnormally organised cells or polyps. 
1.8.3. Genomic ImprintinK 
Another mechanism for inactivating the normal inherited allele is by genomic 
imprinting whereby only one of the parental alleles is expressed, the other silenced by 
allele-specific CpG methylation (reviewed Squire and Weksberg, 1996). Imprinting 
has been demonstrated at the Wilms tumour locus in a tissue specific manner (Zhang et 
ai, 1993; Jinno et ai, 1994). Hypermethylation for 'silencing" gene transcription has 
been demonstrated as a mechanism for a number of other putative tumour suppressor 
genes, including the von Hippel-Lindau (VHL) gene (Herman et ai, 1994) and the 
HIC-I gene (Wales et ai, 1995). In an analogous fashion to "allelotyping" tumours 
(see previous section) to identify regions potentially harbouring tumour suppressor 
genes, a number of chromosomal regions have been demonstrated to be 
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hypennethylated in specific tumour types, for example, chromosome 18q21 in lung 
carcinomas (Nagatake et aI, 1996). 
1.8.4. Tumour suppressor 2enes and breast cancer 
From allelotyping and linkage studies, very few tumour suppressor genes have been 
identified which have a role in breast cancer. Numerous LOH studies have implicated a 
number of genomic regions which may harbour tumour suppressor genes in familial 
and sporadic breast cancer (for example, Devilee et ai, 1989; Lindblom et ai, 1993). 
These regions demonstrate allele loss in greater than 20 % of breast tumours and often 
include multiple sites on various chromosomes. For example, two distinct regions on 
chromosome 3p (Chen et ai, 1994) and at least two regions on 17q (Comelis et ai, 
1993). Genes that have been identified which fulfill the role of tumour suppressors in 
breast cancer progression include: 
1.8.4. (i) E-cadherin 
The E-cadherin gene maps to chromosome 16 in the smallest deletion unit identified in 
breast tumours from allele loss studies, at 16q22.1 (Cleton-Jansen et ai, 1994). 
Reduced expression of E-cadherin has been associated with invasive potential (Oka et 
ai, 1993). In four lobular carcinomas displaying allele loss of this region, somatic 
mutations generating premature stop codons were detected fulfilling its putative 
function as a tumour suppressor (Berx et aI, 1995). E-cadherin is a member of the 
cadherin family which are involved in the formation of intercellular junctions 
(Birchmeier et ai, 1995). A phenotype of lobular breast cancers is that of scattered 
tumour cell growth which would correlate with loss of function of a cell-cell adhesion 
molecule, such as E-cadherin. 
1.8.4. (i i) Retinoblastoma (RB) 
Inherited mutations in the RB 1 gene predispose individuals to predominantly 
retinoblastoma but are also associated with other malignancies such as osteosarcoma 
35 
and to a lesser extent, breast cancer (Friend et ai, 1986). In sporadic breast tumors 
exhibiting allele loss at this locus (13q14), very few somatic mutations have been 
identified in the retained allele (Lee et ai, 1988; TAng et ai, 1988). This could suggest 
that another tumour suppressor gene(s) maps to this region which is the target for 
deletion. 
The RB 1 protein is a transcription factor and in its unphosphorylated form suppresses 
S phase and cell growth (Goodrich et ai, 1991). This protein is expressed in most cell 
types (Lee et ai, 1988), but, when mutated in the germline, only a few tumour types 
develop, mainly retinoblastomas. This would indicate that retinoblasts are highly 
dependent on RB 1 in cell cycle control. For other cell types such as breast epithelial 
cells, cell cycle control may be less dependant on RB 1; RB 1 loss may only be selective 
if mutational events have occurred in other associated cell cycle regulatory genes. 
1.8.4.(iiil p53 
Germline mutations in the p53 gene have been identified in families with the autosomal 
dominant Li Fraumeni cancer syndrome in which breast cancer is a component 
(Srivastava et ai, 1990; Malkin and Friend, 1993). From these studies, it is estimated 
that approximately 1 % of familial breast cancer cases may occur as a result of 
inactivation of this gene. High allele loss rates at the p53 locus have been detected in a 
number of tumour types, including breast tumours (Mackay et ai, 1988; Devilee et ai, 
1990; Prosser et aI, 1990). Mutations in the remaining p53 allele of the tumour have 
been demonstrated supporting a role for this gene as a commonly inactivated tumour 
suppressor gene in breast carcinogenesis (Osborne et ai, 1991; Varley et ai, 1991; 
Coles et ai, 1992). Additionally, homozygous null p53 mice develop normally. but 
have a high rate of spontaneous tumour growth, particularly lymphomas, at an early 
age (Donehower et aI, 1992; lacks et aI, 1994). 
Like RB 1, TP53 protein acts as a transcription factor in the G liS checkpoint in the cell 
cycle in most cell types (reviewed in Cox and Lane, 1995). This transcriptional 
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regulatory role involves targetting numerous genes including MDM2, a putative 
oncogene (Oliner et ai, 1992), and the cyclin dependant kinase (CDK) inhibitor, 
CIPIIWAFl/p21 (EI-Deiry et ai, 1993; Xiong et ai, 1993). One key role of p53 may 
be in the blocking of replication or inducing apoptosis in a damaged cell after exposure 
to DNA damaging agents (Kastan et ai, 1991; Kuerbitz et ai, 1992, Livingstone et ai, 
1992; Cox and Lane, 1995). Additionally, p53 is implicated in a checkpoint for 
spindle formation so loss of TP53 function may affect cell ploidy (Cross et ai, 1995). 
As a consequence of this multi-functional role of p53, a cell not expressing TP53 may 
rapidly accumulate the genetic mutations required for it to become malignant. 
1.9. Oncoeenes 
The second major class of genes involved in the carcinogenic pathway are the 
oncogenes. They differ functionally from the tumour suppressor genes in that a single 
aberrant allele is dominant at the cellular level, resulting in an overproduced or 
overactive form of the protein. The normal form of the gene is termed the proto-
oncogene, but after mutation, gene fusion (for example, chromosomal translocation: 
reviewed Sorensen and Triche, 1996) or DNA amplification, an oncogenic form of the 
gene is produced. Oncogenes stimulate the cell to replicate via a number of growth 
promoting mechanisms (Cooper, 1990; Cantley et ai, 1991; Cavenee and White, 
1995). They are implicated in the various growth stimulatory pathways of the cell and 
include: cell surface receptors which bind growth factors, intracellular signal 
transduction and nuclear proteins involved in cell cycle regulation. 
There are two oncogenes which are transmitted through the germline and known to be 
involved in cancer predisposition: 
(D RET, a tyrosine kinase receptor, which IS mutated in the familial cancer 
syndrome, multiple endocrine neoplasia types, 2A and 2B (Mulligan et ai, 1993; 
Hofstra et ai, 1994). 
(ii) CDK4, a cyclin dependant kinase, mutated in familial melanoma (Zuo et ai, 
1995). This gene forms a complex with cyclin D which regulates RB phosphorylation 
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at the Gl checkpoint in the cell cycle under the mediation of p16ink4a (Serrano et ai, 
1993). Interestingly the inhibitor of the cyelin Df CDK4 complex, p16ink4a, is also 
mutated in a proportion of familial melanoma cases but it functions as a tumour 
suppressor gene (Hussussian et ai, 1994; Kamb et ai, 1994). 
1.9.1. Onco2enes and breast cancer 
None of the oncogenes which have been identified appear to be implicated in breast 
cancer predisposition, though a number have been demonstrated as components in the 
breast tumorigenic pathway. These genes have been identified either by their increased 
expression and/or DNA amplification in tumour cells. Specific regions of the genome 
are amplified in some breast tumours (Kallioniemi et ai, 1994), for example, 
chromosome 2Oq13 (Tanner et ai, 1994). Amplicons may harbour specific oncogenes 
which have a role in the progression of that tumour. Oncogenes implicated in breast 
carcinogenesis inelude: 
1.9.1.(0 Epidermal Growth Factor Receptor (EGFR: ErbB-l>. 
A variant form of this receptor is detected in 78% of infiltrating ductal breast 
carcinomas (Moscatello et ai, 1995). This alternatively spliced form of the gene has 
been demonstrated to be oncogenic from transfection studies into rodent fibroblasts 
(Velu et ai, 1987). EGFR also can form heterodimers with another member of the 
receptor tyrosine kinase family, ErbB-2 (Karunagaran et ai, 1996). ErbB2 is also 
frequently amplified in breast tumours (Slamon et ai, 1987). Overexpression of ErbB2 
has been associated with poor prognosis (Slamon et ai, 1989). 
1. 9.1. (i i) eyclin D 1. 
Elevated expression of cyelin Dl mRNA is found in 45-50 % of breast tumours 
compared to normal breast epithelial cells (Buckley et ai, 1993; Bartkova et ai, 1994). 
Overexpression of cyelin D 1 in the mammary cells of mouse mammary tumour virus-
cyelin D 1 transgenic mice, results in abnormal cell proliferation and a high incidence of 
adenocarcinoma (Wang et ai, 1994). Cyelin Dl is a cell cycle regulator essential for 
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G 1 progression by activating cyclin dependant kinases (CDK) (Matsushime et ai, 
1994). These CDKs phosphorylate the retinoblastoma gene product, pRB, thus 
inhibiting RBfs growth suppressive effect (Sherr, 1994). Additionally, G 1 arrest and 
growth inhibition in breast cancer cells by anti-estrogens has been correlated with a 
decrease in cyclin Dl mRNA levels (Sutherland et ai, 1993). Therefore, there is strong 
evidence that cyclin D 1 is a major oncogenic factor in breast carcinogenesis. The 
observation that cyclin D 1 induced neuronal apoptosis (Kranenburg et ai, 1996) cast 
doubt on its oncogenic role, but the overexpression of cyclin D 1 in this study far 
exceeded that seen in breast tumour cells. This suggests that there may be a selective 
level of cyclin D 1 overexpression in tumorigenesis. 
1.10. Objectives of study 
In 1990, Hall et at provided the first convincing data for linkage of a DNA marker 
locus with familial breast cancer. The marker locus was D17S74 which mapped to the 
chromosomal region 17q21. Initial evidence was strongest in early onset breast cancer 
families. Linkage of this marker with the disease was confirmed in three large breast-
ovarian cancer pedigrees (Narod et ai, 1991). This indicated the familial breast cancer 
gene mapping to this region may also predispose gene carriers to ovarian cancer. The 
disease locus was designated "BRCA 1" (Solomon and Ledbetter, 1990). 
Chapter 3 
This chapter describes the genetic analysis of 17q in ICRF UK breast cancer families. 
The aims being to ascertain families linked to BRCA 1, possibly identify key mapping 
recombinants and analyse candidate genes. Results chapters 4 and 5 describe analyses 
performed which were related to developments occurring in the field of breast cancer 
genetics during the course of this study: 
Chapter 4 
This chapter describes the characterisation of a Y AC contig spanning a second locus 
for breast cancer susceptibility, BRCA2. 
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Chapter 5 
This chapter describes allele loss studies in familial and sporadic breast tumours at 
BRCAI and BRCA2. 
Chapter 6 
A pedigree has been described in which an epidermolytic form of palmoplantar 
keratoderma (EPPK) was segregating with susceptibility to breast-ovarian cancer 
(Blanchet-Bardon et ai, 1987). This chapter describes the genetic analysis of families 
with various forms of non-epidermolytic palmoplantar keratoderma (NEPPK). In a 
proportion of these families, the skin disease was segregating with susceptibility to 
malignancy, particularly squamous cell carcinoma of the oesophagous. The aim of this 
study was to determine the genetic basis of NEPPK and to assess the relationship 
between the various forms of NEPPK and cancer susceptibility. 
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CHAPTER 2: MATERIALS and METHODS 
The majority of media and solutions used in this study were provided by ICRF Media 
Production, Clare Hall Laboratories. Suppliers from which other reagents were 
obtained are indicated in the relevant sections in this chapter. The majority of molecular 
biology procedures are referenced in Sambrook et al (1989) and Asubel et al (1989). 
The water used for experimental procedures was obtained from a Millipore Reverse 
Osmosois System. 
2.1. Family Ascertainment 
2.1.1. Breast and breast-ovarian cancer families 
The majority of families in this study are from the Yorkshire region, with a small 
number from Southampton and Oxford. They were identified, usually through the 
diagnosis of a new case in a family, by physicians, oncologists and radiotherapists 
who then contacted the ICRF Genetic Epidemiology Unit, St. James's University 
Hospital, Leeds. A pedigree worker (either A. Williams, B. Ward or M. Adams) was 
assigned to obtain informed consent to approach other family members from the initial 
case (or proband) and to trace the family history. An important criteria for selection of 
each family was consistency with an autosomal dominant inherited susceptibility to 
breast or breast-ovarian cancer (determined by Prof. T. Bishop, ICRF Genetic 
Epidemiology Unit). Sample availablity was also an important consideration for 
informative linkage analysis. If all the above criteria were met, blood samples were 
obtained from potentially informative and consenting members of the family. In 
addition, verification of cancer diagnosis in each family was obtained from death 
certificates, hospital records andlor pathological material. Further information as to the 
ascertainment of these families can be found in Spurr et ai, (1993). 
2.1.2. Non-epidermolytic palmoplantar keratoderma (NEPPK) families 
Families: 2244, 2242, 2039 and 2239 were ascertained from the London Hospital by 
Drs. H. Stevens and R. Ratnavel (ICRF Skin Tumour Laboratory, The Royal London 
Hospital, Whitechapel, London), after examination of a proband from each family. 
Family 2216 was identified from the literature (Marger and Marger, 1993) and the 
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pedigree extended with the consent of family members by Dr. H. Stevens. For all 
families, the NEPPK segregated as an autosomal dominant trait and was 100 % 
penetrant (though severity was variable between family members: discussed in Chapter 
6). As with the families described in section 2.1.1, informed consent was required to 
contact other affected and unaffected members of the pedigree. Blood samples were 
taken from all potentially informative family members. For each family member, 
disease status was carefully determined by either Drs. H. Stevens. I. M. Leigh or R. 
Ratnavel. A skin biopsy was obtained from the palm from at least two affected 
members of each pedigree to confirm the non-epidermolytic pattern of the palmoplantar 
keratoderma by routine electron microscopy (performed by Dr. H. Stevens and 
colleagues). 
2.2. Source of DNA 
2.2.1. Breast and breast-ovarian cancer families 
Blood samples were taken from potentially informative members of breast and/or 
ovarian cancer families (ascertained as described in section 2.1.1) by the particular 
pedigree worker assigned to each family. The 50 ml blood sample was divided into 25 
ml of Hepes buffered RPM 1 (30 ml of blood) or 4 ml ofO.25M EDTA pH 8.0 (20 ml 
of blood). This was delivered to the ICRF Human Genetic Resources, Clare Hall. 
DNA was extracted, for most individuals analysed in this study, from two sources: 
(i) T and B lymphocytes were isolated from the 30 ml blood sample on a Lymphoprep 
gradient (Nycomed) and stored in 10% DMSO in liquid nitrogen. This procedure was 
performed by B. Laguda (Human Genetic Resources). These lymphocytes were 
transformed with Epstein Barr virus to produce immortalised B lymphoblastic cell 
lines (performed by Cell Production, ICRF, Clare Hall Laboratories). For the majority 
of these cell lines, DNA was extracted using an Applied Biosystems DNA extractor 
following the manufacturer's recommended protocols by L. Rooke and B. Laguda 
(both from ICRF Human Genetic Resources). DNA from cell lines of other breast and 
breast-ovarian family members in the study was extracted using the procedure 
described in section 2.3.1. 
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(ii) DNA was also extracted from the 20 m1 whole blood sample using the procedure 
described in section 2.3.2. This was performed by L. Rooke and B. Laguda for the 
majority of samples. 
2.2.2. Non-epidermolytic palmoplantar keratoderma families 
For all potentially informative family members, DNA was extracted from 20 m1 blood 
in 4 ml of of O.25M EDT A pH 8.0, as described in section 2.3.2. 
2.2.3. Rodent and Somatic Cell Hybrid DNA 
DNA samples from mouse, rat, hamster and human/rodent hybrid somatic cell lines 
for chromosomal assignments (referenced in Spurr et ai, 1991; Black et ai, 1993; 
Kelsell et ai, 1995a) were extracted by L. Rooke, B. Laguda (both from ICRF Human 
Genetic Resources) and H. Nicolai (lCRF Somatic Cell Genetics, Lincoln's Inn Fields 
London). 
2.2.4. Paired breast tumour/lymphocyte DNA 
DNA was extracted (by Dr. D. Barnes and colleagues, ICRF Clinical Oncology Unit, 
Guy's Hospital, London) from 118 paired fresh primary tumour and lymphocyte DNA 
samples from breast cancer patients attending Guy's Hospital, London. Breast cancer 
in the majority of these cases was assumed to have arisen "sporadically", that is, 
without a major genetic susceptibility component. 
2.2.5. Archival patholoKical material 
Archival pathological material (excised tumour sections embedded in paraffin wax for 
long-term storage) was obtained from two sources: 
(i) 10 JlIll histological sections of breast and ovarian tumours were obtained from 
Prof. T. Bishop. 
(ii) 10 Ilm histological sections of paired squamous cell carcinomas of the oesophagus 
(SCCO)/normal oesophageal tissue were obtained from Dr. H. Stevens. 
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For each tumour sample, a 10 Jlm histological section was stained with haematoxylin 
and eosin to confmn the pathology of the tumour (ICRF Histopathology Laboratory, 
London). This was determined by light microscopy analysis of the stained section 
under the guidance of Prof. N. Spurr or Dr. H. Stevens. DNA was extracted using the 
method described in section 2.3.3. 
2.2.6. Placental DNAHuman placental DNA for competition hybridisation (used 
in detection of the D17S74 polymorphic system) was extracted by L. Rooke from 
frozen placentas. 
2.2.7. DNA probes 
Published polymorphic cloned human DNA probes (D17S74, D17S4, LEW101, 
LEW102) for southern hybridisation detection of alleles were obtained from the 
HGMP Probe Resource Centre when based at ICRF Human Genetic Resources. 
Details of these probes can be found in Easton et al (1993b). 
2.2.8. OIiKonucleotide synthesis 
16-25 mer oligonucleotides for polymerase chain reaction (PCR) amplification and for 
sequencing of DNA were synthesised by the ICRF Oligonucleotide Synthesis 
Laboratory, Clare Hall Laboratories. Oligonucleotide primers were synthesised using 
an automated DNA synthesiser (Model 380B, Applied Biosystems), working on 
cyanoethyl phophorarnidite chemistry. Primer sequences for microsatellite marker loci 
were obtained from the Genome Database or Genethon, unless otherwise indicated in 
the text. 
2.2.9. YAC and HAC clones 
Primary and secondary pools of Yeast Artificial Chromosomes (YACs) and Bacterial 
Artificial Chromosomes (BACs) containing cloned human genomic DNA inserts were 
obtained from Research Genetics, Huntsville, USA. Individual Y AC clones were 
obtained from the HGMP Resource Centre, Hinxton Hall, Cambridgeshire. 
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2.2.10. CEPH DNA 
Human DNA samples from lymphoblastoid cell lines derived from three generation 
families were obtained from the Centre d'Etude du Polymorphisme Humain (CEPH), 
Paris. Cell lines were maintained and DNA extracted by L. Rooke. First generation 
members (grandparents) of these families were used for a random control population 
to estimate allele frequencies at the microsatellite marker locus, D17S1603. 
2.2.11 Molecular wei&ht DNA markers 
A DNA digested with HindIIl (Molecular Weight Marker III) and <\>x174 DNA digested 
with Haem (Molecular Weight Marker IX) were obtained from Boehringer 
Mannheim. 
2.3. Extraction of Genomic DNA 
2.3.1. Cell lines 
Approximately 108 cells were washed in PBS (phosphate buffered saline: 140 rnM 
NaCI, 2.6 mM KCI, 10 mM sodium hydrogen phosphate, 1.75 mM potassium 
hydrogen phosphate) and centrifuged in a 50mI Falcon tube at 1500 rpm for 5 minutes 
in a Beckman GP Centrifuge. The PBS was removed and the resulting cell pellet was 
used for DNA extraction. 
I) The cell pellet was resuspended in 15 rnl of Lysis buffer (10 mM Tris-HCI pH 7.6, 
100 rnM EDTA pH 8.0,0.5 % SDS: Applied Biosystems) and 100 Jlglrnl proteinase K 
(Boehringer Corporation) before incubation at 50°C for at least 4 hours. 
2) One volume of a 1:1:1 mixture of phenol:chloroform: H20 (Applied Biosystems) 
was added and the mixture centrifuged again at 1500 rpm for five minutes. The top 
phase was collected. This was performed twice. 
3) One volume of chloroform was added and the top phase collected after 
centrifugation again at 1500 rpm for 5 minutes. 
4) Finally the DNA was precipitated by the addition of 2 volumes of ethanol and 1I1Oth 
volume of 2 M sodium acetate. The DNA was spooled out using a plastic inoculating 
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loop (Nunc). The DNA was dried briefly under vacuum and resuspended at an 
approximate concentration of 250 Ilglml in H20. This solution was then left overnight 
at room temperature to allow the DNA to dissolve completely. 
2.3.2. Whole Blood 
DNA was extracted using the Nucleon II kit (for blood volumes of 0.5 ml to 30 ml) 
from ScotLab using an adapted version of the manufacturer's recommended protocol. 
A summary of the major steps involved is indicated below (for steps 1-3, cells were 
kept on ice unless stated): 
1) Sucrose triton was added to separate red blood cells from lymphocytes. The 
lymphocytes were pelleted at 1500 rpm for 5 minutes in a Beckman GP Centrifuge. 
2) Lysis buffer (Applied Biosystems) was added to the pelleted blood lymphocytes. 
Sodium perchlorate was then added and the cell solution was shaken for 15 minutes at 
room temperature. The cell solution was then incubated at 65°C. 
3) Chloroform was added and the cell solution was shaken for 10 minutes at room 
temperature. After addition of the Nucleon silica suspension, the cell solution was 
centrifuged at 1500 rpm for 3 minutes. 
4) The top phase was removed carefully (above the brown Nucleon silica suspension 
layer) and the DNA was precipitated and resuspended as described in the previous 
section. 
2.3.3. Archival DNA 
A method adapted from Smith et ai, (1992) was used: 
Serial 10 11m histological sections were mounted onto glass slides. One slide was 
stained with haematoxylin and eosin to determine the pathology of the section (as 
described in section 2.2.5). Tumour (or normal) cells were scraped from slides of 
sections taken either side of the stained section into a 1.5 ml tube (Eppendorf) using a 
sterile disposable scalpel. 250 III of buffer (10 mM Tris-HCl pH 8.0, 0.5 mM KC1, 
1.5 mM MgC~, 100 Ilg/ml BSA, 0.45 % Tween and 100 Ilg/ml of proteinase K) was 
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added to the tube. Following an overnight incubation at 55°C, the samples were boiled 
for five minutes. 
2.3.4. Yeast DNA (for YACs) 
This method was adapted from Asubel et al (1989) by Dr. I. Gray (Human Genetic 
Resources). 
1) 5 mls of cells in solution were pelleted by centrifugation at 1500 rpm for 5 minutes 
in a Beckman GP Centrifuge and resuspended in 0.5 ml of sorbitol solution (0.9 M 
sorbitol, 0.1 M Tris pH 8.0, 0.1 M EDT A) and vortexed. 
2) 50 ~ of 1000 units/ml of lyticase (Sigma) in sorbitol solution and 50 ,.Ll of 0.28 M 
f3-mercaptoethanol (Sigma) were added. The solution was vortexed and incubated at 
37°C for 60 minutes in a shaking incubator. 
3) The cells were pelleted by centrifugation again at 1500 rpm for 5 minutes and 
resuspended in 0.5 ml of 0.5% SDS, 100 mM Tris pH 8.0, 50 mM EDTA. After 
transfer to a 1.5 ml tube, the solution was incubated at 70°C for 20 minutes. 
4) After immersion in ice, 80 ,.il of 3M potassium acetatell.8 M formic acid was added 
and solution left on ice for 30 minutes. 
5) Following a 15 minute centrifugation in a microfuge (Centrifuge 5414; Eppendorf), 
the supernatant was transferred to a fresh 1.5 ml tube containing 1 ml of ethanol. 
6) The solution was mixed by inversion and centrifuged for 20 seconds in a 
microfuge. The resulting DNAIRNA pellet was drained and resuspended in 100 III of 
H 20. 
7) 40 III of 7.4 M ammonium acetate was added to the tube and left on ice for 20 
minutes. 0.5 ml of ethanol was added and mixed by inversion. The DNA was 
precipitated by centrifugation for 10 minutes in a microfuge. The pellet was washed 
with 70 % ethanol, air-dried until just moist and resuspended in 50 III of H20 
(approximately 100-200 ng/Ill of DNA). 
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2.3.5. Bacterial DNA (for BACs) 
DNA was extracted using the method provided by the supplier of the BAC clones 
(Research Genetics). A summary of the steps involved are indicated below: 
1) The cells (1.5 ml) in a 1.5 ml tube were centrifuged for 1 minute in a microfuge and 
the pellet resuspended in 100 III of 50 mM glucose, 25 mM Tris-Hcl pH 8.0, 10 mM 
EDT A pH 8.0 and placed on ice. 
2) 200 III of 0.2 M NaOH, 1 % SDS was added and the solution mixed by inversion 
(5-7 times) and placed on ice. 
3) After the addition of 150 III of potassium acetate pH 4.8, the solution was mixed by 
inversion and centrifuged for 6 minutes in a microfuge. 
4) The supernatant was transferred to a fresh tube and the DNA was precipitated by the 
addition of 1 ml of ethanol and pelleted by centrifugation for 6 minutes in a microfuge. 
5) After rinsing the pellet in 70 % ethanol, the DNA was resuspended in 20 J,1l of H20. 
2.3.6. Plasmid DNA (NME2 cDNA cloned in pCRIOOO vector 
(lnvitroaen)) 
Plasmid DNA was extracted using the Plasmid DNA Midi kit from Qiagen according 
to the manufacturer's recommended protocol. 
1) The bacterial pellet was resuspended in 4 ml of PI buffer (50 mM TrisIHCI, 10 mM 
EDTA, pH 8.0,100 Ilg/ml RNase A). 
2) After the addition of 4 ml of buffer P2 (200 mM NaOH, 1 % SDS), the solution 
was incubated at room temperature for 5 minutes. 
3) 4 ml of buffer P3 (2.55 M potassium acetate, pH 4.8) was added and the solution 
was mixed gently. The solution was then centrifuged at 15,000 rpm at 4°C for 30 
minutes in a Beckman 12-21 centrifuge. 
4) The supernatant was added to a Qiagen column (equilibrated with buffer QBT: 750 
mM NaCl, 50 mM MOPS, 15 % ethanol, 0.15 % Triton X-IOO) and allowed to flow 
through by gravity flow. 
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5) 10 ml of buffer QC (1.0 M NaCI, 50 mM MOPS, 15 % ethanol) was added and 
allowed to drip through the column. The DNA was eluted with the addition of 5 ml of 
buffer QF (1.25 M NaCl, 50 rnM MOPS, 15 % ethanol) to the column. 
6) The DNA was precipitated with 0.7 volumes of isopropanol and centrifuged at 
room temperature for 30 minutes at 1500 rpm in a Beckman GP Centrifuge. 
7) The DNA was washed with 70 % ethanol, air dried and resuspended in TE pH 8.0, 
to an approximate concentration of 1 mg/ml. 
2.3.7. Elution of NME2 DNA from aa:arose 
The NME2-specific DNA fragment (either after PCR amplification as described in 
section 2.6.2(1) or after restiction enzyme digestion as described in section 2.4.1) was 
excised from the gel in a minimum volume of agarose with a clean disposable scalpel 
and put into a 1.5 ml centrifuge tube. The DNA was purified from the agarose slice 
using the Geneclean Kit (BI0101 Inc.), according to the manufacturer's recommended 
protocol: 
1) Three volumes of Sodium Iodide was added to the DNN agarose block and 
incubated at 55°C for 10 minutes. 
2) 5 III of glassmilk suspension was added and the tube placed on ice for 5 minutes. 
3) After centrifugation in a microfuge for 5 seconds, the supernatant was removed. 
4) The pellet was washed with 200 III of New Wash. This was repeated three times. 
5) 5 III of H20 was added and the mixture incubated at 550 C for 5 minutes. 
6) After centrifugation in a microfuge for 30 seconds, the supernatant containing the 
DNA was removed. 
7) The yield of purified DNA was estimated on an agarose gel by comparison with 
known concentrations of DNA. 
2.4. Restriction Enzyme Analysis 
Restriction endonucleases were purchased from Gibco-BRL, New England Biolabs 
and the Boehringer Mannheim. Restriction enzyme digestions were performed using 
the buffers supplied by the manufacturers and according to their recommendations. 
49 
2.4.1 Restriction analysis of Plasmid DNA 
11lg of DNA was digested for 1 to 2 hours at 370 C using 10 to 15 units each of EcoRI 
and HindlII in a 20 J.tl reaction. After digestion, the plasmid DNA was electrophoresed 
as described in section 2.4.3 to distinguish the vector fragments from that of the 
cloned insert. The 507 bp cloned NME2 insert was excised from the gel as described 
in section 2.3.7. This DNA fragment was used as a NME2-specific DNA probe as 
described in section 2.5.2. 
2.4.2. Genomic DNA 
Genomic samples containing approximately 7-10 Ilg of DNA were digested for 3 
hours using 20-30 units of restriction endonuclease, usually in a 100 III reaction. After 
reducing the volume to approximately 20 J.tl in a Speedvac microconcentrator (Savant), 
the digested DNA was electrophoresed as described in the following section. 
2.4.3. Electrophoresis conditions 
After the addition of 3 III of loading buffer (0.25% Bromophenol blue, 0.25% xylene 
cyanol FF, 15% Ficoll in water), the digested DNA was electrophoresed through 
horizontal agarose gels (NBL or Scotlab) submerged in 1 X T AE (40 mM Tris-acetate 
pH 7.8, 1 mM EDTA pH 8.0) buffer. Genomic DNA was run at 1 to 2 v/cm and 
plasmid DNA was run at 3 to 5 v/cm. 0.8 % agarose gels made up in 1 X T AE buffer 
were used for most applications. 2 % agarose gels were used for D17S74 southern 
hybridisation for optimal allele separation as some of the alleles were small or of 
similar sizes. 
The 1 X TAE running buffer contained 0.5 mglml ethidium bromide which allowed 
the DNA fragments to be visualised using a UVP transilluminator. DNA fragment 
lengths were determined by using DNA standards of known size, for example A DNA 
digested with HindIII. Permanent records of the gels were obtained by photography 
through an orange membrane using a Polaroid Land camera and Type 57 film. 
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2.5. Southern Blottin2 (Southern. 1975) 
Southern blotting was used for the analysis of restriction enzyme digested genomic 
DNA (described in section 2.4.2). This method was used for genotyping individuals 
from breast and breast-ovarian cancer families using cloned DNA probes (sections 
2.2.7 and 3.2). It was also used for the chromosomal localisation of NME2 (section 
3.9). 
2.5.1. Transfer of DNA from a&arose &els 
After electrophoresis, the DNA was transferred to a Hybond N+ nylon membrane 
(Amersham International): 
1) The gel was soaked in 0.4 M NaOH for 20 minutes with gentle agitation. 
2) The gel was placed on a wick of 3MM blotting paper which had been soaked in 0.4 
M NaOH and draped over a reservoir of the same solution. The nylon membrane 
which had been pre-soaked in 0.4 M NaOH was placed on top of the gel, followed by 
a sheet of 3MM blotting paper, also soaked in 0.4 M NaOH. A stack of blotting towels 
was placed on top of the 3MM paper, followed by a glass plate and a 0.5-1kg weight. 
3) The denatured DNA was transferred to the membrane by capillary transfer in the 
NaOH for 3-16 hours. 
4) After blotting, the membrane was washed in 5 X sse (from a 20 X stock solution: 
3 M NaCl, 0.3 M Tris. sodium citrate pH 7.0) and wrapped in Saranwrap prior to use. 
2.5.2. Generation of labelled DNA probes 
The randomly primed labelling technique (Feinberg and Vogel stein, 1983) was used to 
generate radioactively labelled DNA fragments for use as probes in Southern blot 
analyses. This was performed using the Amersham Multiprirne kit according to the 
manufacturers protocol: 
1) 5- 50 ng of DNA resuspended in a suitable volume of H20 in a 1.5 ml tube was 
denatured by boiling for 5 minutes and placed on ice. 
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2) 10 III of Oligolabelling Buffer, 5 III of Primers (random hexamers), 5 III of [a._32p] 
dCTP (Amersham International) and 2 III of enzyme (klenow fragment of DNA 
polymerase J) was added to the denatured DNA and incubated at 37°C for 30 minutes. 
3) After labelling, the unincorporated dNTPs were removed by running the reaction 
mixture through a Sephadex G50 column (Pharmacia) equilibrated in 3 X SSe. 
4) The DNA probe was denatured by boiling for 5 minutes immediately prior to adding 
to the hybridisation mix (described in the following section). For D17S74, the probe 
was pre-competed (as described in section 2.5.6) before addition to the hybridisation 
mix. 
2.5.3. Hybridisation of labelled DNA probes to DNA immobilised on 
nylon membranes 
The hybridisation solutions used were as follows: 
Prehybridisation Solution 
5 X SSC 
10 X Denhardt's solution (see below) 
0.1% (w/v) SDS 
40 mM NaP04, pH 6.5 
0.1 mg/rnl sheared herring sperm DNA (Sigma) 
100 X Denhardt's Solution 
2% (w/v) BSA (Fraction V, Sigma) 
2% (w/v) Ficoll (Sigma) 
2% (w/v) Polyvinylpyrrolidone (Sigma) 
Hybridisation Solution 
Prehybridisation solution 
10% (w/v) Dextran sulphate 
Denatured DNA probe (see section 2.5.2) 
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1) The membrane (produced as described in section 2.5.1) was prehybridised for 2 to 
4 hours in 20 ml of prehybridisation solution at 650 e in a glass tube (Hybaid) in a 
rotating hybridisation oven (Hybaid). 
2) The prehybridisation mix was then removed and 20 ml of the hybridisation mix 
containing the denatured DNA probe was added. Hybridisation was performed for 
between 12-16 hours at 650 e in the rotating oven. 
3) After hybridisation, the hybridisation mix was removed and the membrane was 
washed in a metal staining tray with shaking. One 10 minute wash (0.2 X sse, 0.1 % 
(w/v) SDS) was performed at room temperature, then one 10 minute wash in a fresh 
batch of the same solution at 65°C. A higher stringency wash was performed if 
required (0.1 % sse, 0.1 % SDS at 65 °e). 
NB. Some hybridisations were carried out using the buffer (7 % SDS, 10 % PEG 
6000, 0.1 mglml sheared herring sperm DNA (Sigma) for both prehybridisation and 
hybridisation. 
2.S.4.Autoradioeraphy 
The membrane was wrapped in plastic fIlm (Saranwrap), placed in an x- ray fIlm 
cassette and exposed to Kodak X-OMAT AR fIlm at -70oe for 1-5 days to visualise 
the hybridised fragments. The fIlm was developed using a commercial fIlm developing 
system (Fugi). 
2.5.5. Removal of Radiolabelled Probes 
Membranes were stripped of radioactive probes by incubation in boiling 0.05% SDS 
for 30 minutes. The stripped membranes were soaked and stored in 2 X sse at 4°e 
until ready for reuse. 
2.5.6. Competition hybridisation 
250 ~g of sonicated human placental DNA was added to the radioactively-labelled 
probe cMM86 (D17S74) and boiled for 10 minutes. After a 1 hour incubation at 650e, 
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the probe was then added to the hybridisation solution. This was used to "compete" 
out the repetitive sequences within the probe, leaving only unique DNA sequences 
available for hybridising to the genomic DNA on the membrane. 
2.6. DNA Amplification by the Polymerase Chain Reaction 
The polymerase chain reaction (PCR), developed by Saiki et al. (1988), was used to 
amplify DNA between two regions of known sequence. 
2.6.1. Basic Protocol 
The general guidelines for designing each oligonucleotide primer pair was that each 
primer was about 50% GC rich, non-self complementary and non-complementary to 
each other. Ideally the oligonucleotides were between 17-24 nucleotides long with a 
melting temperature of about 600C (assuming A, T = 2°C: G, C = 40C). 
Microsatellite marker oligonucleotide primer sequences were obtained from the 
literature, for example, Dib et al (1996). 
PCR was performed in either 25,50 or 100 ~l reactions containing 30-50 ng template 
DNA, 1 X PCR buffer (Boehringer Mannheim), 2Opmol of each primer, 200mM 
dNTPs (Boehringer Mannheim) and 1 unit of Taq polymerase (Boehringer Mannheim) 
on a GeneAmp 9600 thermal cycler (Perkin-Elmer Cetus). Reaction mixtures were 
generally given 35 cycles of 30 seconds at 94oC, 30 seconds at 550 C and 30 seconds 
at 72oC. 
17 ~l of the PCR amplification reaction (plus 3 ~l of loading buffer: 0.25% (w/v) 
Bromophenol blue, 0.25% (w/v) xylene cyanol FF, 15% (w/v) Ficoll in water: all 
obtained from Sigma), was run on a 2 % agarose gel made up in 1 X TBE buffer 
(0.045 M Tris-borate, 0.001 M EDTA). 0.5 mg/rnl ethidium bromide in the 1 X TBE 
running buffer allowed the DNA fragments to be visualised using a UVP 
transilluminator. DNA fragment lengths were determined by using DNA standards of 
known size, for example, q,x 174 DNA digested with HaeIll. Permanent records of the 
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gels were obtained by photography through an orange membrane using a Polaroid 
Land camera and Type 57 film. 
2.6.2. NME2 localisation 
1) Generation of human NME2 peR fraa:ment for clonina: 
Using the published NME2 cDNA sequence (Stahl et ai, 1991), oligonucleotide 
primers were designed. The primer sequences used were primer A: 5' ATC CCT TCf 
GCT CTC CCA GC 3' (nucleotide position 16-35 bp) and primer B: 5' GAC CCA 
GTC ATG AGe ACA AG 3'(nuc1eotide position 522-503 bp). These primers PCR 
amplified the predicted 507 bp product (data not shown) of the coding sequence from a 
human cDNA library derived from HeLa cells that had been stress induced by heat 
shock (gift from Dr. S. Keyes). The PCR amplification conditions were as described 
in section 2.6.1. The PCR product was gel purified and cloned as described in 
sections 2.3.7 and 2.9, respectively. 
2) Localisation of human NME2 by PCR amplification. 
The PCR amplification conditions were as described in 2.6.1., except the annealing 
temperature for the cycling was at 60°C. The oligonucleotide primer sequences are as 
indicated in Figure 3.9 in Chapter 3. 
2.6.3. PCR amplification products for seguencina: EDH17Bl and 
EDH17B2 
Oligonucleotide primer sequences are as indicated in Figure 3.11 (b) in Chapter 3 and 
the combinations of primers used to generate EDHI7Bl- and EDH17B2-specific PCR 
amplification products is as described in section 3.12 and Figure 3.11(a). For primer 
sets AI C and BI D, the PCR amplification conditions were as described in section 
2.6.1., except the extension time (72°C) for the cycling was 2 minutes. For primers E 
to M, one of the oligonucleotides from each pair used for PCR amplification was 
biotinylated at the 5' end and the PCR amplification conditions were as described in 
section 2.6.1. 
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2.6.4. Brush 1 localisation 
Primer sequences were designed from the published sequence of Brush 1 (Schott et ai, 
1994) and were as follows: primer A: 5' GTT TAA TGT CTC CTA AGC 3' 
(nucleotide position 965-983 bp) and primer B: 3' CAT CAG TGT AGC CAA GC 3' 
(nucleotide position 1128-1112 bp). The PCR amplification conditions were as 
described in section 2.6.1, except the annealing temperature for the cycling was 600C. 
The primers amplified the expected 162 bp when human genomic DNA was the 
template in the PCR amplification reaction. 
2.6.5. D13S178E and D13S181E localisation 
Primer sequences for D13S178E (clone ESTOO273) were designed from the available 
published DNA sequence (accessed via the Genome Database) and were primer A: 5' 
CCC AGG TGT GCA OCT AAC CT 3' (nucleotide position 32-51 bp) and primer B: 
5' CGG TAA GTA TAT TCA TIT CTG 3' (nucleotide position 239-219 bp). Primer 
sequences for D13S181E (clone ESTOO297) were as described in Hawthorn and 
Cowell (1996). The PCR amplification conditions for both gene loci were as described 
in section 2.6.1. 
2.6.6. D13S178E cDNA analysis 
The same pair of primers used for the localisation of DI3S178E (previous section) 
were used to PCR amplify from a number of tissue-specific cDNA libraries (Clontech; 
obtained from L. Rooke, Human Genetic Resources). A 100 III aliquot from each 
cDNA library was boiled for 10 minutes (to lyse bacterial cells) before 2 III was added 
to each PCR reaction. The PCR amplification conditions were as described in section 
2.6.1. 
2.6.7. Envoplakin localisation 
Oligonucleotide primers were designed from the last predicted exon of the Envoplakin 
cDNA sequence. This unpublished sequence was obtained from C. Ruhrberg and Dr. 
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F. Watt, ICRF Keratinocyte Laboratory, Lincoln's Inn Fields, London. The primer 
sequences used were 5' GCA GGA GGA GTC GAA GCT G 3' (nucleotide position 
4937-4955 bp) and 5' GCA GGC GAG GAA GAG CAT C 3' (nucleotide position 
5072-5054 bp). The PCR amplification conditions were as described in section 2.6.1, 
except the annealing temperature for the cycling was at 600 C. 
2.7. Detection of alleles at microsatellite marker loci 
Three methods of detection were used and are described below: 
2.7.1. Ethidium bromide detection 
This method is published in Watkins et al (1991). 
1) 3 III of loading buffer (0.25% Bromophenol blue, 0.25% xylene cyanol FF, 15% 
Ficoll in water) was added to 17 III of each PCR amplification reaction. 
2) Products were run on a 6% non-denaturing polyacrylamide gel (Protogel: Flowgen) 
in 1 X TBE running buffer using a 2lcm X 50cm sequencing electrophoresis kit (Bio-
Rad) at 50 W. Gel thickness was doubled to 0.8mm for increased rigidity as the gel 
has to be manipulated in the ethidium bromide detection step (see below). A DNA 
standard of known size, for example <j>x174 DNA digested with Haem (Boehringer 
Mannheim), was also loaded to aid in gel orientation and allele size estimation. The 
bromophenol blue (in the loading buffer) was used for estimating the gel running times 
to achieve good separation of different sized PCR amplification products. For 
example, good allele separation for a microsatellite marker locus with alleles in the 
range of 150-180 bp was accomplished when the bromophenol blue loading dye was 
at the bottom of"the gel. 
3) After gel running, the portion of the gel with the PCR amplification products 
(usually the middle third) was removed by placing a piece of blotting paper (Whatman) 
on the gel and then peeling the gel (adhered to the blotting paper) away from the glass 
plate. The gel was stained for 5 minutes in 0.5 mglml ethidium bromide in water and 
the PCR amplification products visualised using a UVP transilluminator. A permanent 
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record of the gel was obtained by photography through an orange membrane using a 
Polaroid Land camera and Type 57 film. 
4) The alleles were scored by eye with an arbitrary numbering system. Confirmation 
of genotyping was performed by loading the samples in a different lane order and! or 
pooling samples in the same lane. 
2.7.2. Radioactive detection 
1) 2 ~l of the PCR reaction was mixed with 3 ~l of loading buffer (95% (w/v) 
Formamide, 0.05% (w/v) xylene cyanol , 0.05% (w/v) bromophenol blue, 20 mM 
EDT A pH 8.0), incubated at 95 oC for five minutes and then placed on ice. 
2) The PCR amplification products were run on a 6% denaturing sequencing gel 
(Sequagel, Flowgen) in 1 X TBE running buffer using a 21cm X 50cm sequencing 
electrophoresis kit (Bio-Rad) at 50 W (or a 44 cm X 50 cm sequencing electrophoresis 
kit (Bio-Rad) at 100 W). As in section 2.7.1., the position of the bromophenol blue 
(in the loading buffer) was used for estimating gel running times. 
3) The DNA was transferred by blotting in 10 X TBE for 2-3 hours onto Hybond N+ 
membrane (Amersham International). This was achieved by placing the membrane 
(previously soaked in lOX TBE) onto the gel, followed by three pieces of blotting 
paper (Whatman) and the glass plate of the sequencing apparatus (the one not attached 
to the gel). 
4) The membrane was washed in 0.4 M NaOH for 15 minutes and then in 2 X SSC 
for 10 minutes. After washing, the membrane was wrapped in Saranwrap until 
hybridisation. 
5) One of the PCR primers was radioactively labelled using a terminal transferase (TT) 
labelling kit (Gibco) according to the manufacturer's recommended protocol: 
A 50 ~l reaction containing: 100 ng oligonucleotide primer, 1 X TT buffer, 3 ~l of [a-
32p] dCTP (Amersham International) and 1 ~l of Terminal Transferase was incubated 
for 30 minutes at 370C. 
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6) The end-labelled oligo was hybridised to the membrane for 2 to 4 hours at 42°C in 
20 ml of hybrid is at ion solution (7 % SDS, 10 % PEG 6000, 250 mM NaCI, 12 mM 
phosphate buffer, pH 7.0) in a rotating hybridisation oven (Hybaid). 
7) After hybridisation, the membrane was washed in a metal staining tray with 
shaking. One 10 minute wash (2 X SSC, 0.1 % (w/v) SDS) was performed at room 
temperature. 
8).The membrane was wrapped in plastic film (Saranwrap), placed in an x-ray film 
cassette and exposed to Kodak X -OMA T AR film at -70°C for 3-12 hours to visualise 
the hybridised PCR amplification fragments. The film was developed using a 
commercial film developing system (Fugi). 
9) The alleles were scored by eye with an arbitrary numbering system. Confirmation 
of genotyping was performed by loading the samples in a different lane order and/or 
pooling samples in the same lane. 
2.7.3. Fluorescence detection 
One of the two oligonucleotide primers used in the PCR amplification reaction was 
labelled at the 5' end with one of two fluorescent dyes: FAM (blue) or HEX (green). 
0.5 III of each PCR amplification product(s) was mixed with 0.5 III of a ROX(red)-
labelled internal DNA size standard (GS2500 or GS350; Perkin Elmer) and 2 III of 
deionised formamide. Prior to loading, the PCR products were denatured for 5 
minutes at 95°C and plunged into ice. Samples were run on a 12 cm (well to read) 
denaturing polyacrylamide gel (Sequagel) at 800 V for 4- 5 hours (depending on allele 
size) on a 373A Automated DNA Sequencer running Genescan software (Applied 
Biosystems). 
Alleles were analysed using Genotyper software (Applied Biosystems) according to 
the manufacturer's protocol. As there is an internal DNA size standard in each lane, 
each allele could be accurately sized in base pairs. Multiplexing of PCR products was 
also performed by loading microsatellite markers of diferent allele size ranges and 
fluorescent dye labelling in the same lane. Alleles were visualised in a graphical 
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fonnat, with a peak representing an allele. This method was used predominantly in this 
study after the laboratory acquired the 373A DNA Sequencer and the appropiate 
computer software (Applied Biosystems). 
2.8. Assessment of allele loss 
Allele loss was determined as complete or almost complete reduction to hemizygosity 
in constitutively heterozygous individuals. Complete loss of the deleted allele was 
rarely evident due to the presence of a small percentage of contaminating nonnal cells 
(stroma) in each tumour sample. Loss was scored using the allele detection systems 
described in sections 2.7.1 and 2.7.2 if there was a clear difference in allele intensity 
in the tumour profile compared to those for the nonnal DNA sample. Loss was scored 
using the allele detection system described in section 2.7.3 if there was a clear 
difference in allele peak: heights in the tumour profile compared to those for the nonnal 
DNA sample. 
2.9. NME2 cionin2 
The 507 bp NME2 PCR amplified fragment (as described in section 2.6.2(1» was gel 
purified (as described in section 2.3.7) and cloned into the plasmid vector pCR ™ 1000 
using the T A cloning kit (Invitrogen). 
2.9.1. Li2ation 
The ligation reaction was perfonned in a 10 Jll volume according to the manufacturer's 
recommended protocol with an approximate 1: 1 molar ratio of vector to PCR 
amplification product: 
50 ng of vector 
25 ng of NME2 PCR amplification product 
1 X ligation buffer 
1 JJ.l of T4 DNA ligase 
The reaction was incubated for 12 hours at 12°C. 
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2.9.2. Transformation 
Transformation of E.coli was as recommended by the manufacturer's (Invitrogen) 
recommended protocol: 
1) 2 III of 0.5 M ~-mercaptoethanol was added to the vial of competent cells, INV uF 
(all supplied in kit). The cells were kept on ice. 
2) 1 j..tl ofthe ligation reaction (section 2.9.1) was added to the vial of cells and placed 
on ice for 30 minutes. 
3) The cells were then given a 1 minute "heat shock" at 42°C, and then plunged into 
ice for 2 minutes. 
4) 450 J.11 of SOC media (2% Bacto tryptone (Difco), 0.5% Bacto yeast extract 
(Difco), 10 mM NaC!, 2.5 mM KC1, 10 mM MgC12, 10 mM MgS04, 20 mM glucose) 
was added to the vial and incubated at 37°C in a shaking incubator for 1 hour. 
5) 10 III of the transformation mix was spread onto a 10 cm diameter LB (1 % (w/v) 
Bacto-tryptone (Difco), 0.5 % (w/v) Bacto-yeast extract (Difco), 1 % (w/v) NaC!, pH 
7.0 with NaOH, 1.5 % (w/v) Bacto-agar (Difco)) agar plate containing 50 Ilg/ml of 
kanamycin (Sigma). This antibiotic selected for bacterial cells carrying the plasmid. 
Prior to plating, 25 III of X-Gal (40 mg/ml stock solution: Boehringer Mannheim) was 
spread over the plate and allowed to diffuse into the agar over a period of one hour. X-
Gal allows blue/white colour selection (recombinants are white). 
6) After an overnight incubation at 37°C, a number of white colonies were selected 
and the cells grown up in 400 ml of L-broth (as for LB agar but without the Bacto-
agar) containing 50 Ilglml of kanamycin. Plasmid DNA was extracted as described in 
section 2.3.6. Positive clones were identified by restriction enzyme digestion as 
described in section 2.4.1. 
2.10. Seguence Analysis of DNA 
DNA sequencing was performed as described for the Sequenase system (United States 
Biochemicals), which is a modification of the chain termination protocol (Sanger et ai, 
1977). 
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2.10.1.Denaturation of Plasmid DNA 
This method was used for the preparation of denatured plasmid DNA containing the 
cloned 507 bp NME2 PCR amplification product. 
2 Ilg of template DNA was denatured in a 10 X volume of 0.2 M NaOH and 0.2 lIM 
EDTA pH 8.0, at 37°C for at least 30 minutes. The DNA was precipitated by the 
addition of 1111 th volume of sodium acetate pH 4.5 and 2 volumes of ethanol. After 
centrifugation the resulting pellet was washed with 70% ethanol, dried briefly and 
resuspended in 7 III of H20 for direct DNA sequencing (section 2.10.3). 
2.10.2. Dynabead separation of double stranded DNA 
Dynabeads (Dynal) were used to generate single-stranded DNA for sequencing using 
the manufacturer's recommended protocol. This method was used for the sequence 
analysis of EDH17Bl and EDH17B2. One of the oligonucleotides in the PCR 
amplification reaction was biotinylated at the 5' end (section 2.6.3.). 
1) 30 III of Dynabeads were washed in 60 III of TES (10 mM Tris-HCI pH 8.0, 1 lIM 
EDTA, 100 mM NaCl) in a 1.5 rnl tube. After each wash, the tube was placed in a 
magnet (Dynal) to capture the beads. 
2) 40 III of PCR amplification product was added to the beads and incubated at 28°C 
for 15 minutes. 
3) The tube was placed on the magnet and the supernatant removed. The beads were 
washed again with TES. 
4) 30 III of 0.15 M NaOH was added, followed by 5 minutes incubation at 28°C. 
5) The tube was placed on the magnet and the supernatant removed. The biotinylated 
DNA strand remained in the tube. 
6) The beads/ DNA mixture was washed 5 times with H20 and then resuspended in 7 
III of H20 for direct DNA sequencing (section 2.10.3). 
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2.10.3. Sequencin.: Reactions 
Sequencing reactions were performed using the Sequenase kit according to the 
manufacturer's recommended protocol. Composition of the solutions used are below 
the protocol summary. 
1) For the annealing reaction, 7 III of DNA template (either from sections 2.10.1 or 
2.10.2) was mixed with 2 pm of primer and 1 X annealing buffer in a 10 III reaction. 
The oligonucleotide primer sequences for sequencing EDH17B 1 and EDH17B2 PCR 
amplification products are as described in Chapter 3: section 3.12. The 
oligonucleotides, T7 Promoter and M13 Forward Primer were used to confim the 
integrity of the cloned NME2 DNA fragment. These correspond to vector sequences 
flanking either side of the cloning site. 
2) The annealing reaction was incubated at 6SoC for 2 minutes before cooling to room 
temperature for S minutes. 
3) For the labelling reaction 10 III of the annealed template/primer solution was mixed 
with 1 III of DTI (0. 1M), 2 III of labelling mix (SX), SmCi of [35S] dATP as 
(Amersham International) and -3 units of Sequenase Version 2.0 (2 III of an 8-fold 
dilution in TE pH 7.6). This reaction was incubated at room temperature for 3 
minutes. 
4) 3.5 III of the labelling reaction was added to 2.S III of each of the four dideoxy 
termination mixes, which had been prewarmed to 37°C, in four separate tubes. These 
mixtures were incubated for 3 minutes, before the reactions were stopped by the 
addition of 4 III of stop solution. 
SX Annealing Buffer 
200 mM Tris.HCl pH 7.S 
100 mMMgCI2 
2S0mMNaCl 
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5X Labelling Mix 
7.SIlM dCTP 
7.SIlM dGTP 
7.SIlM dTTP 
ddA Termination Mix 
80~dATP 
80 liM dCTP 
80~dGTP 
80~dTTP 
8~ddATP 
50~NaCI 
ddG Termination Mix 
80 J.LM dATP 
80 J.LM dCTP 
SO~dGTP 
SO~dTTP 
S~ddGTP 
50~NaCI 
Stop Solution 
95% (v/v) formamide 
20 mM EDT A pH S.O 
0.05% (w/v) Bromophenol Blue 
0.05% (w/v) Xylene Cyanol FF 
2.10.4. SeguencinK Gels 
ddC Termination Mix 
80~dATP 
80~dCTP 
80 liM dGTP 
80~dTTP 
8 liM ddCTP 
50~NaCl 
ddT Termination Mix 
80~dATP 
80 liM dCTP 
SO j.lMdGTP 
SOIiMdTTP 
8~ddTTP 
50 j.lMNaCl 
Heat-denatured samples were run on a 6 % denaturing sequencing gel (Protogel, 
Flowgen) in 1 X TBE running buffer using a 21 cm X 50 cm sequencing 
electrophoresis kit (Bio-Rad) at 50 W. The wells were formed with a sharks tooth 
comb. After running, the gel was removed from the glass plate with a piece of blotting 
paper and fixed in a I: 1 mixture of 10% acetic acid: 10% methanol for 10 minutes. The 
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gel surface was covered in cling film and the gel was dried for 1 to 2 hours (Bio-Rad 
Model 583 gel dryer, cycle two). Sequencing gels were then autoradiographed and 
exposed at room temperature overnight or for several days. 
2.11. Yeast Artificial Chromosome (YACl identification 
Y ACs were identified from the whole genome CEPH (Centre d'Etudes du 
Polymorphisme Humaine) library which contains approximately 33, 000 clones with 
an average human insert size of 0.9 Mb, representing the equivalent of ten haploid 
genomes (Cohen et ai, 1993). This was achieved by two approaches, direct selection 
and PCR library screening: 
2.11.1. Direct selection 
To date, 225 YAC contigs spanning an estimated 75 % of the human genome have 
been constructed (Chumakov et ai, 1995). The CEPH Y AC database was searched 
using Genethon' s Quickmap program suite via the computing facility accessed at the 
Human Genome Mapping Project (HGMP) Resource Centre, Hinxton Hall, 
Cambridgeshire, UK. This allowed direct selection of Y ACs which were likely to 
contain microsatellite marker loci mapping in the two regions of interest (and Y ACs 
which may overlap with these clones) in this study (BRCA2: Chapter 4 and TOC: 
Chapter 6). Each identified Y AC clone (given a grid reference number representing its 
position in the library) was ordered from the HGMP Resource Centre (section 2.2.8). 
YACs were propagated and manipulated as described in section 2.3.4. 
2.11.2. YAC library screenin& by peR amplification 
CEPH Y AC DNA library pools were obtained from Research Genetics, Huntsville, 
USA. Microsatellite marker loci (STSs) were screened across the YAC DNA samples 
by PCR amplification as described in section 2.6.1 in a PCR reaction volume of 25 ,.Ll. 
Presence or absence of STS-specific PCR amplification products was determined by 
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ethidium bromide detection of DNA on 2% agarose gels (section 2.4.3). The 
identification of each Y AC involved a two tier screening procedure: 
1) Primary screening of YACs. 24 block pools were screened by PCR 
amplification with each block containing 8 pooled microtitre plates of Y ACs. A 
positive detennined which block of Y ACs to screen in the next tier. 
2) Secondary screening of Y ACs. One block is divided into 28 pools which are 
then screened by PCR amplification to give the exact position of the Y AC in one of the 
8 microtitre plates within that "block". Three positive PCR amplification products 
indicate the plate, and the column and row within that plate in which the Y AC is 
located. Any identified Y AC clone could then be obtained from the HGMP Resource 
Centre (or Research Genetics) as in section 2.2.8. 
2.11.3. Growth of Y ACs 
1) Platina: 
Each Y AC was streaked on agar (see below) in a petri dish and grown up at an 
incubation temperature of 300 C for 1- 2 days. An individual clone was "picked" with a 
sterile pipette tip and inoculated into 5 mls of broth and grown up as described in the 
following section. 
AGAR: 0.8% yeast nitrogen base (Difco), 0.01 % adenine HCL, 0.0055% tyrosine, 
1.1 % casamino acids (Difco) and 2% agar. After autoclaving, 2% membrane sterilized 
dextrose and 0.005% ampicillin (Sigma) was added. 
2) Broth 
Y ACs were grown up at 30 °c in a shaking incubator for 1-2 days in 5 ml of broth (as 
for the agar described above but without the addition of agar). Cells were then pelleted 
and DNA extracted (as described in section 2.3.4). A stock of cells for each YAC was 
stored at -800 C in 20% glycerol. 
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2.12. RAC library screenina: by PCR amplification 
BAC DNA library plates and clones were obtained from Research Genetics, 
Huntsville, USA. Microsatellite marker loci (STSs) and Envoplakin mapping 
oligonucleotides (see section 2.6.7) were screened across the BAC DNA samples by 
PCR amplification as described in section 2.6.1, in a PCR reaction volume of 25 Ill. 
Presence or absence of STS-specific PCR amplification products was determined by 
ethidium bromide detection of DNA on 2 % agarose gels (see section 2.4.3). The 
identification of each BAC involved a two tier screening procedure: 
1) Plate screen of BACs. 24 pools were screened by PCR amplification with each 
pool containing 384 BAC clones. A positive determined which plate of BACs to 
screen in the next tier. 
2) Individual BAC clone screen. PCR screening of the 384 BACs within each 
positive plate was performed as follows: 
a) A 384-pin device (Genetix) was used to spot the clones onto a LB agar plate with 
12.5 Ilg/ml of chloraphenicol (Sigma) added to select for bacterial cells containing the 
vector. These clones were grown up overnight in a 37°C incubator. 
b) A small amount of each clone was directly added to a 25 III PCR reaction (as 
described in section 2.6.1). A pooling strategy was used to minimise the number of 
PCR reactions required before identification of the individual positive BAC clone. A 
small amount of the positive BAC clone was used to inoculate 5 ml of L-Broth with 
12.5 Ilglml of chloraphenicol added and grown up overnight in a 37°C shaking 
incubator. DNA was extracted as described in section 2.3.5. 
2.13. LinkaKe analysis 
Linkage analyses for the breast cancer study was performed by Prof. T. Bishop and 
G. Crockford (both from ICRF Genetic Epidemiology Unit). S. Bryant (ICRF Human 
Genetic Resources) performed the analyses for the NEPPK study. The models used in 
the analyses are briefly described below: 
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2.13.1. BRCAI 
2.13.1.1. Two-point Iinka2e analysis 
Lod score analysis was performed using the MLINK program of LINKAGE version 
5.2 and FASTLINK version 2.3P (Lathrop et ai, 1988; Schaffer et ai, 1994). 
Statistical analysis was conducted based on the CASH model derived by Claus et ai, 
(1991), modified as described in Easton et ai, (1993b). Breast cancer susceptibility 
was modelled as an autosomal dominant allele, with a population frequency of 0.0033. 
Age-specific liability classes were incorporated into the analysis accumulating to an 80 
% breast cancer risk at age 70. 
2.13.1.2. Multipoint Iinka2e analysis 
Statistical analysis was performed as described in the previous section. Multipoint 
analysis was conducted using microsatellite marker loci proximal (either D17S250, 
THRAI, D17S857, D17S800 or D17S776), intragenic (D17S855) and distal (either 
Dl7S579 or D17S791) to BRCAI. Allele loss was incorporated into the analysis 
based on a model proposed by Dr. D. Easton and Prof. T. Bishop (personal 
communication). Basically, if allele loss was detected in a tumour, the affected women 
displaying loss was replaced in the pedigree by a person of unknown phenotype with 
the same genotype information. This individual was then given an imaginary offspring 
whose affected status was identical to the original individual replaced in the analysis. 
This offspring had a genotype that gave unequivocal evidence that the retained alleles 
from the allele loss analysis were transmitted to this individual. 
2.13.2. NEPPK 
Linkage analysis was performed with the MLINK module of the F ASTLINK software 
package version 2.2 (Cottingham et al, 1993), assuming an autosomal dominant 
inheritance for NEPPK, with a gene frequency of 0.003 and a penetrance of 100%. 
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Allele frequencies for the rnicrosatellite marker loci were either computed from the data 
or else were estimated to be equifrequent. 
2.14. Estimation of allele frequencies 
The frequency of the disease allele shared at the D 17S 1603 locus for the focal 
NEPPKI oesophageal families from the UK and Germany was estimated as follows. 
CEPH DNA samples (section 2.2.9) were used as templates in PCR amplification 
reactions using D17S1603 primers as described in section 2.6.1. Alleles were detected 
and sized as described in section 2.7.3. In total 33 of these 'random" individuals were 
genotyped at this locus. The allele frequencies were calculated as a fraction of the 
number of chromosomes with each allele over the total number of chromosomes 
analysed (66 in total). 
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CHAPTER 3: GENETIC MAPPING OF BRCAI 
3.1. Introduction 
In this chapter, genetic analysis of the long ann of chromosome 17 in sixteen breast 
and breast-ovarian cancer families was conducted to confinn linkage to the putative 
breast cancer predisposition locus, BRCA 1, and to identify any recombinants which 
may reduce the region in which this gene lies. The focus for this study was a large 
breast-ovarian cancer family designated BOV3. Analysis and exclusion of a number of 
candidate genes for BRCA 1 was perfonned. 
3.2. Linkaa:e analysis of 16 breast and breast-ovarian cancer families 
17q linkage analysis was conducted on 16 families, selected from a set of 180 
ascertained as described in section 2.1.1. These families were chosen as being the 
most infonnative for linkage studies by the following criteria: 
(i) consistency with dominant inheritance for early onset breast or breast- ovarian 
cancer 
(ii) availability of DNA samples from family members, m particular, affected 
individuals 
Thirteen of these pedigrees were classified as site-specific breast cancer families due to 
the presence of breast cancer in noticeable excess over the expected incidence of 
sporadic occurrence. The remaining three families were classified as breast-ovarian 
cancer, due to the presence of one or more women who are at high risk of being gene 
carriers (25% or more, as determined by pedigree analysis) who had developed 
ovarian cancer. 
Lymphocyte DNA samples (see sections 2.2.1, 2.3.1 and 2.3.2) from infonnative 
family members were genotyped (as described in sections 2.5, 2.7.1 and 2.7.2) from 
a selection of 17 DNA marker loci mapping to the long arm of chromosome 17 (Figure 
3.1). These loci span a sex-averaged genetic distance of approximately 50 cM (Cox et 
ai, 1994). Statistical analysis was perfonned by Prof. T. Bishop and O. Crockford 
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following the model described in section 2.13.1.1. Two-point LOD scores for some of 
the DNA marker loci are shown as an aggregate for all families analysed and, for the 
more informative markers, by family in Table 3.1. 
13 MR322 
P 12 0178250 THRAI 
IL2 0178579 
0178190 
11.2 GIP 
12 0178293 
21.2 0178588 -SOcM 
21.3 NME COLlAl q 22 017874 
0178178 
23 MPO 
24 0178308 
GH 
25 017S587 
017S4 
17 
Figure 3.1. Genetic map of DNA marker loci mapping to the long arm of 
chromosome 17. Chromosome 17 ideogram is shown to the left and the genetic 
order of the seventeen DNA marker loci used in this study shown to the right. 
These marker loci span a genetic disance estimated to be approximately 50 cM 
(from Cox et ai, 1994). The DNA marker locus D17S74, to which initial evidence 
of linkage to breast cancer susceptibility was observed, is also shown. 
The Variable Number Tandem Repeat (VNTR) DNA marker locus, 017S74, 
originally indicating linkage to BRCAI (Hall et aI, 1990), provided weak evidence for 
linkage to the disease in these families with a maximum aggregate LOD score of 0.92 
at a recombination fraction of 0.20. However, the LOD scores for some of the DNA 
marker loci proximal to D 17S74 suggested that a breast cancer susceptibility gene in a 
number of the ICRF families may be located more centromeric than D 17 S7 4. The 
strongest evidence for linkage to the disease was from the large breast/ovarian 
pedigree, BOV3, with the highest LOO score of 2.35 at a recombination fraction of 
0.001 at the NMEllocus. The magnitude of this LOO score implied that cancer in this 
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Table 3.1. Two-point LOD scores for 17g DNA marker 
loci seKreKatinK in 16 breast cancer families 
Marker Family LOO score at recombination fraction of: 
.001 .01 .05 .10 .20 
1HRAl 
BOV3 .59 .58 .52 .45 .31 
0175579 
BOV3 1.58 1.72 1.89 1.83 1.45 
BC19 -.22 -.20 -.14 -.10 -.04 
BC1 -.14 -.13 -.09 -.06 -.02 
BC2 -.23 -.21 -.17 -.13 -.07 
BC3 .23 .23 .21 .18 .12 
BC9 .09 .09 .07 .05 .03 
BC12 .15 .15 .13 .11 .07 
BC14 .21 .20 .17 .14 .08 
BC15 .19 .19 .16 .13 .08 
BC20 -.60 -.55 -.41 -.28 -.14 
BC22 .07 .07 .06 .05 .03 
BC23 .22 .21 .16 .12 .05 
10fAL 1.58'" 1.77 2.07'" 2.05'" 1.64 
0175588 
BOV3 2.11 2.06 1.88 1.65 1.14 
other families .16 .23 .41 .48 .40 
10fAL 2.27'" 2.29 2.29 2.13 1.54 
NME1 
BOV3 2.35 2.30 2.09 1.82 1.27 
BC19 .34 .33 .28 .22 .13 
BC1 -.14 -.13 -.10 -.06 -.02 
BC2 .21 .20 .18 .15 .09 
BC3 .57 .55 .49 .41 .26 
BC7 -.37 -.35 -.27 -.20 -.10 
BC12 -.15 -.15 -.13 -.10 -.06 
BC15 .13 .13 .11 .09 .05 
BC20 .46 .45 .40 .34 .23 
BC23 .02 .02 .02 .01 .01 
BOV2 .20 .19 .16 .13 .08 
10fAL 3.63'" 3.56'" 3.25'" 2.81 1.94 
017574 
BOV3 -.15 .35 1.03 1.26 1.19 
other families -1.15 -.1.08 -.83 -.58 -.27 
10fAL -1.30 -.73 .20 .68 .92 
.30 
.19 
.93 
-.01 
.00 
-.03 
.06 
.01 
.03 
.03 
.04 
-.06 
.01 
.01 
1.03'" 
.60 
.23 
.83 
.71 
.06 
.00 
.04 
.13 
-.04 
-.03 
.02 
.11 
.00 
.04 
1.04 
.85 
-.13 
.72 
* entries do not exactly sum to "total" because of rounding error. 
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.40 
.09 
.37 
.00 
.00 
-.01 
.02 
.00 
.01 
.01 
.01 
-.01 
.00 
-.01 
.38'" 
.14 
.06 
.20 
.25 
.01 
.00 
.01 
.03 
-.01 
-.01 
.01 
.03 
.00 
.01 
.29'" 
.39 
-.07 
.32 
family is highly likely to be due to BRCAL NMEI maps centromeric to D17S74, with 
a genetic distance of 3cM in males and l1cM in females (Easton et al. 1993b). The 
highest aggregate LaD score was also obtained at the NMEIlocus (3.63 at e =0.001). 
Although the majority of evidence came from the BOV3 family, five other families 
gave small positive LaD scores at NMEI: BCI9, BC3, BOV2, BC2 and BC20 with 
maximum LaD scores of 0.34, 0.57, 0.20, 0.21 and 0.46 at a recombination fraction 
of 0.001, respectively. Multilocus haplotypes were constructed for the BOV3 family 
and the latter five families in an effort to define more precisely the region in which 
BRCAI may lie. The most informative of these families are discussed below (Figures 
3.2, 3.3). 
3.2.(3) BOV3 
Haplotype data for members of the BOV3 family is shown in Figure 3.2. A number of 
recombination events with the disease and the DNA marker locus, MR322, suggested 
that the disease gene lay distal to this centromeric marker, with affected individuals 
either bearing a "1" allele ( 3540, 3563, 3550 and 3566) or a "2" allele (3677 and 3684) 
or a "3" allele (3543) on the disease chromosome. The rnicrosatellite marker locus, 
DI7S250 which maps distal to MR322, revealed no recombination with the disease. 
For example, D 17S250 had a "1" allele shared by all affected individuals tested which 
suggested that the recombination event had been resolved proximal to this locus. 
However, Dl7S250 was homozygous for the "1" allele in a number of individuals 
which could mask potential recombination events. The telomeric boundary for BRCAI 
appears proximal to D 17S74 which shows clear recombination events within the 
family: 3563 has the "5" allele and the mother-daughter pair (3677 and 3684) share the 
"1" allele whilst the affected individuals (3540, 3550, 3566, 4351 and 4352) share a 
"6" allele at this locus on the disease chromosome. These cross-overs appear to be 
resolved at the NMEI locus with all typed affecteds bearing a "1" allele on the putative 
disease chromosome. The ovarian cancer case 3552 shared the disease haplotype distal 
to the marker Dl7S588 which suggested that BRCAI lay telomeric to this marker 
locus. Her mother (3540) had breast cancer diagnosed at age 42 and her affected sister 
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Fia:ure 3.2. Haplotype construction for 17q DNA marker loci in BOV3 
Affected status is indicated from the key in left hand comer of the figure with age of 
diagnosis (dx) underneath the affected individual (if known). Sex of individuals is as 
described in Figure 1.1. A diagonal slash indicates individual deceased. The order of 
DNA marker loci is shown in the top left comer of the figure. Haplotypes are displayed 
under the individual. Numbering of alleles for each marker locus is arbitrary. The 
putative disease haplotype segregating through the family is indicated in red text. 
Inferred haplotypes were constructed from genotyped family members for 4345, 3535, 
4351, 4352, 3541 and 3552. Haplotype construction for 4351, 4352 and 3552 was 
inferred from the typing of spouses and offspring; this genotyping is not shown as it is 
clinically relevant. A zero (0) allele indicates allele unknown due to not being typed, 
failed peR reaction or allele status cannot be inferred. 
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(3550) had bilateral breast cancer at ages, 44 and 54. This would suggest that 3552 
was a BReAl gene carrier. If this were the case, BReA1 would be localised in the 
chromosomal interval spanned by D17S588 and D17S74 from haplotype analysis of 
the BOV3 family. The other possibility was that 3552 had sporadic disease, 
particularly as the ovarian cancer was diagnosed at 59 years, which is a relatively late 
age of onset for familial cancer. Further studies on this individual and other members 
of this family are described (section 3.5). 
3.2.(b) BOV2 
BOV2 consisted of only two affected sisters; one individual 489 had both breast and 
ovarian cancer (Figure 3.3a). The affected sister pair demonstrated clear discordance 
for D 17S250 but not for the more distal marker loci. This suggested BReA 1 lay 
telomeric to D 17S250, but the limited size of this family prohibited statistical 
confirmation of linkage to BReA 1. 
3.2.(cl BC19 
Be 19 was a site specific breast cancer family with three affected women. A consistent 
disease haplotype was shared distal to the marker D 17S579, with clear discordance at 
this locus and centromeric to it (Figure 3.3b). This suggested, if the disease was 
linked to BReAl in this family, that BReAl maps telomeric to D17S579. 
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Fi2ure 3.3. Haplotype construction for 17g DNA marker loci in 
families: (a)BOV2 and (b) BCI9. 
Affected status and age of diagnosis indicated under the affected individual. BC=breast 
cancer, OV=ovarian cancer. Sex of individuals is as described in Figure 1.1. The 
order of DNA marker loci are shown to the right of each pedigree. Haplotypes are 
displayed under each typed individual. The putative disease haplotype in BC 19 is 
indicated in red. For BOV2, both affected sisters have common haplotypes distal to 
D 17S250 for each chromosome homologue. Haplotype information for the unaffected 
sisters of 489 and 487 in BOV2 are not shown as they are clinically relevant. 
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Figure 3.3. Haplotype construction for 17<) D A marker loci 
in familie : (a)BOV2 and (b) BCI9. 
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3.3. Breast Cancer Linkage Consortium Analysis (Easton et aI. 1993bl 
The results of the ICRF 17q linkage data were combined with data from a number of 
groups worldwide in a collaborative study. The aims of this study were threefold: 
(i) to confirm linkage of breast cancer susceptibility to BRCAI and to define its 
genetic location more precisely. This was achieved by each group typing the same set 
of marker loci centromeric and telomeric to the marker D 17S74. Data was submitted 
without bias towards family structure or the likelihood of a family being linked. 
(ii) to estimate the proportion of BRCA I-linked breast cancer pedigrees. 
(iii) to estimate the penetrance of BRCAI and possible risk of other malignancies in 
gene carriers. 
214 breast cancer families, including 57 breast! ovarian families, were typed with six 
DNA marker loci spanning a region of 30cM on chromosome 17q. The statistical 
model is summarised in section 2.13.1 (further details in Easton et ai, 1993b). The 
DNA marker loci (D17S250, D17S579, D17S588, NME1, D17S74, GH) used in this 
study are shown in Figure 3.1. Results from the mUltipoint linkage analysis indicated 
that the most likely location for the BRCA 1 gene was distal to D 17S250 and proximal 
to D17S588; a genetic distance of 8.3cM in males and 18cM in females. The location 
of the gene within this interval could not be clearly defined due to individual 
recombination events placing BRCAI either side of the marker D17S579. 
Heterogeneity analysis implied that the majority of breast-ovarian cancer families were 
likely to be due to an inherited mutation in BRCAI. There was clear heterogeneity in 
breast cancer only families with approximately 45% likely to be due to BRCAI. Breast 
cancer risk in BRCAI gene carriers was estimated to be 59% by age 50 years and 82% 
by age 70 years. 
3.4. Re-evaluation of ICRF mapping study 
The mapping results generated from the three ICRF families (BOV3, BOV2 and 
BC 19) were re-evaluated with respect to the Consortium study and are discussed 
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below. An additional 47 ICRF families were also assessed for BRCAI linkage and 
some of this work is described in Chapters 4 and 5. 
3.4.(a) BOV3 
Cancer in the large breast-ovarian family BOV3 is clearly linked to BRCAI but 
appeared to provide very little infonnation as to fine genetic localisation of BRCA I. A 
re-evaluation of the ovarian cancer case 3552 (Figure 3.2) suggests this is likely to be 
a case of sporadic disease. A number of recombination events with the disease in the 
consortium data set placed BRCAI centromeric to D17S588, however, 3552 shared a 
disease haplotype distal to this marker locus. This family has been genotyped with 
further marker loci mapping within the minimally defined genetic interval for BRCA I 
and the analysis extended to other family members (section 3.5). 
3.4.(bl BOV2 
From the consortium study, disease in the majority of breast -ovarian cancer families is 
likely to be BRCA I-linked. Therefore, although BOV2 is only an affected sib-pair, 
cancer susceptibility in this family is possibly due to BRCA I. Mapping data from this 
family placed BRCAI telomeric to DI7S250 which is consistent with the consortium 
data. 
3.4. (e) BC19 
Family BC19 localised BRCAI distal to DI7S579 but there was no convincing 
evidence that breast cancer susceptibility in this family is due to BRCA 1, particularly 
as Chamberlain et al (1993) provided strong evidence that BRCAI maps proximal to 
this marker locus. As BC 19 is a breast cancer only family, there is a 55% chance 
(from Easton et ai, 1993b) that disease in this family may not be due to an inherited 
mutation in BRCAI. Recently, individual 4477 (Figure 3.3(b)) was diagnosed with 
breast cancer at age 55. As this individual does not share a common haplotype with her 
affected cousin (4474), this further supports the likelihood that disease in this family is 
unlinked to BRCA 1. 
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3.5. Further eenetic analysis of BRCAI in BOV3 
BOV3 is a single extended family with thirteen cases of breast cancer (with ages of 
diagnosis ranging from 28 to 63 years) and three cases of ovarian cancer (diagnosed at 
43,59 and less than 58 years). Cancer susceptibility in this family is linked to BRCAI 
(Table 3.1, section 3.2.a). In this section, genotyping of further individuals is 
described. Individuals 3552 and 3542 were genotyped from archival pathological 
material (extracted as described in section 2.3.3). All available individual DNA 
samples have been genotyped with DNA marker loci mapping within the minimal 
region defined by the consortium study: D17S250 to D17S588. The majority of these 
marker loci were highly informative 'CA' microsatellite repeats which were genotyped 
by PCR amplification (as described in section 2.7.1 and 2.7.2). In total, 29 DNA 
marker loci have been screened across this family and haplotypes for nine 
microsatellite marker loci mapping within the minimal region for BRCAI are shown in 
Figure 3.4. 
3.5.(a). Genetic analysis of the ovarian cancer case 3552 
Further mapping of the ovarian cancer case, 3552, confirms that disease in this 
individual is sporadic. Genotyping of archival DNA from this individual and 
lymphocyte DNA from the close relatives (3553, 3568, 3567) clearly demonstrated 
that 3552 had inherited the maternal wildtype BRCAI chromosome (Figure 3.4). In 
addition, the fine scale mapping of this region reduces the possibility of an unusual 
double recombination event having occurred in this individual. Therefore, ovarian 
cancer in individual 3552 was likely to have occurred sporadically, or as a result of the 
inheritance of a distinct cancer susceptibility mutation to that segregating in the rest of 
the family. 
3.5.(bl. Reduction of the minimal eenetic interval for BRCAI 
Haplotypes constructed for the affected individual 3684 clearly show maternal 
inheritance of the disease-bearing haplotype distal to D 17S800 and the non-disease 
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Fieure 3.4. Haplotype construction of 17g DNA marker loci mappine 
between D17S250 and D17S293 in the BOV3 family 
Symbols are as defined in Figures 1.1 and 3.2. Age of diagnosis (dx) is shown under 
the affected individual, if known.The order of DNA marker loci and the putative 
disease haplotype are shown in the top left hand comer of the figure. The putative 
disease haplotype is indicated in red. Genotyping for individuals: 4351, 4352, 3535, 
3541, 3532 and 3533 are inferred. Some haplotypes are not shown as they are of 
possible clinical relevance. Individuals 3552 and 5367 were typed from archival breast 
tumour tissue sections. A zero allele indicates allele unknown due to not being typed, 
failed peR reaction or allele status cannot be inferred. 
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Fi2ure 3.5. Mappin2 the recombination event in individual 3684 from 
BOV3 
Examples of genotypes scored for individuals 3684, 3677 and other putative BRCAI 
gene carriers from the BOV3 pedigree are shown (see Figure 3.4). The alleles for each 
of the three DNA marker loci shown were detected (as described in 2.7.1) and 
numbered arbitrarily. The individual identification number is shown under each lane. 
The number designated for each allele is shown either side of the gel photograph. The 
genotype is shown above each lane. 
(i) Thral. Allele 1 is segregating with the disease in the BOV3 family. 3684 is 
heterozygous at this locus (1: 2) and has inherited allele 1 from her mother, 3677. 
However, as 3677 is homozygous for allele 1, the homologue passed onto her 
daughter cannot be determined. 
(ii) D17S800. Allele I is segregating with the disease in the BOV3 family. 
3684 has inherited the 4 allele from her mother, 3677, indicating a cross-over 
with this DNA marker locus and BRCAI. 
(iii) D17S846. Allele 1 is segregating with the disease in the BOV3 family. 
3684 has inherited the I allele from her mother 3677 who is heterozygous at 
this locus (1 :2). This indicates the cross-over identified at D 17S857 and 
D 17S800 has been resolved at D 17S846. DNA marker loci mapping distal to 
D 175846 confirm this result and demonstrate 3684 has inherited the disease 
chromosome telomeric to D17S800 (Figure 3.4). 
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Fi2ure 3.5. Mappin2 the recombination event in individual 3684 from BOV3 
(i) Thral 
(ii) D17S800 
allele 2 ~ 
allele 5 ~ 
(iii) D17S846 
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... allele I 
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allele 2 
allele 1 
chromo orne proximal to D 17S846. Fine mapping of thi recombination event is 
shown in Figure 3.4 and 3.5. Thi cro s-over event was unidentifiable from previous 
haplotype analy i as it wa rna ked by the homozygosity of the two genotyped 
proximal micro atellite marker loci, 017S250 and THRAI in the mother (3677) of this 
individual (Figure 3.5(i». Individual 3684 had bilateral breast cancer diagnosed at 36 
and 41 year , whil t her mother had breast cancer and her grandmother had ovarian 
cancer. Bilateral di ea e i a feature of inherited cancer predi position, particularly if 
pre ented at an early age. In addition, individual 3543 and 5376 al 0 present with 
bilateral breast cancer in thi family. Thi ugge t that 3684 i unlikely to be a 
poradic case and that BRCAI lies di tal to D 17S800 (Figure 3.6). No other 
recombination event refining the locali ation for BRCAI were detected in thi family . 
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Figure 3.6. Reduction of the minimal region for BRCAl._ 
The ideogram 0 f micro atellite marker loci panning the B RCAI locus on 
chromosome 17 i a de cri bed in Figure 3.1. Th e genetic d i tance of the 
previou ly defined publi hed minimal region for BRCAI (THRAI to 
D17S183: Bowcock et ai, 1993) i shown on the far right of the ideogram. 
The identification of the cro -over identified in individual 3684 from the 
BOV3 family refined the centromeric boundary for BRCAI to being 
telomeric to D 17S800. Thi reduced the minimal region to between 
D17S800 and D17S183, a phy ical di tance of 1- 1.5 Mb. 
3.S.(ct BRCAI homozY2ote? 
A further, intriguing, branch of thi family was analysed. Thi involved the affected 
daughter of the uncle-niece marriage of 5352 and 5355, who were potentially 
homozygou for the BRCAI mutation ince both parents were putative carriers (from 
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pedigree analysis) . If this was the case, it would suggest that a fully functional copy of 
the BReAI gene was not required for normal development. However, analysis of 
DNA from a section of archival pathological breast tissue containing both tumour and 
apparently normal cells (extracted as described in section 2.3.3) from individual 5367 
revealed that this individual was heterozygous for two of the three rnicrosatellite 
marker loci analysed, DI7S800 and D17S579 (Figures 3.4 and 3.7). DNA was 
unavailable from the parents of 5367 for detell'Ttination of transmission of the disease 
chromosome, but it is possible that it was inherited from the unaffected mother 5355 
who had a sister (5361), diagnosed with breast cancer at the age of 50. Subsequent to 
the cloning of BRCA I, putative BReAI homozygotes have been identified in two UK 
families and are discussed in section 5.2. 
1 2 
~ Allele 1 
~ Allele 3 
Fi2Ure 3.7. HeteroZY2osity at D17S800 in individualS367. 
PeR amplification at D17S800 of two archival DNA samples from individual 
5367 (detected as de cribed in 2.7.2). The template DNA in lane I was extracted 
from a section of archival breast tumour, which had a high breast tumour cell 
content. The template DNA in lane 2 was also extracted from a section of 
archival breast tumour, but included some apparently normal breast cells. The 
alleles are indicated to the right of the gel autoradiograph. Allele 1 is egregating 
with the di ease in the BOV3 family. Allele 3 is clearly present in lane 2; the 
DNA template with a greater proportion of normal breast cells. 
3.S.(d), Risk of cancer in male BRCAI carriers 
Two males were diagnosed with cancer in this family (3534, 3542) and are at 50% 
risk (from pedigree analysis) of being carriers of the BReAI mutation segregating 
through the BOV3 family. No material was available for the colon cancer case, 3534, 
but haplotype analy is of archival pathological DNA from the stomach cancer case, 
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3542, showed that the individual had not inherited the disease chromosome (Figure 
3.4). The Breast Cancer Linkage Consortium analysis of risk of other cancers in 
BRCA I gene carriers revealed an increased risk of colon cancer (relative risk [RR] of 
4.11) and prostate cancer (RR of 3.33) (Ford et ai, 1994). 
3.S.(el. Summary of I:enetic mappinl: in BOY3 
The results of the analysis of the BOV3 family confirm cancer predisposition in this 
family is due to an inherited mutation in BReA 1. The recombination event in 
individual 3684 places BReA 1 distal to D 17S800. A recombination event identified by 
Bowcock et al., (1993) suggests that BRCAI is proximal to D17S183. These two 
recombination events define a minimal region bearing BRCAI to between D17S8oo 
and D 17S 183 (Figure 3.6), a distance estimated to be between 1.0 and 1.5 Mb based 
on a physical map of the region (Brown et ai, 1995). Analysis of other ICRF breast 
cancer families revealed no further mapping information but identified other families in 
which cancer predisposition was due or likely to be due to an inherited mutation in 
BRCA 1 (Chapter 5). 
3.6. Candidatel:ene analysis for BRCA 1 
Having defined the genetic boundaries flanking BRCA 1, genes situated within this 
chromosomal location could be analysed as potential candidates for BReA 1. In this 
section, the analysis of a number of candidate genes for BRCA 1 are described in 
historical order. The identification of a locus on 17q predisposing to breast and ovarian 
cancer suggested a number of potential candidate genes, which map to this 
chromosome arm, for BRCA 1. The quickest and most convincing method of 
exclusion is identifying affected individuals from BRCA I-linked pedigrees displaying 
recombination events between the candidate gene and the disease locus. If no 
recombination events are detected, the gene maps within the minimum region and then 
mutation studies are performed to identify any potentially disease-causing mutations in 
BRCAl-linked families. BRCAI candidate gene analyses are described below. 
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3.7. NME 1 and 2 (NM23) 
NM23 is a heterodimeric protein which acts as a nucleoside diphosphate (NDP) kinase 
(Gilles et ai, 1991). NDP kinases are involved in the synthesis of nucleoside 
triphosphates and the NM23 protein may act in the regulation of signal transduction by 
complexing with G-proteins causing activation! inactivation of developmental 
pathways (Wallet et ai, 1990; Biggs et ai, 1990). 
Two cDNAs, NMEI and NME2, were isolated from murine K-1735 melanoma cell 
lines using differential hybridisation (Steeg et ai, 1988; Stahl et ai, 1991). Comparison 
of cell lines displaying low and high metastatic rates indicated two cDNAs that were 
down regulated in the highly metastatic melanoma cell line. Upon NMEI cDNA 
(isolated from a cell line showing reduced metastatic potential) transfection into these 
cells, metastatic potential was significantly reduced. These two NME cDNAs, NMEI 
(Steeg et ai, 1988) and NME2 (Stahl et ai, 1991), have been shown to encode the A 
and B polypeptide chains of an NDP kinase (NM23), respectively. Both chains consist 
of 152 amino acid residues and share 88% nucleotide homology. Human NME2 is 
identical to the B subunit of human erythrocyte NDP kinase (Gilles et ai, 1991). It has 
been proposed that NM23 may have a role as a tumour suppressor gene (Steeg et ai, 
1988; Rosengard et ai, 1989; Steeg and Liotta, 1990). 
The human NMEI geQe has been assigned to 17q21-q22 (Varesco et ai, 1992) and 
could be considered as a candidate for BRCA 1. The following section describes the 
localisation of NME2. 
3.8. Clonin& of NME2 
From the published NME2 cDNA sequence (Stahl et ai, 1991), oligonucleotide 
primers (A and B) were designed from 5' and 3' coding regions of NME2 which 
demonstrated reduced nucleotide homology with the corresponding region in NMEI 
(described in section 2.6.2.1). Using this primer pair, the predicted 507bp product of 
the coding sequence was PCR amplified from a human HeLa cDNA library (as 
, 
described in section 2.6.2.1: data not shown). This product was subcloned by TA 
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vector cloning (as described in section 2.9) and sequenced (as described in section 
2.10). Sequencing revealed 100% nucleotide identity with that of the published 
sequence of NME2 (data not shown). The nucleotide homology of this region between 
NMEI and NME2 was found to be 74% (data not shown). This 507 bp DNA 
fragment was used as a gene specific probe for chromosomal localisation of NME2 
(section 3.9). 
3.9. Localisation of NME2 by Southern hybridisation 
The 507 bp NME2 fragment was used to probe a southern blot of EcoRI digested 
DNA from a variety of human-rodent somatic cell hybrids (Black et ai, 1993) and 
human and mouse controls (as described in section 2.5). An example of such a 
southern blot is shown in Figure 3.8(a). A complex pattern of fragments was detected 
in the human and mouse DNA controls (Figure 3.8(a) lanes 10 and 9 respectively). A 
24 kb fragment in the human DNA control was distinguishable from a number of 
cross-hybrid ising mouse fragments. This fragment was present in the hybrid 
PCfBAI.8 (Figure 3.8(a) lane I) which contains chromosome 17 as its only human 
contribution. A series of hybrids containing fragments of chromosome 17 were also 
analysed and the results are shown in lanes 2-8 (Figure 3.8(a». The presence of the 
human-specific 24kb fragment in a proportion of these hybrids suggested the 
localisation of NME2 to the region 17 q21-q22, the same localisation as NME 1. The 
localisation is summ~ised in an ideogram of chromosome 17 in Figure 3.8(b). 
However due to the ambiguity of the fragment pattern in the human and murine DNA, 
in particular, the presence of a 13kb human-specific fragment (tracks 4 and 5, Figure 
3.8(a» which does not map to chromosome 17, and the previous suggestion that an 
NME2 gene may be located on chromosome 16 (Steeg and Liotta, 1990), a second 
mapping strategy was employed to determine unequivocally that NME2 maps to 
17q21-q22 (see following section). 
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Fia:ure 3.8. Southern hybridisation of NME2 to chromosome 17q21-22. 
The 507 bp NME2 fragment (described in section 3.8) was used to probe a southern 
blot of EcoRI digested DNA from a variety of human-rodent somatic cell hybrids. 
(a) An autoradio2raph of somatic cell hybrid and control DNA samples 
hybridised with the NME2 fraa:ment. 
Marker sizes (in kb) indicated on the left-hand side are estimated from A DNA digested 
with Hind III. The approximately 24 kb human specific fragment is also indicated on 
the left of the autoradiograph. The lane order and approximate human chromosome 17 
content (Black et ai, 1993) is: lane 1) PCTBA1.8 (17 only), lane 2) TRID62 (17q), 
lane 3) pJT2/Al (17qI2-qter), lane 4) p12.3B6 (pter-17qI2), lane 5) DCRI ( 17qll-
qter) , lane 6) KLT8, lane 7) PLT6B, lane 8) PLT8 (KLT8, PLT6B and PLT8 are 
chromosome-mediated gene transfectants and contain multiple fragments of 
chromosome 17; however, PLT8 appears to have 17q23-qter as its only human 
chromosome 17 complement), lane 9) mouse and lane 10) human DNA. Lanes 1, 
2,3,5 and 10 have the 24 kb human NME2-specific fragment. 
(b) Ideo2ram of chromosome 17 showina: localisation of NME2 to 
17q21-22. 
The approximate positions of the chromosome 17 bands are shown to the left of the 
chromosome ideogram. To the right of the ideogram, the approximate chromosome 17 
content of four of the hybrids is indicated. (a) PCTBA1.8, (b) TRID62, (c) PLT8, (d) 
PLT6B. The localisation of NME2 on chromosome 17 is shown to the right of the 
hybrids. The human NME2-specific 24 kb fragment was detected in the hybrids (a) 
and (b) but not in (c) and (d); localising NME2 to 17q21-22. 
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Fieure 3.S. Southern hybridisation ofNME2 to chromosome 17q21-22 
I NME2 
3.10. Localisation of NME2 to 17q21-22 by peR amplification 
From the published DNA sequence (Stahl et al 1991), oligonucleotide primers were 
designed from the 3' untranslated region of the human NME2 gene. This region was 
chosen on the basis of the following observations: 
(i) comparison of the cDNA sequences of this region ofNMEl and NME2 identified a 
number of sequence mismatches allowing NME2-specific oligonucleotide primers to 
be designed 
(ii) the 3' untranslated regions of genes are often under reduced interspecies sequence 
conservation suggesting NME2 oligonucleotide primers designed from this region 
would be less likely to PCR amplify rodent NME2 (the DNA background of the 
somatic cell hybrids is rodent) 
The position of the NME2 oligonucleotide primers, indicated as C and D, used in the 
human/rodent somatic cell hybrid mapping are shown in Figure 3.9(a). The sequence 
comparison of NME2 primer sequences with the equivalent region in NMEI and 
NME2 is also shown. PCR amplification from a panel of monochromosomal humanJ 
rodent somatic cell hybrids (Kelsell et ai, 1995a) and hybrids containing a number of 
human chromosomes (Spurr et al, 1991) was performed using the human NME2 
specific oligonucleotide primers C and D (as described in section 2.6.2.2). A NME2-
specific PCR amplified product was obtained using human (lane 6) and a selection of 
somatic cell hybrid DNAs (lanes 2, 4, and 5) as templates (Figure 3.9(b». Lane 2 
contains DNA from the hybrid PCTBA1.8 which has chromosome 17 as its only 
human complement. Lanes 4 and 5 contain DNA from the hybrids Dur4.3 and 
3W4CL5 respectively, which have chromosome 17 and other chromosomes as their 
human complements. To further localise NME2, the series of hybrids containing 
fragments of chromosome 17 used in the localisation of NME2 by southern 
hybridisation (previous section) were analysed by PCR amplification with primers C 
and D. The expected 169bp product was present in the following hybrids: PCTBA1.8, 
TRID62, pJT2/Al, OCR! (data not shown). These results confirm the localisation of 
NME2 to 17q21-q22 (Kelsell et ai, 1993b). 
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Fieure 3.9. Localisation of NME2 to 17q21-22 by PCR amplification 
(a) NME2 oligonucleotide primers, C and D, used for PCR 
amplification. 
The position of each primer relates to its nucleotide position for the published sequence 
of NME2 (Stahl et ai, 1991) and is shown above each primer sequence. The primer 
sequence is shown in bold: lower case indicates a different nucleotide in that position 
compared to NME 1 (Steeg et ai, 1988); uppercase indicates identical nucleotide to that 
ofNMEI. 
(b) Mapping of NME2 to chromosome 17 by PCR amplification 
Photograph of an ethidium bromide-stained 2% agarose gel showing the NME2-
specific PCR amplified product. The 169 bp NME2-specific amplification product is 
indicated by an arrow to the left of the photograph and was present in lanes 2, 4, 5 and 
6. The lane order is as follows: lane M) ct>x174 DNA digested with HaeIII ; lane 1) 
FG 10; lane 2) PCTBA1.8, lane 3) 2860H7, lane 4) Dur4.3, lane 5) 3W4CL5, lane 6) 
human, lane 7) mouse, lane 8) hamster. The human chromosome complement of the 
somatic cell hybrids: FG 10, Dur4.3 and 3W4CL5 are referenced in Spurr et ai, 
(1991). Hybrid PCTBA1.8 contains chromosome 17 as its only human complement 
and 2860H7 contains only human chromosome 16 (Kelsell et ai, 1995a). 
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Fiaure 3.9. Localisation of NME2 to 17<121-22 by PCR amplification 
(a) 
(b) 
primer C (5' to 3' from position 500 to 522) 
GtctTGTGCTCAtgACTGGgTC 
Mismatches with human NMEl: 6/22 nucleotides 
Primer D (3' to 5' from position 669 to 646) 
cggctTCCAAaAGCTTtatTggc 
Mismatches with human NME 1: 12/23 nucleotides 
M 12345678 
169bp~ 
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However, from the genotyping of affected individuals from BReAl-linked breast 
cancer families using a microsatellite marker locus mapping close to NME 1 and 
NME2, recombination events between the disease and this marker locus have been 
identified (see Figure 3.10). These observations have genetically excluded NMEI and 
NME2 as candidates for BReA 1. 
3.11. Genetic exclusion of other B RCAI candidate Kenes 
With the narrowing of the minimal region containing BReA 1 and the refinement of the 
genetic map, a number of candidate genes for BReA 1 have been eliminated. Analysis 
of recombinants in clearly linked extended pedigrees placed BRCAI in the interval 
telomerictoTHRAl (Bowcock etal, 1993), 017S800 (Section 3.5 (b); Kelsell etal, 
1993a) and o 17S776 (Goldgar et ai, 1994), and centromeric to D17S183 (Bowcock et 
al, 1993) and D 17S78 (Simard et al, 1993). This region genetically excludes a number 
of candidate genes including NME1 and 2, ErbB2 which is amplified in a proportion 
of breast tumours, the putative oncogene THRA1 and Prohibitin (PHB), in which 
somatic mutations in a small proportion of sporadic breast tumours have been detected 
(King, 1992; Sato et aI, 1992; Bowcock et al , 1993; Kelsell et ai, 1993b». The 
mapping positions of these and other excluded candidate genes are shown in Figure 
3.10. 
3.12. DNA mutation analysis of EDH17Bl and EDH17B2 
Two 17~-oestradiol dehydrogenase genes, EDH17B1 and EOH17B2, are both 
localised on a 13kb genomic DNA fragment (Luu-The et al, 1990) which maps within 
a defined minimal region for BReA1 between D17S776 and D17S78 (Figure 3.10). 
17~-oestradiol dehydrogenase catalyses the interconversion between the weak 
oestrogen, oestrone, and the more potent oestradiol, the levels of which have been 
shown to be much higher in some breast tumours than in normal breast cells (McNeil 
et ai, 1986; Vermeulin et al, 1986). Two mRNA species have been identified, one of 
1.3 kb and another of 2.2 kb, in varying abundance in most tissues, including the 
breast and ovary (Luu-The et aI, 1990). Nucleotide sequence comparison of the two 
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Fii:ure 3.10. Exclusion of candidate eenes for BRCAI 
Th order of loc i mapping in the 17q 12-22 interval are hown to the ri ght of the 
ideogram of chromo om 17. 017S74, th DNA marke r locu fir. t indicating 
linkage with fami li al breast cancer, map approximate ly 24 cM telo meric to 
o 17S579 (Cox ef ai, 1994). The c urre nt minimal ge ne tic reg ion harbo urin g 
BR A I i between Ol7S776 and 017S7 8 (loci hi ghli ghted in blue). Gene 
previou ly implica ted a candidate gen f r BRCAI including M 2 are in bold 
text and, a they map outside the minim al region, can be genetically excluded a 
candidate fo r BRCA I. The l 7~-oestradio l dehydrogena e genes (hi ghli ghted in 
red te t), EOH 17B I and EOH 17B2, are locali ed within the minim al region. The 
g netic location and biolugical ro le of the e gene implicate them a piau iblc 
candidate for BRCA I. 
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genes over their exons and introns shows 89% homology. EDH l7B 1 has a stop 
codon at position 218 instead of the amino acid GIn as in EDH 17B2 and is likely to be 
a pseudogene. However, it could still transcribe and encode a protein of 214 amino 
acids (Luu-The et ai, 1990). The regulation of 17J3-EDH expression may be important 
in the initiation and/or progression of breast (and ovarian) tumours. The genetic 
location and biological role of these genes implicated them as potential candidates for 
BRCAI. 
Sequence analysis of these candidate genes was performed on genomic DNA extracted 
from lymphoblastic cell lines from three affected individuals (3550, 3543 and 3677) 
and one unaffected non-gene carrier (3079) from the BOY3 pedigree. The whole 
coding region of both EDHl7Bl and EDH17B2 was sequenced in an attempt to 
identify any disease-causing mutations in their constitutive DNA. 
Oligonucleotide primers 5' and 3' to the coding region and specific for either 
EDH 17B 1 and EDH 17B2 were designed from the published sequences (Luu-The et 
ai, 1990). These are shown in Figure 3.11(a) and (b). The two gene specific templates 
produced using these primer sets following peR amplification were added to a series 
of nested PCR amplification reactions (as described in section 2.6.3). The combination 
of internal primers (E to M) were used to amplify shorter PCR products which are 
more amenable for DNA sequencing. These primers are shown in Figure 3.11(b). 
Given the high degree of nucleotide homology between the two genes, these internal 
primers were designed from regions of high conservation so that identical sets of 
primers could be used to amplify each of the six exons from both genes. One of the 
internal primers from each pair was biotinylated to allow the isolation of single-
stranded DNA and direct sequencing (described in section 2.10). An example of the 
specificity of the technique is shown in Figure 3.11(c), which shows partial sequence 
of exon 5 for both genes. 
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Sequencing of these genes revealed that there was no apparent variation between 
affected individuals and the unaffected individual from the family: no individual gave a 
sequence which differed from that of the published sequence. All individuals were 
homozygous for the published exon polymorphisms (Normand et ai, 1993). In 
support of this data, EDH 17B2 has been sequenced in a number of other BRCA 1 gene 
carriers and no disease causing mutations have been identified (Simard et ai, 1993). 
Complete confidence in the elimination of these genes as candidates for BRCA 1 
requires identifying a recombination event between this locus and BRCAI or, indeed, 
identifying BRCA 1. 
3.13. Summary of Chapter 3 
Linkage studies were performed on 16 breast and breast-ovary cancer families to 
confirm linkage to 17q and to identify closer flanking DNA marker loci to the disease 
susceptibility gene, BRCA1. The data was analysed independently and also in 
combination with other family data from the Breast Cancer Linkage Consortium 
group. In the largest of the ICRF families studied (BOV3), linkage to the long arm of 
chromosome 17 was confirmed and a number of recombinants were identified. One 
such cross-over event (identified in individual 3684) enabled the reduction of the 
interval harbouring BRCAI to a region estimated to be between 1-1.5 Mb. Using this 
information a number of candidate genes for BRCA 1 could be genetically excluded. 
Sequence analysis did not identify any disease-causing mutations in the genes, 
EDH17BI (which codes for 17~-oestradiol dehydrogenase) and EDH17B2 which are 
localised within the published minimal genetic region for BRCA 1. 
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FiJ:ure 3.11. SequencinJ: of EDH17Bl and EDH17B2. 
(a) A schematic representation (not to scale) of the structure of the EDHl7BI and 
EDH 17B2 genes is shown. The exons are boxed and are labelled above each box. The 
positions and orientation of the oligonucleotide primers used in the gene-specific peR 
amplification and sequencing are indicated by labelled arrows. 
(b) Primer sequences used in the PCR amplification and sequencing of the two genes 
are shown. The gene-specific primer sequences are indicated (A, B, C and D) which 
were used to PCR amplify gene-specific template. The asterisk (*) indicates that the 
position of the primer sequences are relative to the first nucleotide of the translation 
initiation codon labelled 1. 
(c) Examples of autoradiographs from sequence analysis of the same region of exon 5 
for each gene: (i) EDH l7B I and (ii) EDH 17B2. The specific dideoxy terminator is 
indicated above each sequencing lane. 
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(a) 
(b) 
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A~IDH I 
• ~IDHI 
E~ 
_, 
-.z 
I'd"",r Sequence 
A (EOH1) S' GGATGAGTTCTTCACCTTCTG 
8 (EOH2) S' CTCCTGGGCTCCAACAATCC 
C (EOH1) S' GCCGCGCAGATATAACGGGC 
0 (EOH2) S' GCTGCGCTGGTAAAACTGGC 
E S' GCGAAGCAGGTGATATCAAGC 
F S' GCTGAGGGTGATGCTGAGGC 
G S' CAGGCCCAGGCCTGCGTTAC 
H 5' TGCTCGGCATCTCTAGGTCAG 
5' GTTCTGGTTATCCCCAGCGC 
J 5' ACCGCCTTCATGGAGAAGGT 
K 5' CACCTCCTCAGGGTTCTGCG 
L 5' ACTACGTCACCGCCATGCAC 
M 5' CAGACCCAGGGCACAAAGAA 
-.s E-.4 -., -., 
f~ I~ J~ l~ 
~ G ~H ~I( ~M 
IDH Z ~O 
(C) (i) (ii) IDH 1 ~c 
Nucleotide position* A C G T A C G T 
-810 -789 
-803 -783 
2137 2117 
2138 2118 
-S4 -33 
4S8 478 
527 S07 
1011 990 
1310 1330 
1501 1521 
1643 1623 
1841 1861 
2055 2035 
3.14. The donin&: of the BRCA1 gene 
After an intense search in this gene rich region by a number of research groups 
worldwide, BRCA1 was identified (Mild et ai, 1994). The gene consists of 22 coding 
and two non- coding exons spanning a genomic region of around 100 kb and 
encompasses the rnicosatellite marker locus, D 17S855 (Figure 3.12). 
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Figure 3.12.Map location of BRCAI. 
The ideogram of chromosome 17 shows the relati ve position of the ide ntified 
BRCAI gene ( D 17S855 is intragenic ). BRCA 1 maps within the mi nimal region 
defined by genetic analysis of BRCAI-Iinked breast cancer pedigrees. 
The resulting 1863 amino acid protein bears little homology to any other known 
protein. However in the amino terminus of the protein, there is a putative RING finger 
(zinc- binding) domain which uggests a transcriptional regulatory role for BRCA 1. 
Thompson et al (1995) proposed that BRCA1 may act as a growth suppressor of 
breast epithelial cells, though other functional studies are required. Previous studies 
had indicated that BRCA1 act as a tumour suppressor gene (see Chapter 5). 
Developmental studies of murine BRCAI in the mammary gland suggest its 
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expression is induced in response to ovarian hormones at, for example, puberty, and 
is involved in proliferation and differentiation in breast epithelial cells (Marquis et ai, 
1995). As BRCA 1 is expressed in a number of tissues other than the breast and ovary, 
studies are required to determine why BRCA 1 mutations confer cancer susceptibility in 
such a tissue specific manner. The possible function of BRCAI is discussed further in 
Chapter 7. 
Over 100 BRCA 1 mutations have been identified which cover a wide spectrum of the 
gene (Miki et ai, 1994; Shattuck- Eidens et ai, 1995; Gayther et ai, 1995; Friend et ai, 
1995). Over 75 % of detected mutations result in a truncated BRCAI protein. Several 
common mutations have been identified, in particular, a 2 bp deletion resulting in a 
frame shift at position 185 in exon 2 (185deIAG). This mutation appears to have arisen 
independently in a number of populations but a proposed ancestral mutation has a 
carrier frequency of around 1 % in the Ashkenazi Jewish population (Streuwing et ai, 
1995a). Interestingly, the same mutation is the genetic basis of disease predisposition 
in the BOV3 family but, from haplotype analysis, arose independently to that found in 
the Ashkenazi Jewish population (Neuhausen et ai, 1996a). Other BRCAI mutations 
detected in the ICRF pedigrees are discussed in Chapter 5. There is the suggestion that 
there may be a genotype- phenotype correlation; with the risk of ovarian cancer being 
reduced if the mutation occurs in the 3' third of BRCA 1 (Shattuck -Eidens et ai, 1995; 
Gayther et ai, 1995). Two population based surveys to estimate the prevalence of 
BRCA I mutations in women diagnosed with breast cancer at an early age have been 
performed (Fitzgerald et ai, 1996; Langston et ai, 1996). Minimum estimates suggest 
that between 10-15 % of early onset breast cancer cases carry a gerrnline mutation in 
BRCAI. 
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CHAPTER 4: PHYSICAL MAP OF THE BRCA2 REGION 
4.1. Introduction 
Linkage studies have demonstrated that the majority of families with multiple cases of 
breast and ovarian cancer, but only around 45% of breast cancer only families, are due 
to inherited mutations in BRCA 1 (Easton et aI, 1993b; Narod et aI, 1995). Examples 
of ICRF families in which the cancer is likely to be unlinked to BRCA 1, from 
haplotype and multi-point linkage analysis (as described in section 2.13.1. 2) with 
microsatellite marker loci flanking the BRCAI locus, are shown in Figures 4.1 and 
4.2. These observations suggested that there is at least one other major locus for breast 
(and ovarian) cancer predisposition. Steichen-Gersdorf et ai (1994) demonstrated 
evidence in favour of linkage of the disease to BRCA 1 in seven site specific ovarian 
cancer families; however, OV579 is a site-specific ovarian cancer family (all three 
cases diagnosed under the age of 40 years) in which ovarian cancer does not segregate 
with a BRCA I haplotype (Figure 4.1.(i». 
From a genomic linkage search using 15 families unlinked to the BRCA 1 locus, a 
second breast cancer susceptibility locus, BRCA2, was localised to a 6 cM interval on 
13qI2-13, flanked by D13S289 and D13S267 (Wooster et ai, 1994). Interestingly, a 
previous study excluded linkage of familial breast cancer to the retinoblastoma gene 
locus (RB 1) (Bowcock et ai, 1990). RB maps approximately 20 cM distal to the most 
telomeric marker locus, D 13S267, for BRCA2 (Kooy et ai, 1994, Dib et ai, 1996). 
The penetrance of breast cancer among female BRCA2 carriers is similar to that for 
BRCAI carriers; estimated to be about 87% from segregation analysis of a large breast 
cancer family in which the disease is linked to BRCA2 (Bishop et ai, 1988; Wooster et 
ai, 1994). However, BRCA2 appears to confer a lower risk of ovarian cancer, but a 
much higher risk of male breast cancer compared to BRCA 1. Male breast cancer is a 
hundred times less common than that of female disease in the general population. 
(Germline mutations in the chromosome X-linked androgen receptor gene have been 
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Fi2ure 4.1. Three breast and breast-ovarian cancer families not linked to 
BRCA1. 
Three examples of ICRF breast and breast-ovarian pedigrees which appear unlinked to 
BRCAI from haplotype and linkage analysis. The sex of each individual is as described 
in Figure 1.1. Filled boxes indicate affected individual; red=ovarian cancer; blue = 
breast cancer. Underneath each individual is their identification number plus either 
BC=breast cancer or OV=ovarian cancer (if affected) and the age of diagnosis of the 
cancer (if known). Haplotypes are shown underneath each individual for which DNA 
was available with microsatellite marker loci order (centromere to telomere) tested in 
each family to the right of each pedigree. LOD scores at the BRCAI locus are shown 
under the pedigree identification number and were calculated as described in section 
2.13.1.2. 
(n OV579. This is a site specific ovarian cancer family. A negative LOD score of -
0.90 at BRCAI suggests disease susceptibility in this family is not linked to BRCAI. 
This is clearly demonstrated from haplotype comparison of 15709 and 15697. Affected 
individual 15697 appears to have inherited the haplotype (1 :3:3: 1: 1) from her father (as 
inferred by the observation that her uncle 15703 has the same haplotype). This 
haplotype has not been transmitted to her affected cousin 15709. 
(m BC3. This is a breast-ovarian cancer family with one case (111) of bilateral breast 
cancer. A negative LOD score of -0.27 at BRCA 1 suggests disease susceptibility in this 
family is not linked to BRCA 1. This again can be demonstrated from comparison of 
haplotypes between affected members (120, 116, 111 and 145) and the obligate gene 
carrier (140). A haplotype of 1 :2: 1 is shared by 140, 116, 111 but not 120 or 145 or, 
alternatively, a haplotype of 2:1:1 is shared by Ill, 116 and 120 but not 140 and, 
therefore, not 145. 
(iii) B C 12. This is a site specific breast cancer family consisting of four affected 
individuals. A negative LOD score of -0.58 at BRCA 1 suggests disease susceptibility 
in this family is not linked to BRCAl. This is reflected by the observation that 3349 
does not share a BRCA 1 haplotype with her affected cousins, 3352 and 3354. 
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Fij!ure 4.1. Three breast and breast-ovarian cancer families not linked to BReA I. 
(n OV 579 (ij) BC3 
LOD score (BRCAl) = - 0.90 LOD score (URCA t ) = - 0.27 
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Fieure 4.2. ICRF 26. a breast cancer family not linked to BRCAI. 
The pedigree is constructed as described in Figure 4.1. Cancer at other sites are 
present in this family indicated by green filled box (circle for females, square for 
males); the specific cancer is described under the individual. A zero allele indicates lack 
of PCR product. Haplotypes for affected individuals: 17209, 17405 and 20576 were 
genotyped using DNA extracted from archival pathological tumour material (as 
described in section 2.3.3). A negative LOD score of -1.47 (calculated as described in 
section 2.13.1.2) suggests disease susceptibility in this family is not linked to 
BRCA1. There is no evidence of BRCAI haplotype sharing amongst breast cancer 
affecteds in this family except for the sisters, 17199 and 17209 who share the 
haplotype: 1: 1 :4:5. However, this is of paternal origin and not from their affected 
mother 17187. For affected individual 18080, it is possible that a breast cancer 
susceptibility mutation may have been inherited paternally (father's sister had breast 
cancer diagnosed at 37 years) or maternally. 
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Fiaure 4.2. ICRF 26. a breast cancer family not linked to BRCAl. 
Key: 
e Breast cancer 
LOD score (BRCA1) = -1.47 1_ Other cancer 
17194 17190 liver uterus 17187 173991 17189 205761 oesophageal dx:37 
dx:58 ,72 dx:39 dx:46 
3 2 2 1 2 3 o 0 
1 2 1 1 3 1 3 1 
3 3 5 6 5 3 o 0 
1 9 6 4 1 2 o 0 
17221 17203 17209 17208 17199 17406 17405 18080 
dx:41 dx:36 dx:48 dx:30 dx:38 
2 1 2 1 3 1 3 2 2 1 1 2 o 0 2 2 THRAt 
3 4 2 1 1 1 1 1 2 1 1 3 o 0 1 6 D17S800 
5 3 3 4 3 4 3 1 3 4 5 5 3 5 5 7 D17S8SS 
1 4 9 5 1 5 1 3 9 5 6 1 o 0 8 9 D17SS79 
demonstrated in males with breast cancer and androgen insufficiency: Wooster et ai, 
1992; Lobaccaro et ai, 1993). Studies of families, in which male and female breast 
cancer was segregating, indicated that in the majority of these, the disease was 
unlinked to BRCA1 (Stratton et ai, 1994). Subsequently, there have been reports of 
BRCAI mutations segregating with breast cancer in a small number of families with a 
single case of male breast cancer (for example, Streuwing et ai, 1995b). Other reports 
have confinned linkage of breast cancer susceptibility to BRCA2 in a family with an 
excess of male breast cancer (Thorlacious et ai, 1995) and a breast cancer family with 
cancer at other sites (Tonin et ai, 1995). 
In this study, a physical contig of the BRCA2 region was constructed based on a 
series of overlapping Yeast Artificial Chromosomes (YACs) containing human DNA. 
(The Y AC (Yeast Artificial Chromosome) cloning system is capable of cloning large 
DNA fragments. The YAC vector contains the requirements for nonnal chromosomal 
replication including a centromere sequence, a telomere sequence, an automonous 
replicating system and an origin of replication: reviewed in Strachan and Read, 1996.) 
The contig provided a resource for identifying new genetic markers and candidate 
genes for BRCA2. 
4.2. Physical map of the BRCA2 rea=ion 
Fourteen Y AC clones containing fragments of human DNA tentatively mapping in the 
BRCA2 interval were selected directly (as described in section 2.11.1). Human DNA 
inserts had been sized previously by pulsed-field gel electrophoresis (Cohen et ai, 
1993). DNA extracted from these Y ACs were used as hybridisation probes to nonnal 
human lymphocyte metaphase spreads by fluorescence in situ hybridisation (FISH) to 
confinn their localisation to 13q12-13 (S. Ford, personal communication). From this 
analysis, two clones, 851_b_2 and 793_b_6, were shown to be chimeric and were 
discarded from the study. 
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DNA extracted from the non-chimeric YACs (as described in section 2.3.4) were 
screened by PCR amplification with microsatellite marker loci mapping within or just 
outside the minimal genetic location of BRCA2 (as described in section 2.6.1). All 
Y ACs tested contained at least one of the micro satellite marker loci. A typical result of 
the mapping of microsatellite marker loci sequences to the YAC contig is shown in 
Figure 4.3(a). The results are summarised in Table 4.1. 
Initially, two minimal tiling path contigs were generated on the basis of their 
microsatellite marker loci content, one linking D 13S289 with D 13S260, and the other 
linking D 13S 171 with D 17S267 (Figure 4. 3(b». An STS, STS 1002, isolated from 
YAC 746~_1O (Dr. R. Wooster, personal communication) was screened across the 
YACs using PCR amplification (as described in section 2.6.1). STS 1002 was found 
to be present in the Y ACs 931j_ 4 and 746_g_lO. This result physically links these 
two Y ACs and the microsatellite marker loci, D 13S260 and D 13S 171, and is shown in 
a graphic representation of the contig in Figure 4.4. Adding the human DNA insert 
sizes of the smallest Y ACs (91O_h_2, 931_C5, 886_d_8, 95 La_3) spanning the 6 
cM region between D13S289 and D13S267, the region can be no more than 5.27 Mb. 
The exact physical size of the interval cannot be calculated until the precise positions of 
the overlaps are determined. 
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J'able 4.1. Summary of marker loci content of Y ACs in the BRCA2 
region by PCR amplification 
YAC LOCUS SIZE (in kb) 
91O_e_ 11 013S289 1720 
940~4 013S289 1170 
013S290 
013S 1226 
962_a_8 013S289 1210 
013S290 
013S1226 
91O_h_2 013S289 1030 
013S290 
013S 1226 
93LC4 013S 1226 1520 
013S2OO 
(STS 1002) 
931_C5 Ol3S 1226 1510 
013S2OO 
(STS 1002) 
833_d_2 013S2OO 810 
834_c_8 013S2oo 750 
851_b_2* 013S2oo 400 
793_b_6* (STS 1002) 400 
013S171 
746~_1O (STS 1002) 1650 
013S171 
886_d_8 (STS 1002) 970 
013S171 
951_a_3 013S171 1760 
013S267 
941_d_4 013S267 1580 
STSI002 is shown in brackets as it was isolated from Y PC 746_g_1O ONA 
after the initial microsatellite marker loci screen of the YAC ONA panel 
(Figure 4.4). 
* Y PCs found to be chi meric 
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Fieure 4.3. YAC characterisation of the BRCA2 minimal reeion 
This figure shows the initial analysis of the 12 non-chimeric YAC DNAs selected, 
which tentatively mapped to the BRCA2 region. These were screened for presence or 
absence of specific microsatellite marker loci by PCR amplification. 
(a) D13S260 PCR screen of the YAC DNA panel. 
D13S260 PCR-specific products (sized previously as described in section 2.7.3) were 
obtained in lanes 1 (931_C4), 6 (833_d_2), 8 (931_C5), 9 (834_d_2) and 16 (human 
genomic DNA control). No PCR product was detected in the remainder of the lanes: 2 
(94Ld_ 4),3 (91O_e_ll), 4 (951_a_3). 5 (886_d_8), 7 (91O_h_2), 10 (962_a_8), 11 
(746~_1O), 12 (940~_ 4), 13 (total yeast/Y AC genomic DNA). No DNA template 
was added to the PCR reactions loaded in lanes 14 and 15 (water controls). 
(b) Graphic representation of results from microsatellite marker loci 
screen of Y AC DNA panel 
The order of STSs are shown positioned along the single line, including their 
orientation with respect to the centromere (CEN) and telomere (TEL) on the long arm 
of chromosome 13. The relative position and sizing of Y ACs (in brackets) is shown 
below this line. The estimated genetic distance between microsatellite marker loci in 
centimorgans (cM) is indicated above the map. Two contigs are indicated: one 
physically linking D 13S289 with D 13S260 and the other linking D 13S 171 with 
D13S267. 
112 
-.10 
~ 
w 
Fieure 4.3. Y AC characterisation of the BRCA2 minimal rqion 
(a) D13S260 PCR screen or YAC DNA panel 
1 2 3 4 5 6 7 8 9 10 II 12 13 14 15 16 
170bp ~ 
(b ) Graphic representation or results rrom microsatellite marker loci screen of YAC DNA panel 
3cM lcM •• 2cM -... 
D1 3S289 D13S290 D13S1 226 D13S260 D13S 171 D13S267 
CEN I I I I • I TEL 
91O_e_II(I7201cb) 
746-8-10 (I 65Okb) 
940-8-4 (II701cb) 
962_a_8 (I2101cb) 
886_d_8 (9701cb) 
910Jd (I0JOkb) 
93U_4 {15201cb) 951_a_3 ( l760kb) 
941 _d_4 (1580lb) 
93U_5 (15101cb) 
833_d_2 (SIOkbl 
834_c_8 (7501cb) 
FiKure 4.4. Graphic representation of the minimal tilinK path of YACs 
spanninK BRCA2 on 13g12-13. 
The figure is as described in Figure 4.3(b), with the addition of colour. The order of 
marker loci are shown positioned along the blue line. The relative position and sizing 
of Y ACs is indicated by a green line. Y ACs highlighted in red are those used to 
estimate the approximate physical size of the region, 5.27 Mb (shown at bottom of the 
figure). A single contig spans the minimal published genetic interval for BRCA2, 
flanked by D 13S289 and D 13S267. The marker locus, STS 1002 (highlighted in black 
above the blue line), links the two YAC contigs described in Figure 4.3(b). 
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Figure 4.4. G raphic r epresentation of the minimal tiling path of Y ACs spanning BReA2 on 13qJ2-13 
.- 3cM .. ~ 1cM ~ ... 2cM ~ 
D13S289D13S290 D13S1226 D13S260 ST51002 D13S171 D13S267 
CEN I I I I •• I TEL 
910_e_11 (1720kb) 
940_9_4 (1170kb) 
962_a_8 (121 Okb) 
746_9_10 (1650kb) 
910 h 2 (1030kb) 
886 d 8 (970kb) 
931 _1_4 (1520kb) 
931 f 5 (151 Ok b) 951 _a 3 (1760kb) 
833_d_2 (810kb) 941 _d_4 (1580kb) 
834_c_8 (750kb) 
--
5.27 Mb 
4.3. AssiKnment of BRCA2 candidate Ilenes 
An analysis of the Genome Database (GDB; accessed via the HGMP computing 
facility) identified three possible candidate genes for BRCA2 mapping to the long arm 
of chromosome 13. These were the receptor-type tyrosine kinase genes, FLTI and 
FLT3, and Brushl, a tyrosine kinase shown to be underexpressed in a proportion of 
breast tumours (Schott et ai, 1994). FLTI-specific primers (Han et ai, 1993) were 
used to determine if the FLT genes map to the contig; since it was known that FLTI 
and FLT3 map within 600 kb of each other (Rosnet et ai, 1993). Primers designed 
from the published sequence of Brushl (as described in section 2.6.4) were also 
screened across the Y ACs. No positive PCR amplification signal for any of these three 
genes was present in the Y ACs, only in the human DNA control (data not shown). 
Recent physical and genetic maps from the chromosome 13 workshop confirm this 
result and position the two FL T genes and Brush 1 centromeric to the BRCA2 gene 
region (Washington et ai, 1995). 
A number of partially sequenced, randomly isolated cDNAs have been identified (for 
example, Adams et ai, 1995) and are referred to as expressed Sequence Tagged Sites 
(eSTSs). These sequences are usually from the 3' untranslated regions of genes, 
where there is less tendency for interspecies conservation and the insertion of intronic 
sequences. Two eSTS sequences, D 13S 178E and D 13S 181 E, were shown to map to 
the chromosome interval on 13q which also harbours BRCA2 (Hawthorn and Cowell, 
1996). Oligonucleotide primers designed for these transcribed gene sequences were 
screened across DNA from the Y AC contig spanning the BRCA2 region by PCR 
amplification (as described in section 2.6.5). One of these genes, D 13S 178E, was 
found to map to the BRCA2 Y AC contig. D 13S 178E-specific PCR products were 
obtained when the template DNA was isolated from the Y ACs 886_d_8 and 951_a_3, 
but not for the YACs 931_C5 and 91O_h_2 (Figure 4.5 (b)). Therefore, D13S178E 
maps telomeric to the rnicrosatellite marker locus D13S260 (Figure 4.5.(a)). The 
position of D 13S 178E in relation to the microsatellite marker locus D 13S 171 could not 
be determined from present Y AC data. 
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FiKure 4.5. D13S178E. a candidate Kene for BRCA2? 
This figure shows the assignment of D 13S 178E to the BRCA2 region and a 
preliminary investigation by PCR amplification as to its pattern of expression. 
(a) AssiKnment of D13S178E to the BRCA2 YAC contiK. 
This figure is as described in Figure 4.3 with the exception that only four Y ACs which 
span the region harbouring BRCA2 are shown below the single line.The relative 
position of D 13S 178E is shown above the line mapping to the region where D 13S 171 
is located (the orientation of Dl3S178E to D13S171 cannot be determined from this 
analysis). 
(b) MappinK of D13S178E to the BRCA2 YAC contiK. 
The expected 207 bp D 13S I 78E-specific PCR product (when compared to the <l>x 174 
DNA digested with HaeIII molecular weight marker in lane M) was present in lanes: 1 
(886_d_8 DNA), 2 (951_a_3 DNA) and 5 (human genomic DNA) but not detected in 
lanes: 3 (91O_h_2 DNA) and 4 (931_C5 DNA). 
(c)D13S178E expression pattern. 
The 207 bp D 13S 178E specific PCR amplification product (size confirmed previously 
from Figure 4.5 (b» were obtained in lanes: 1 (normal breast cDNA), 3 (foetal brain 
cDNA) and 7 (human genomic DNA. No PCR amplification product was detected in 
lanes: 2 (HeLa eDNA), 4 (placental cDNA), 5 ( breast adenocarcinoma cDNA) and 6 
(retina eDNA). 
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Fieure 4.5. D13S178E, a candidate 2ene for BReA2? 
(a) Assignment of D13S178E to BRCA2 YAC contig 
D13S178E 
013S289 013S290 D13S1226 013S260 STSlOO2 013S171 013S267 
CEN I I _ I ____ I I. I TEL 
931_C5 95C a_3 
910_h_2 886_d_8 
(b) Mapping ofD13S178E to BRCAl YAC contig (c) D13S178E expression pattern 
1 234 5 M 
123456 7 
~207bp ~ 
The sequence of D 13S 178E was screened across the GenEMBL sequence database 
(using the GCG package accessed via the ICRF computing facility) and revealed no 
homology to any previously identified genes or gene families (data not shown). To 
determine the expression pattern of D 13S 178E, the oligonucleotide mapping primers 
were screened across a panel of cDNA libraries by PCR amplification (as described in 
section 2.6.6). The 207 bp PCR product (confirmation of size determined from Figure 
4.5 (b)) for D 13S 178E was present in normal breast and foetal brain cDNA libraries, 
but not in, for example, a breast adenocarcinoma cDNA library (Figure 4.5.(c)). The 
presence of a transcript in the normal breast but not in the breast adenocarcinoma 
library suggested that the full length cDNA of this gene could be regarded as a strong 
candidate for the proposed tumour suppressor gene, BRCA2. However, it is possible 
that the particular tissue-specific cDNA libraries used in this analysis were not fully 
representive of the number of genes expressed in those tissues. 
4.4. Summary 
A gene for breast/ovarian cancer predisposition, BRCA2, had been assigned to the 
region 13q 12-13 (Wooster et ai, 1994). Towards the identification of this gene, a YAC 
contig was constructed spanning the published minimal genetic interval between the 
marker loci D 13S289 and D 13S267. Physical mapping of these Y ACs using 
microsatellite marker loci suggested complete coverage of the region spanning a 
distance of 5.27 Mb or less. To identify candidate genes for BRCA2, the Genome 
Database was searched for genes mapping in this region. Three possible candidate loci: 
FL T 1 , FL T3 and Brush 1 were found to map outside the contig. One gene, 
D 13S 178E, was mapped to the contig and was regarded as a candidate for BRCA2. 
This contig provided a framework for the generation of new polymorphic markers to 
assist in reducing the minimal genetic region for BRCA2, and for the isolation of other 
transcribed sequences. This work was continued to characterise the full length cDNA 
for D13S178E and to identify other candidate genes for BRCA2 (Drs. R. Wooster, M. 
Stratton and colleagues). Mutation analysis of DNA from BRCA2 gene carriers would 
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detennine if D 13S 178E, or indeed another gene in the region, coded for the familial 
breast cancer gene, BRCA2. 
4.5. Identification of BRCA2 
The genetic interval harbouring BRCA2 was reduced to 600 kb from the identification 
of recombinants in BRCA2 linked breast cancer families (Wooster et ai, 1995). One 
key observation came from the identification of a founder effect in a series of breast 
cancer families from Iceland (Gudmundsson et ai, 1996). The region was reduced 
potentially to an interval of 300 kb just centromeric to D 13S 171, by the detection of a 
homozygous deletion in a pancreatic carcinoma (Schutte et ai, 1995). The close 
proximity of this deletion with BRCA2 suggested the same gene may be involved in 
both cancer types. 
A partial cDNA (not D13S178E) isolated from the minimal region for BRCA2 was 
identified in which six distinct germline mutations were found in BRCA2 linked breast 
cancer families (Wooster et ai, 1995). As each mutation would disrupt the open 
reading frame and lead to a truncated protein, this cDNA was likely to be encoded by 
BRCA2. BRCA2 codes for a transcript of 10-12 kb which bears little homology to any 
known protein; though a region of the protein shows weak homology to a portion of 
the BRCA 1 protein. The significance of this homology and other characteristics of 
BRCA2 require further elucidation (discussed further in Chapter 7). 
(The families: OV579; BC3; BC 12; ICRF26, described at the beginning of this 
chapter, show some evidence of linkage to BRCA2 but, as yet, no BRCA2 germline 
mutations have been detected (E. Mavraki, personal communication). 
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CHAPTER 5: ALLELE LOSS AT DRCAI AND DRCA2 
5.1. Introduction 
This chapter describes allele loss studies with microsatellite marker loci flanking the 
BRCA 1 and BRCA2 loci in breast carcinomas. These were performed on DNA 
extracted from tumours of putative BRCAI gene carriers and a population of breast 
cancer patients unselected for family history. The majority of tumours from the latter 
group are assumed to have arisen without a highly penetrant inheritable susceptibility 
component, that is, they are sporadic. The initial aim was to investigate whether 
BRCA 1 functions as a tumour suppressor gene in familial and sporadic disease. A 
number of these tumour DNA samples were also assessed for allele loss at the BRCA2 
locus. Further genetic linkage studies incorporating tumour DNA analysis in ICRF 
breast cancer families are also described. 
S.2. Is BRCAI a tumour suppressor a:ene? 
The focus for this study involved the analysis of carcinomas from the BOV3 pedigree 
(described in Chapter 3). In this family, an AG deletion in codon 185 of BRCA 1 has 
been determined as the genetic basis of cancer predisposition (Shattuck- Eidens et ai, 
1995; Xu et ai, in press). Allele status of BRCAI in breast carcinoma'> from this 
family would provide convincing evidence as to a proposed tumour suppressor 
function for BRCA 1. Breast tumour DNA was analysed using microsatellite marker 
loci flanking BRCA 1. The nine breast carcinomas were from family members who 
were highly likely to be BRCA 1 gene carriers from haplotype analysis of microsatellite 
marker loci flanking BRCAI (Chapter 3 and subsequently confirmed from mutation 
analysis: E. Mavraki, personal communication). All tumour DNA analysed was 
extracted from archival pathological slide preparations (as described in section 2.3.3). 
The results for these nine carcinomas are shown in Figure 5.1; examples of allele 
status in tumour DNA are shown in Figure 5.2. Allele loss of the BRCA1 region was 
detected in all nine breast carcinomas with microsatellite marker loci localised to 
17q12-21. 
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Fi2ure 5.1. Allele loss on chromosome 17 in BOV3 breast tumours 
This figure summarises the results obtained from the nine BOV3 breast carcinomas 
assessed for allele loss with microsatellite marker loci mapping to chromosome 17. All 
tumours shown in this figure are from BOV3 family members carrying the 185delAG 
mutation in BRCA 1. The microsatellite marker loci screened across the tumours are 
shown to the left of the figure. The order of microsatellite marker loci is as described 
in Figure 3.10. All loci map to the region 17qI2-21, with the exception of the TP53 
microsatellite locus which maps on the short arm of chromosome 17. The pattern of 
allele loss/retention (as indicated from the key at the bottom of the page) is shown 
underneath the identification number of the individual (at top of figure) from which the 
tumour was derived. Lack of a symbol indicates allele status was not assessed at that 
locus. Each tumour displayed allele loss with the BRCA 1 intragenic microsatellite 
marker locus D 17S855, and/or microsatellite marker loci flanking BRCA 1. 
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Figur lIeJ Joss on chromosome 17 in BOV3 breast tumours 
BOV3 brea t tumours from gene carriers 
lARKER 4352 4351 3677 36M 3566 5367 5376 3548 3563 
17p TPS 0 0 0 0 
THRAI 0 0 
017.' 0 
BR 1 I 017,' 55 0 0 0 
017,' ) 3 0 0 0 0 17q 
0 017:579 
017.'791 0 0 
17S1 0 
0 17S29_ 0 
17. 5 0 0 
KE : 
o no allcl Ie , 
all Ic I 
o uninfom1ati 
12 3 
(h) 
1 
FllUre 5.2. Examples of chromosome 17 allele status in breast carcinomas from 
BOY3 
3548T 
3548 N 
Examples of microsatellite allele loss analysis of tumour DNA from the BOV3 pedigree. 
The personal identification number is indicated above each lane (further individual details 
such as sex, disease and gene carrier status can be interpreted from Figure 3.4). T = tumour 
DNA, TI = approximately 90 % tumour cell content (estimated as described in section 
2.2.5), T2 = approximately 70 % tumour cell content, N = lymphocyte DNA. Allele typing 
is shown beneath each lane; allele in bold and underlined indicates the allele deleted in 
each tumour. For (h), the individual identification number and tumour type is shown to the 
right of each lane. Approximate allele size range (in base pairs: bp) in brackets after each 
marker locus. 
(a) DI7S293 (115-125 bp): allele 2 is from the disease haplotype. 
(b) D 17S8OO (168-178 bp): allele I is from the disease haplotype. 
(c) DI7S293 (115-125 bp): allele 2 is from the disease haplotype. 
(d) D17S855 (145-160 bp): allele I is from the disease haplotype. 
(e) DI7S19O (190-200 bp): allele 1 is from the disease haplotype. 
(f) D 17S 183 (90-100 bp): allele 1 is from the disease haplotype. 
(g) TP53 microsatellite locus in intron 4 (110-125 bp): representation of allele retention at 
this locus. 
(h) D 17S855 (145-160 bp): allele I is from the disease haplotype. 
Allele detection in (a), (f) and (g) as described in section 2.7.1; in (b), (c), (d) and (e) as 
described in section 2.7.2; (h) as described in section 2.7.3. Allele loss was assessed as 
described in section 2.8. 
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Fia:ure 5.3. Loss of the wildtype BRCAI chromosome in breast 
tumours from the BOV3 family. 
The pedigree is as described in Figure 3.4. Haplotypes for micro satellite marker loci 
(as indicated in top left of figure) are shown under each individual typed (as described 
in Figure 3.4). The haplotype segregating with the disease is indicated in red text 
( 185delAG carrier status was confirmed for all individuals shown to carry the disease 
haplotype: E. Mavraki, personal communication). Alleles deleted in tumour DNA 
extracted from archival pathological material are highlighted in blue text: see Figure 5.1 
for summary of allele loss data. Loss of the wildtype BReAI chromosome was 
demonstrated in all tumours typed from disease gene carriers. Allele loss was also 
demonstrated in the DNA extracted from the ovarian tumour of the non-carrier 3552. 
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In all nine cases, the alleles that are segregating with the disease in the family were 
retained in the tumours whilst alleles of the chromosome inherited from the non-carrier 
parent were deleted (Figure 5.3). The resulting hemizygosity for the mutated BRCAI 
allele suggests that BRCAI acts as a tumour suppressor gene, with loss of the 
wildtype BRCAI allele a common occurrence in BRCA1-linked breast tumorigenesis 
(Kelsell et ai, 1993a). Loss of the wildtype BRCAI allele has been demonstrated in 
another study of breast tumours from BRCA 1 gene carriers (Smith et ai, 1992). 
The 'knock-out' of the wildtype BRCAI allele in each tumour involved a deletion of 
genetic material either side of the BRCAI region (Figure 5.1). Though the limits of 
each deletion were not fully characterised, 8 of the carcinomas must have a distal 
boundary telomeric to BRCA 1 with allele loss detected for the microsatellite marker 
loci: D17S190, D17S293 or D17S588. Deletions for the carcinomas (3563, 3677, 
3684, 5367, 5376) extended outside a proximal boundary (D17S800) for BRCAI. 
Results could not be obtained to define the proximal extent of the deletions on 17q for 
the other three carcinomas (4352, 4351, 3566) due to uninformativeness of the 
proximal microsatellite marker loci in these individuals or lack of a PCR amplification 
product. Tumour DNA from individual 3548 demonstrated allele loss at D17S855 an 
intragenic BRCAI marker locus. However, allele loss was not assessed for other 
microsatellite marker loci. 
A plausible target gene other than BRCA 1 for this allele loss could be the tumour 
suppressor gene, TP53 which maps to the short arm of chromosome 17 and in which 
mutations have been detected in a number of breast carcinomas (see section 1. 14.3(iii): 
for example, Coles et ai, 1992). To investigate this possibility, a microsatellite marker 
locus mapping within the TP53 gene (Jones and Nakamura, 1992) was used to 
determine TP53 allelic status in the carcinomas. Allele loss at the TP53 locus was 
detected in two of the five informative BRCAI familial carcinomas analysed (Figure 
5.1). This suggests that the focus for allele loss on chromosome 17 in the BOV3 
tumours is on the long arm encompassing the BRCA I locus. This is supported by the 
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observation that for each BRCAI-associated tumour, loss of the wildtype copy of 
BRCA I was demonstrated. An example of retention of both copies of the TP53 locus 
is shown for the tumour DNA from individual 3684 in Figure 5.2(g). The intensity of 
the alleles at TP53 in the tumour DNA was comparable to that of the nonnal 
lymphocyte DNA from individual 3684 (gel data not shown). Potentially, genes other 
than BRCAI on 17q could also be the target for allele loss but, as each deletion spans 
the wildtype BRCA I allele, BRCA I is the likely target. 
An additional tumour from the BOV3 pedigree was assessed for allele loss at the 
BRCA I locus. This was from the single sporadic ovarian tumour in individual 3552. 
DNA from this tumour was hemizygous for the BRCAI region, having retained the 
maternally derived chromosome. This is consistent with a role for BRCAI in sporadic 
ovarian tumorigenesis (Foulkes et ai, 1993; Saito et ai, 1993).The possible 
involvement of BRCA I in sporadic breast cancer is addressed in section 5.4. 
5.3. Allele loss at UReAl in familial breast tumours 
From analysis of breast tumour DNA from the BOV3 family (previous section) and 
from other BRCA I-linked tumours (Smith et ai, 1992), there is strong evidence that 
BRCA I acts as a tumour suppressor gene. As loss of the wildtype BRCA 1 appears to 
be a common event in the BRCA1-linked tumours analysed thus far, tumour DNA 
analyses were conducted in a series of ICRF breast and breast-ovarian cancer families. 
The purpose of this study was twofold: 
(i) to extend the pedigrees by typing archival tumour material from deceased affected 
family members for haplotype and linkage analysis 
(ii) to assess allele loss in tumours from putative gene carriers and to use this 
infonnation to evaluate the likelihood of disease in each family being linked to 
BRCAI. 
Individuals from 63 ICRF breast cancer pedigrees were typed with microsatellite 
marker loci spanning the BRCA I locus (alleles detected as described in sections 2.7.1 
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and 2.7.3, unless otherwise stated) and, depending on tumour sample availability and 
the generation of PCR products. assessed for allele loss at BRCAI (as described in 
section 2.8). All tumour DNA was extracted from archival pathological sections (as 
described in section 2.3.3). The same set of families were also typed with 
microsatellite marker loci flanking BRCA2 to determine the proportion of those 
families likely to be linked to each cancer susceptibility locus (see Chapter 7 for brief 
analysis of results from this study). Allele loss data was incorporated into the multi-
point linkage analysis using the method described in section 2.13.1.2 (Prof. T. 
Bishop. personal communication). Examples of families analysed with allele loss data 
are described below. 
S.3(i) BeS 
This family is classified as a breast-ovarian cancer family (Figure 5.4). The majority of 
cancers were diagnosed before age 40, with three female family members diagnosed 
with bilateral breast cancer (295) or breast-ovarian cancer (289, 291). The haplotype 
(1: 1:3) appears to be segregating with the disease. Unaffected individual 287 has 
inherited only one of the inferred parental chromosomes (constructed on the basis of 
each haplotype being present in at least two family members). Non-paternity would 
seem the likeliest interpretation of this result. 
DNA was analysed from two archival pathological breast tumour samples from this 
family. Tumour DNA from individual 285 revealed loss of the "5" allele at Dl7S855 
with retention of the "I" allele (gel data not shown: interpreted in Figure 5.4). 
Confirmation for this individual carrying the putative disease haplotype was 
demonstrated from typing her son's lymphocyte DNA (individual 309). Allele loss at 
D 17S855 was also likely from analysis of tumour DNA from individual 288 (Figure 
5.4). Only allele" 1" was detected from the PCR amplification of DNA from this 
tumour at this locus (gel data not shown: interpreted in Figure 5.4). Though a non-
tumour DNA sample was unavailable for this individual, from the construction of the 
inferred parental haplotypes for this individual only one parental haplotype can bear the 
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Fi&ure 5.4. Haplotype and allele loss analysis of BeS 
Symbols are as described in Figure 1.1. The order of microsatellite marker loci and the 
putative disease haplotype segregating with disease in this family are shown in the 
bottom left hand comer of the figure. The putative disease haplotype is indicated in 
red. Haplotypes for individuals 293 and 290 are inferred as are those of their parents. 
Some haplotypes for individuals at risk of being BRCAI gene carriers (from pedigree 
analysis) are not shown as they are of possible clinical relevance. It is likely that the 
paternal haplotype of individual 287 was inherited from a different father to that of her 
brother and sisters (a cross-over event between THRAI and D17S855 is likely to have 
occurred on the maternal chromosome homologue transmitted to individual 287). This 
is partly based on the observation of a 6:4:3 haplotype in individual 297 (likely to have 
been transmitted from the mother of 278 who is the sister of the mother of the large 
sibship) which is also present in individual 290. In addition, the observation of the 
haplotypes; 3:2: 1 and 1 :5: 1 present in at least three sibs supports 287 having inherited 
the haplotype 2:5:2 from a different father. Individuals 288 and 285 were typed from 
archival breast tumour tissue sections (indicated by an asterisk). The allele deleted in 
the tumour is indicated in blue text. A zero allele in a tumour DNA sample indicates 
either unable to generate a PCR amplification product or predicted hemizygosity (at 
D l7S855 in tumour DNA of individual 288). LOD scores supporting disease 
susceptibility and the inheritance of a mutated BRCAI gene are shown in the bottom 
right of figure. A frameshift mutation in one allele of BRCA 1 (deletion of nucleotide T 
at position 3896: 3896delT) has been detected in lymphocyte DNA extracted from 
individuals: 291,289 and 316: Xu et ai, in press). 
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"1" allele at D 17S855. This suggests tumour DNA from individual 288 is hemizygous 
at D17S855 with the same allele retained as that detected in the tumour DNA from 285. 
Haplotype data from her offspring conftrmed this analysis (data not shown as 
clinically relevant). 
Analysis of these two tumours and the segregation of a 17 q 12-21 haplotype with the 
disease suggests cancer predisposition in this family is due to an inherited mutation in 
BRCA 1. A LOD score at BRCA 1 of 1.41 incorporating the allele loss data (Prof. T. 
Bishop, personal communication) supports disease in this family being linked to 
BRCAI (Figure 5.4). Subsequently, a frameshift mutation in one allele of BRCAI 
(deletion of nucleotide T at position 3896; 3896delT) has been detected in the germline 
DNA from gene carriers (identifted from haplotype analysis: this section) in this family 
(Xu et ai, in press). 
5.3.00 BOV 4 
This pedigree is classifted as a breast-ovarian cancer family with seven female 
members affected with either breast or ovarian cancer, or both (Figure 5.5). The 
majority of affected members in this family are deceased. However archival tumour 
DNA was available from four affected women in this family: 8199, 8203, 8190 and 
8213. Microsatellite analysis of DNA extracted from these tumours showed only a 
single allele at each locus tested (for example, D 17S855). This could be explained by 
either homozygosity in the germline or hemizygous loss in the tumour DNA at 
BRCA 1. A signal of reduced intensity for allele "4" was detected in the ovarian tumour 
DNA from individual 8190 at the THRAllocus indicating a reduction to hemizygosity 
with retention of allele 3 (Figure 5.6). 
Though the constitutive allelic status of the tumours could not be conftrmed (due to 
lack of a "normal" DNA sample), the observation that all the affected members share a 
common haplotype (including that detected in the tumour DNA) would support disease 
in this family being linked to BRCAI. A LOD score at BRCAI of 1.43 incorporating 
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Fia:ure 5.5. Haplotype and allele loss analysis of BOV 4 
Symbols are as described in Figure 1.1. Key indicating the cancer type for affected 
individuals is indicated in the top left hand comer of the figure. The specific cancer 
type for those individuals affected with cancer other than breast and/or ovarian cancer 
is indicated under the individual's identification number with the age of diagnosis (dx). 
The order of microsatellite marker loci and the putative disease haplotype segregating 
with disease in this family are shown in the bottom right hand comer of the figure. The 
putative disease haplotype is indicated in red. Individuals 8199, 8203, 8190 and 8213 
were typed from archival breast tumour tissue sections (indicated by an asterisk). 
Allele deleted in tumour is indicated in blue text. A zero allele in a tumour DNA sample 
indicates either unable to generate a PCR amplification product, or unable to determine 
if tumour DNA is hemizygous or constitutively homozygous at that locus. LOD scores 
(particularly that generated from the incorporation of allele loss data) supporting 
disease susceptibility and the inheritance of a mutated BRCA 1 gene are shown at the 
bottom right of the figure. A frameshift mutation in one allele of BRCAI (deletion of 
four nuc1eotides at position 3875: 3875de14) has been detected in lymphocyte DNA 
extracted from individuals 8219 and 8206 (Xu et ai, in press). In addition, individual 
8219 has inherited a BRCAI mutation in the paternally transmitted BRCAI allele (Dr. 
D. Black, personal communication). 
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F'&ure 5.6. Allele loss at the TURAllocus in ovarian tumour DNA of individual 8190 
from BOY4 
Examples of the results of microsatellite marker loci analysis of tumour DNA from the 
BOV4 pedigree. The personal identification number is indicated above each lane (further 
individual details such as sex, disease and gene carrier status can be interpreted from Figure 
5.5). DNA was extracted from pathological material with approximately 70-90 % tumour 
cell content (estimated as described in section 2.2.5). Allele numbering i shown to the right 
of the figure. Allele 3 at the THRAl locus is segregating with breast and ovarian cancer (see 
Figure 5.5). All three samples have inherited allele 3. Loss of allele 4 (from comparison of 
allele 3 and 4 intensities) is clearly evident in the ovarian tumour DNA extracted from 
individual 8190. The loss of the wildtype allele in thi tumour supports BRCA 1 acting as a 
familial tumour suppressor gene in BRCAl-associated ovarian tumorigenesis. As non-
tumour DNA was unavailable for analysis for the individuals 8213 and 8203, allele loss in 
their respective tumour DNA could not be determined as both individual may be 
constitutively homozygous at the THRAI locus. However, it is possible that allele 4 is also 
deleted in the tumour DNA from individual 8213. 
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the allele loss data (Prof. T. Bishop, personal communication) further suggests that 
disease in this family is linked to BRCAI (Figure 5.5). Subsequently, a frarneshift 
mutation (3875deI4) in one copy of the BRCAI gene has been detected in the two 
family members from this pedigree for which lymphocyte DNA was available (8206, 
8219: Xu et ai, in press). Interestingly, a BRCAI mutation (41480: Arginine to 
Glycine amino acid change) has also been detected in the paternally inherited BRCAI 
allele in individual 8219 (Dr. D. Black, personal communication). This compound 
heterozygote is the second reported case of an individual with two putative mutant 
BRCA 1 alleles. The other was detected in a woman diagnosed with breast cancer at 
age 32 who was homozygous for an AA deletion at position 2800 (Boyd et ai, 1995). 
Both women appear normal and developed breast cancer at a comparable age to 
BRCA I heterozygotes from each pedigree. The biological significance of carrying two 
abnormal copies of BRCA I requires investigation and is discussed further in Chapter 
7. 
These results (including those generated from the analysis of the BOV3 tumour DNA) 
were combined with data generated by other members of the Breast Cancer 
Consortium Linkage Group. 86% of BRCAI-linked breast-ovarian carcinomas 
showed loss of the BRCA1 region with the disease haplotype retained in each case 
(Cornelis et ai, 1995). This analysis provided firm evidence that BRCAI acts as a 
tumour suppressor gene and deletion of the wildtype allele is a common mechanism of 
inactivation in breast and ovarian carcinomas from BRCAI gene carriers. Additionally, 
there was no indication of an imprinting effect as chromosomal losses involved both 
paternally and maternally derived chromosomes (Cornel is et ai, 1995). An imprinting 
effect could not be excluded as a possibility from the allele loss study of breast 
tumours from the BOV3 pedigree (Figure 5.3) as all tumours from gene carriers 
analysed had inherited the mutant BRCA I allele from their mothers. 
A selection of the other ICRF pedigrees analysed by incorporating allele loss data are 
described in the following sections: 
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Fi&ure 5.7. BRCAl haplotype and allele loss analysis in three ICRF 
pedi&rees 
The pedigrees are constructed as described for other pedigrees, for example, Figure 
3.4. Affected status of family members is as described in the key (in bottom left of 
figure). The cancer type is indicated under the identification number for each affected 
member: BC=brea~t cancer; OV=ovarian cancer; BOV=breast and ovarian cancer. An 
asterisk * to the left of an individual's symbol indicates genotyping and allele loss 
assessment of tumour DNA was performed. For individuals 6435 (Figure 5.7(i», 
24178 and 24179 (Figure 5.7(ii), lymphocyte DNA was also available for genotyping 
and comparison of allele status to that obtained from tumour analysis. Haplotypes for 
microsatellite marker loci (as indicated to the left of typed individual in last generation 
of each family) are shown under each individual typed. The haplotype putatively 
segregating (in pedigrees BOV178 and BC2148) with the disease is indicated in red 
text. Alleles deleted in tumour DNA extracted from archival pathological material are 
highlighted in blue text. Loss was detected in each tumour for each locus analysed or 
for which a PCR amplification product was generated. Linkage analysis was 
conducted as described in section 2.13.1.2. 
(n BOVl78 
Allele loss was detected in both tumours analysed with the retention of the same 
haplotype: I: 2: 3: 3. This haplotype appears to be segregating with the disease in the 
family. Incorporation of allele loss data into the linkage analysis supports the 
implication that disease in this family is due to a mutation in BRCAI (see LOD scores 
under the BOV 178 pedigree). Subsequently, a 185deiAG mutation has been detected 
in one allele from individuals 6432 (diagnosed with breast and ovarian cancer) and 
16919 (unaffected male gene carrier) (Xu et aI, in press). 
(m BC2148 
Allele loss was detected in both tumours analysed with the retention of the same 
haplotype: I: 1: I. This haplotype appears to be segregating with the disease in the 
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family. Incorporation of allele loss data into the linkage analysis supports the 
implication that disease in this family is due to a mutation in BRCAI (see LOD scores 
to the left of the BC2148 pedigree). No BRCAI mutation has been reported in this 
family as yet (Prof. E. Solomon, personal communication). 
(iii) Be 1777 
Allele loss was detected at all three rnicrosatellite marker loci analysed fom the breast 
tumour of individual 24449. However, the haplotype retained (l: 4: 1) was not the 
haplotype in common with the two other genotyped affected pedigree members. This 
suggests disea~e susceptibility in this family is not due to an inherited mutation in 
BRCA 1. Linkage analysis has yet to be conducted in this family (Prof. T. Bishop, 
personal communication). No BRCAI mutation has been reported in this family (Prof. 
E. Solomon, personal communication). 
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5.3.(iii) ICRF 178 
This pedigree consists of three affected sisters; two who developed both breast-ovarian 
cancer (6431 and 6432) and the third, who developed ovarian cancer (6435: Figure 
5.7(a». Lymphocyte DNA was available from two of the affected sisters (6432, 6435) 
and a number of unaffected family members. Breast and ovarian tumour DNA from 
archival pathological material was available for the affected family members: 6431 and 
6435, respectively. From comparison of the three affected sister's haplotypes, all three 
have inherited the same maternal and paternal chromosomes (if a recombination event 
occurred between BRCA I and D l7S579 in 6431). From pedigree analysis, it is likely 
that cancer susceptibility was inherited from their mother, who had breast cancer 
diagnosed at age 47. DNA was unavailable from their parents to determine which 
haplotype was inherited from each parent. However, DNA from the two tumours 
analysed revealed allele loss at BRCAI with retention of the same alleles suggesting 
the haplotype (I ;2;3;3) wa" segregating with disease in this family. These results were 
combined into the linkage analysis, generating a LOD score of 0.99 at 0.00 
recombination fraction with BRCAI and the disease (Prof. T. Bishop, personal 
communication). Subsequent to this analysis, a 185deiAG mutation in BRCAI was 
detected in this family (Xu et ai, in press). 
5.3.(iv). Ancestral mutation? 
The ICRF 178 BRCA I mutation is identical to that seen in the BOV3 family (Chapter 
3) and in a third family, ICRF546 (Xu et ai, in press). Disease haplotype comparison 
of gene carriers from these three ICRF pedigrees was performed using microsatellite 
marker loci intragenic to BRCA 1 (detected as described in section 2.7.3). As DNA 
was only available from one gene carrier from ICRF546 and ICRF178 (at time of this 
analysis), haplotype construction was impossible to infer if the microsatellite marker 
loci tested were heterozygous in each gene carrier. However, a common disease 
haplotype could be inferred (by the observation of alleles in common at each locus in 
gene carriers from each family) suggesting that disease in all three families is due to the 
same ancestral mutation (Table 5.1). Interestingly, an ancestral 185deiAG BRCAI 
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mutation has been demonstrated to segregate in the Ashkenazi population at a 
frequency of approximately 1% (Streuwing et al. 1995a). However from gene carrier 
haplotype analysis, the ICRF I 85deiAG mutation arose independently to that found in 
the Ashkenazi population (Neuhausen et al. 1996a). 
The haplotypes from the ICRF gene carriers were extended by genotyping with 
rnicrosatellite marker loci centromeric and proximal to BRCAI (Table 5.1). Shared 
alleles were present in all gene carriers over a region spanning at least 23-25 cM. As 
the putative shared disease haplotype is extensive, this would suggest that the BRCAI 
mutation is of a similar age in all three familes, having only very recently diverged. 
However. interviewed individuals from each family are unaware of any genealogical 
link between the three families (Prof. T. Bishop, personal communication). There is a 
divergence of the BOY3 disease haplotype from the other two, centromeric to BRCAI 
at D 17S925 and telomeric to BRCA 1 at D 17S787. The two gene carriers from 
ICRF546 and ICRF178 have a possible disease haplotype in common which spans at 
least 30 cM (diverge at D 17S948) which suggests they may be more closely related to 
each other than to the BOY3 family. Indeed, a common family name has ben identified 
in earlier generations of the ICRF546 and ICRF 178 families supporting this 
observation (Prof. T. Bishop, personal communication). However, no genealogical 
link has been confinned as yet. 
S.3.(iv) BC 2148 
In this family. the two affected daughters (24308 and 24197) share the same 
haplotypes (Figure 5.7(b». Breast tumour DNA was available from the mother, 
24178. and the daughter. 24179. and both were assessed for allele loss at BRCAL 
Loss wa<; detected in both tumours with the same sized alleles retained in each tumour. 
This tentatively supports linkage to BRCA 1 and is reflected in the increase of the LOD 
score following incorporation of the allele loss data (Prof. T. Bishop, personal 
communication). 
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Table 5.1. Haplotype comparison of the three ICRF breast-
ovarian cancer families carryin2 the 185deiAG mutation in 
BRCAI 
Mi!rk~r 12!'; Y:i ICRFS46 ICRF178 BOV3 
017S953 123 1231129 129 
(7 cM) 
017S925 1651172 165 165 
(6cM) 
017S798 218/225 2251227 225 
(5 cM) 
017S933 189/191 189/197 189 
(3 cM) 
THRAI 167 167/177 167 
(1-2 cM) 
017S776 122 122 122 
(0-1 cM) 
BRCA I( 185de1AG) 126 126 126 
D17S1327 135 135/153 135 
D17S1323 145/149 145/149 145 
D17S1322 128 128 128 
D17S8SS 153 1511153 153 
D17S1326 101 1011109 101 
(1-2cM) 
017S579 120/128 1201114 120 
(3 cM) 
o 17S806 187 187 187 
017S1827 128/145 145 145 
(3 eM) 
017S1820 2651277 267/277 277 
(4cM) 
017S787 139/153 137/153 141 
(13 eM) 
017S948 143/151 133/145 143 
One gene carrier was typed from ICRF546 (13523: pedigree not shown) and ICRF178 
(16919; see pedigree in Figure 5.7(i)) and two gene carriers from BOV3 (3540 and 
3550: see pedigree in Figure 3.4). Allele detection (and sizing) was as described in 
section 2.7.3. Size of PCR amplification ONA products shown in base pairs (bp). For 
microsatellite marker loci in which the disease allele could not be determined, both 
alleles are shown (if heterozygous at that locus). Intragenic (or closely flanking) 
BRCA 1 marker loci are indicated in bold text. Approximate genetic distances in 
centiMorgans (cM) between marker loci is shown in brackets (from Gyapay et ai, 
1994: Albertsen et al. 1994: Dib et al. 1996). There is a divergence of the BOV3 
disease haplotype from the other two. centromeric to BRCAI at 017S925 and 
telomeric to BRCA I at D 17S787. 
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S.3.(v) BC 1777 
Lymphocyte DNA was available from three female members of this family who have 
developed breast cancer (24202,21881 and 24449: Figure5.7(c)). Analysis suggested 
a putative common haplotype in the BReAI region from D17S800 to D17S855, 
though other haplotypes could be constructed. Allele loss was detected in breast 
tumour DNA from individual 24449. However, the alleles retained (1:4:1) were not 
from the putative "shared" haplotype (2:3:311). This would indicate that breast cancer 
in this family is not linked to BReAl, or, that individual 24449 has "sporadic" disease 
(or has inherited a distinct cancer susceptibility mutation). Linkage analysis has yet to 
be performed in this pedigree (Prof. T. Bishop, personal communication). 
S.3.(vi) ICRF 510 
This pedigree is a multi-site cancer family, including five confirmed diagnosed cases 
of breast cancer and one case of ovarian cancer. There is no common BReAl 
haplotype shared in the majority of the breast cancer cases or with the ovarian cancer 
case (Figure 5.8). This would indicate that disease susceptibility in this family is not 
linked to BReA 1, reflected in a LOD score of -0.44 for BReAl and the disease (Prof. 
T. Bishop, personal communication). Analysis of tumour DNA from family members 
supports this finding. No allele loss at BReAI was detected in breast tumours from 
individuals 12230 and 12236. Other compelling evidence comes from the analysis of a 
brea<;t tumour from individual 12259. Allele loss was detected at the BReAl locus 
(Figure 5.9), but the allele retained was from the paternal chromosome (Figure 5.8). 
From pedigree analysis, the putative cancer susceptibility locus appears to be inherited 
from her mother. 
Microsatellite marker loci mapping to other candidate regions which harbour cancer 
susceptibility genes, for example, TP53, have been screened across lymphocyte and 
tumour DNA samples from this family. No indication of linkage with the disease to 
these loci or common patterns of allele loss have been found (data not shown). 
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Fia=ure 5.S. ICRF510 BRCAI haplotype and tumour DNA analysis 
Symbols are as described for previous pedigrees, for example, Figure 3.2. The key 
indicating the cancer type for affected individuals is indicated in the top left hand 
corner of the figure. The specific cancer type for those individuals affected with cancer 
is under the individual's identification number: BC=breast cancer, OV=ovarian cancer, 
SCCO=squamous carcinoma of the oesophagous, Lym=lymphoma, Ton=tongue 
carcinoma, Lip=lip carcinoma, Mel=melanoma. The order of microsatellite marker loci 
is shown in the bottom left hand corner of the figure. Haplotypes are shown under the 
identification number for each individual genotyped. For individuals 12259, 12233, 
12230. 12236 and 12247. archival breast tumour DNA was analysed (indicated by an 
asterisk·). However. for individuals: 12233 and 12247, tumour DNA was only 
available for genotyping. A zero allele indicates they are either hemizygous or 
homozygous at that locus (as genotyped from tumour DNA with no normal DNA 
sample available). Allele deleted in tumour is indicated in blue text. Allele loss was 
detected in three of the tumours analysed. For tumours: 12233 and 12247, the same 
haplotype (3: 5: 5) was retained in each tumour. However, for breast tumour DNA 
derived from 12259, the haplotype retained was inherited from the non-disease 
transmitting parent (from pedigree analysis). Example of allele loss in the tumour DNA 
from this individual is shown in Figure 5.9. Haplotype and allele loss data suggests 
disea~e in this family is not due to an inherited mutation in BRCAI (supported by a 
LOD score of -0.44 at BReA 1 with the disease in this family: Prof. T. Bishop, 
personal communication). 
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The per nal identification number i indicated above each lane (further 
individual detail uch a ex disea e and gene carrier status can be 
interpreted fr m Figure 5. ). Allele tatus of breast tumour DNA from 
individual 12259 at THRA I i hown in the lane indicated by the label, 
12259T. The ther two lane how allele status at the same locus in 
lymph yte D from the arne individual 12259 and her twin sister, 12260. 
Tumour D A was e tracted from pathological material with approximately 
80 Oh tumour cell ontent (e timated as described in section 2.2.5). Allele 
numbering i hown to the right of the figure. Allele detection is as described 
in ection 2.7.1 and allele 10 interpreted as described in section 2.8. Loss of 
allele 1 (fr m mp ri on of allele tatu in DNA from lymphocyte DNA of 
the arne individual) i clearly evident. The allele retained (allele 1) in the 
tum ur D A wa likely to have been inherited from her father (based on 
hap) typ c n truction for that branch of the family: see Figure 5.8). From 
p digree analy i , di ea e u eptibility appears to be tran mitted from her 
affe ted m ther, 12240. 
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5.4. URCAI allele loss in sporadic breast carcinomas 
118 paired tumour and lymphocyte DNA samples were analysed from a sporadic 
female breast cancer population (individuals who have no apparent family history) in 
the south east of England. No selection for histology or age of onset of cancer was 
used in sampling. The DNA analysed was extracted from fresh tumour material and 
lymphocytes (as described in section 2.2.4). These breast tumourlblood DNA pairs 
were screened with microsatellite marker loci flanking BRCAI (THRA1, D17S800, 
Dl7S855, D17S579: see Figure 3.1). Analysis of the BRCA1 status in these 
carcinomas might indicate a possible role for this gene in sporadic disease. All 
microsatellite allele profiles were detected and analysed as described in sections 2.7.3 
and 2.8, respectively. Allele loss at BRCAI was identified as complete or almost 
complete reduction (for the majority of cases, a 20-50% reduction was observed) to 
hemizygosity at the closest informative loci to BRCA1(at least two loci). 
47 % of carcinomas (561118) were hemizygous at BRCAL Background or random 
allele loss rates are estimated to be seen in between 10 and 15 % of tumours, implying 
that loss of the BRCA 1 chromosomal region is a common event in sporadic breast 
tumorigenesis. This has been demonstrated by a number of other studies (for example, 
Futreal et ai, 1992). However since the identification of the BRCAI gene, a second 
somatic mutation event in the retained allele from sporadic breast carcinomas 
demonstrating allele loss at this locus has not been identified (Futreal et ai, 1994; 
reviewed Szabo and King, 1995). Therefore, the role of BRCA 1 as a classical tumour 
suppressor gene in sporadic disease is unclear. 
It has been proposed that there are other target regions for allele loss in breast (and 
ovarian) tumours on the long arm of chromosome 17 which are distinct from BRCAI 
(Comelis et ai, 1993: Saito et ai, 1993; Jacobs et aI, 1993; Radford et aI, 1993). One 
of these proposed target regions for allele loss is 17q24-25. Twenty of the 118 
sporadic carcinomas were examined for allele loss in this region (detected as described 
in section 2.7.3). Of interest to this study is that the TOC locus associated with 
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oesophageal cancer susceptibility also maps in this region (Chapter 6). These breast 
tumourllymphocyte DNA pairs were screened with rnicrosatellite marker loci mapping 
to the TOC region (D 17S929 and D 17S 1603: see Figure 6.5). The results are 
summarised in Table 5.2. 
Table 5.2. 17g allele loss in sporadic breast tumours 
Chromosomal Region Number of tumours 
Loss at BRCA 1 and 17q24-25 10 
Retained at BRCAI and 17q24-25 6 
Loss at BRCA 1 only 3 
Loss at 17q24-25 only 1 
A number of the tumour DNA samples analysed demonstrated specific sites of deletion 
on 17q. Three breast carcinoma" demonstrated allele loss at BReAI but not at 17q24-
25, suggesting that the target tumour suppressor gene may be BRCA 1. One tumour 
(1133) demonstrated allele loss at 17q24-25 but not at BRCAI (Figure 5.10). 
However. the number of tumours analysed in this study are too small to support the 
presence of a tumour suppressor gene telomeric to BRCA 1. Indeed, from analysis of 
rnicrosatellite marker loci mapping to the region harbouring TP53 at 17p 13 in the panel 
of 118 breast tumourlblood pairs, allele loss was detected in the vast majority of 
tumours also displaying allele loss on 17q (data not shown and V. Murray, personal 
communication). This suggests loss of the whole of one copy of chromosome 17 may 
be a common mechanism in breast tumorigenesis. 
5.5. BReA2 allele loss in sporadic breast carcinomas 
Studies have shown that like BRCA I, BRCA2 also acts as a tumour suppressor gene 
with characteristic loss of the wildtype chromosome in tumours from BRCA2 gene 
carriers (Collins et aJ 1995; Thorlacious et ai, 1995; Gudmundsson et ai, 1995). The 
118 paired breast tumour and lymphocyte DNA samples, previously assessed for 
BRCA I allele loss (section 5.3). were screened with microsatellite marker loci 
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(a) D17S579 (b) D17S929 
T T 
N N 
154 156 222 228 
Fi&ure 5.10. Pattern of allele loss on 17Q in DNA from a "sporadic" breast tumour 
llJJ 
Allele status in tumour DNA from 1133 at two microsatellite loci on the long arm of 
chromosome 17. In this tumour. loss of the region 17q24-25 (017S929) is demonstrated, 
but there was no evidence of allele loss at 17q 12-21 (017S579). 017S579 maps 
approximately 1-2 cM distal to BReA I (Albertsen et ai, 1995). The alleles were detected 
(and sized) as described in section 2.7.3 and allele status interpreted as described in section 
2.8. At each locus. the tumour ONA profile (T) is shown above that obtained from the 
lymphocyte DNA (N) of the same individual. Allele sizes (bp) are shown underneath each 
allele peak. 
(a) D 17S579. Identical allele profile in the tumour DNA compared to that in the 
lymphocyte DNA indicates no allele loss in the tumour at this locus. 
(b) D 17S929. Reduction in the relative peak height of allele 222 in the tumour ONA 
compared to that in the lymphocyte DNA indicates loss of this allele in the tumour. 
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flanking BRCA2 (DI3S260, D13S171, D13S267 (Figure 4.2». Allele profiles were 
detected and assessed as described in sections 2.7.3 and 2.8. 
At BRCA2, 45 % of breast carcinomas (53/118) were found to demonstrate allele loss. 
This would suggest that deletion of BRCA2 is also a common mechanism in breast 
carcinogenesis. Genes other than BRCA2 mapping to 13q could be the target for this 
deletion event, for example, the retinoblastoma gene (RB l). However a number of 
breast tumours have been demonstrated to show specific loss of the BRCA2 region 
and not at RB 1 (for example: Gudmundsson et ai, 1995; Cleton-Jansen et ai, 1995). 
Recent studies have demonstrated that somatic DNA mutations in the BRCA2 gene in 
breast tumours are, like BRCA 1, extremely rare (Lancaster et ai, 1996: Teng et ai, 
1996; Miki et ai, 1996). 
5.6. Allele loss of BRCAII BRCA2 in 2rade 3 breast carcinomas 
Breast tumour pathological material from seven affected members of the BOY3 
pedigree (see section 5.2) known to carry a BReAl mutation was analysed and all 
were found to be grade 3 infiltrating ductal carcinomas (Gusterson et ai, 1996). In 
contrast, the histology of the ovarian tumour from a non-gene carrier in the family 
(individual 3552: section 3.5(a» was described as a well to moderately differentiated 
tumour (Dr. B. Gusterson, personal communication). Other observations support a 
significant association of grade 3 infiltrating ductal carcinoma of the breast with female 
BRCAI gene carriers (Jacquemier et ai, 1995; Eisinger et ai, 1996). Preliminary 
histological analysis of breast carcinomas from affected individuals from ICRF 
families likely to be BRCA2 gene carriers (from haplotype, linkage and, for one 
family, mutation analysis) found no association with any particular histological grade 
(Prof. T. Bishop, personal communication). 
By studying somatic events in phenotypically similar tumours with similar genetic 
susceptibility backgrounds, it may be possible to identify common pathways of 
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somatic alterations and identify the genes mutated during tumour progression. This 
section describes an investigation into the relationship between BRCAI and BRCA2 in 
the carcinogenic process and. in particular. to determine whether BRCAI and BRCA2 
are involved in the same or separate tumour development pathways. The initial focus 
were seven grade 3 carcinomas from the BOV3 pedigree which all carry the same 
BRCAI mutation (Chapter 3). Previous tumour DNA analysis in the seven breast 
carcinoma'i had shown that all demonstrated loss of the chromosome harbouring the 
wildtype copy of BRCA I (section 5.2). These tumour DNA samples were screened 
with microsatellite marker loci flanking BRCA2 (DI3S260. D13S171, SLS234, 
D13S267: see Figure 4.1) to alisess the extent of allele loss at this tumour suppressor 
gene locus (detected as described in 2.7.3). 
Interestingly. allele loss was clearly observed in five BOV3 carcinomas with at least 
two informative markers flanking the minimal interval for BRCA2 (Table 5.3 and 
Figure 5.11 (a). The other two carcinomas: 4351 and 4352 gave equivocal evidence 
(due to lack of a normal DNA control for these individuals; allele profiles were 
compared to those of their offspring). This result suggests that somatic inactivation of 
at lea'it one copy of BRCA2 may have an important role in the development of grade 3 
tumours derived from BRCA I gene carriers. DNA mutation analysis in the retained 
BRCA2 allele hao; not yet been performed in the BOV3 tumours. 
Two other chromosomal regions putatively harbouring tumour suppressor genes were 
also examined and the results are also shown in Table 5.3. Allele loss with a 
microsatellite marker locus (NEFL) at 8p12-22 in the five informative tumours from 
BOV3 suggests a tumour suppressor gene in this region may also be implicated in the 
pathway of grade 3 breast carcinomas. A high level of allele loss (67 %) at this region 
was also demonstrated from the analysis of the sporadic breast tumourflymphocyte 
DNA pairs (previously assessed for allele loss at BRCAI and BRCA2 in sections 5.3 
and 5.4. respectively: V. Murray. personal communication). Other allele loss studies 
have suggested the presence of a tumour suppressor gene deleted in breast tumours in 
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Table 5.3. Similar patterns of allele loss in Krade 3 breast tumours from BOV3 
Chromosomal regions assessed 
10 BRCAI BRCA2 8p12-22 10q24-25 
3563 LOH 
3566 LOH 
3548 LOH 
4352 LOH 
3677 LOH 
4351 LOH 
3684 LOH 
KEY: 
LOH= loss of heterozygosity (allele loss) 
RET= retained heterozygosity 
NI= constitutively homozygous 
ND= not determinable (equivocal) 
LOH LOH RET 
LOH LOH RET 
LOH LOH RET 
NO NI NI 
LOH LOH RET 
ND ND RET 
LOH NI RET 
(The microsatellite marker locus analysed for each region 
are described in section 5.5.) 
Flpre S.l1. Pattern o( allele loss in tumour 3548 (rom the BOV3 (amily 
Examples of the results from microsatellite marker loci analysis of tumour DNA of 
individual 3548 from the BOY3 pedigree (further details can be interpreted from Figure 
3.4). Allele loss of allele 146 at D 17S855 (intragenic to BRCA 1) in tumour DNA from 
3548 is shown in Figure 5.2 (h). The results are comparable to those obtained for breast 
tumours from other members of the BOY3 pedigree (see Table 5.3). The top allele 
profile at each locus is from the tumour DNA (T), and the allele profile is that obtained 
from the lymphocyte DNA (N). Alleles were detected (and sized) as described in section 
2.7.3. and allele status interpreted as described in section 2.8. Allele typing (in bp) is 
shown below each lane~ allele in bold and underlined indicates the allele deleted in each 
tumour (except in (c) where no allele loss as observed). 
(a) Loss of allele 224 at SLS234 (maps proximal to BRCA2) in tumour DNA 
(b) Loss of allele 134 at NEFL (8pI2-22) in tumour DNA 
(e) Retention of both alleles at AFM337xf9 (lOq24-25) in tumour DNA. 
(a) (b) (c) 
T 
N 
218 no 138 
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this region (Kerangueven et aJ 1995). Conversely, no allele loss was detected with 
AFM337xf9 (which maps in the region lOq24-25 which is frequently deleted in 
prostate tumours: Gray et ai, 1995) in the six BOV3 breast tumour DNA samples 
which were infonnative at this microsatellite marker locus. 30 % allele loss at lOq24-
25 was observed from the analysis of the panel of sporadic breast tumours which were 
previously assessed for BRCAI, BRCA2 and 8p12-22 allele loss (V. Murray, 
personal communication). An example of the pattern of allele loss detected in the 
BOV3 breast tumour DNA samples is shown in Figure 5.11. 
To evaluate the finding of combined loss of BRCAlI BReA2 in the grade 3 ductal 
breast carcinomas from BOV3, the 118 sporadic paired tumour and lymphocyte DNA 
samples, previously assessed for BRCA I and BRCA2 allele loss (sections 5.3 and 
5.4), were examined. Allele loss had been assessed without prior knowledge of the 
histology or other clinical parameter of each carcinoma. A similar pattern of allele loss 
at BRCA I and BRCA2 with that observed from the BOV3 tumours was revealed 
when 45 grade 3 infiltrating ductal carcinomas from the sample set were analysed 
separately (Table 5.4). 
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J'able 5.4. Distribution ofBRCAl and BRCA2 allele loss among 45 sporadic grade 3 
infdtrating ductal breast carcinomas 
BRCA2 allele loss 
No Yes 
C'I.l 
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..... 
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== 
Yes 8 21 == 
A test of independence of allele loss showed strong evidence against this hypothesis 
(Fisher's exact test, p = 0.004: Dr. P. Smith, personal communication) with an excess 
of carcinomas being concordant for BRCA 1 and BRCA2 loss or retention in grade 3 
breast carcinomas. Similar tests of the sporadic carcinomas for grade 1 and grade 2 
infiltrating ductal carcinomas or infiltrating lobular carcinomas showed no such trend 
(seventy three carcinomas in total, data not shown). Also, joint allele loss at BRCAI 
and BRCA2 did not correlate with size of tumour at presentation, stage or ER status 
(data not shown). 
These observations support a combined role for BRCAI and BRCA2 in the 
tumourigenic pathway of some familial and sporadic breast cancer, in particular, those 
histologically described as grade 3 (Kelsell et al. 1996a). Although a definitive role for 
BRCA 1 and BRCA2 in sporadic tumorigenesis has not been forthcoming, this 
analysis does suggest that grade 3 breast carcinomas with concordant allele loss at 
BRCA 1 and BRCA2 should be further investigated for germline mutations and/or 
somatic mutations in these genes. Alternatively, hemizygous loss of BRCAI and 
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BRCA2 may be sufficient for the development of sporadic breast tumours. This is 
discussed further in Chapter 7. 
5.7 Summary 
Allele loss studies were performed and demonstrated that in breast carcinomas from 
BRCAI gene carriers, loss of the wildtype allele is a common event. This supports 
BRCA 1 acting as a tumour suppressor gene. Additionally, a number of ICRF breast 
cancer pedigrees were assessed for linkage to BRCA 1, using a combination of 
haplotype and allele loss studies. The incorporation of allele loss data increased the 
power of linkage analysis, particularly for small pedigrees or those with few surviving 
cases. 
Hemizygous loss of BRCAI and BRCA2 are common events in sporadic breast 
carcinomas, but, at present, there is no supporting evidence that the retained copy of 
each gene is somatically mutated. However, analysis of familial and sporadic 
infiltrating ductal grade 3 breast carcinomas revealed a pattern of combined loss or 
retention of BRCA 1 and BRCA2. This supports a role for both genes in the 
development of this tumour type. 
The observed pattern of LOH at BRCA 1 and BRCA2 could be explained by either of 
the following hypotheses: 
(i) There being at least two types of grade 3 tumours, one of which involves 
preferential LOH at BRCAI and BRCA2, or 
(ii) There being at least two types of grade 3 tumours, one of which has a high level of 
genomic instability indicated by frequent LOH at a number of loci. 
This latter hypothesis is independant of BRCA 1 and BRCA2 and so can be tested by 
examining LOH at other chromosomal regions. Allele loss performed on the 45 
sporadic grade 3 breast tumour/lymphocyte pairs with microsatellite marker loci 
mapping to 8p12-22 and lOq24-25 revealed no correlation with combined allele 
loss/retention at BRCAI and BRCA2 (data not shown). This supports the former 
hypothesis and would indicate that BRCA 1 and BRCA2 function on compensatory 
pathways, rather than being involved in the same tumourigenic pathway. 
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CHAPTER 6: PALMOPLANTAR KERATODERMA AND CANCER 
SUSCEPTIBILITY 
6.1 Concept 
An alternative approach to identify cancer susceptibilty gene loci is described in this 
chapter. This approach is based on the observation that, in some families, cancer 
susceptibility appears to segregate with a distinct autosomal dominant disease 
phenotype. Linkage studies are performed to localise the fully penetrant disease locus. 
From identification of this disease locus, it is possible to explore if the same gene 
defect confers the cancer susceptibility segregating through the family. An alternative 
explanation is that the two phenotypes may be due to the segregation of two 
independent but tightly linked gene loci. The latter scenario may be apparent if there 
are observed cross-overs between the two diseases. This approach has the following 
advantages over that of mapping a highly but only partially penetrant cancer 
susceptibility gene: 
(i) the disease manifests usually before puberty, so that gene carriers can be 
phenotypically identified at an early age 
(ii) the disease susceptibility allele is fully, or almost fully, penetrant 
(iii) the incidence of disease in the population is relatively uncommon compared to, for 
example, breast cancer, so the problem of phenocopies for the non-malignant 
phenotype is reduced. 
6.2. Keratin diseases 
Keratins have been implicated, by morphological and genetic studies, as candidate 
genes in diseases displaying epidermal fragility (reviewed Lane, 1994). The keratin 
intermediate filaments form the cytoskeleton of all epithelial cells. Each keratin filament 
consists of a long a-helical rod domain between non-helical ends. Within the rod 
domain are a series of hydrophobic amino acid heptad repeats, which allow obligatory 
heterodimerisation between a type 1 (acidic) and a type II (basic) keratin forming a 
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coiled-coil dimer (reviewed Steinhert, 1993). It is these heteropolymers which 
assemble into the cytoskeletal filaments. Specific type I1type II keratin pairs are co-
expressed at particular stages of epithelial differentiation and in a cell specific manner 
(reviewed Fuchs and Coulombe, 1992). 
Keratin mutations have been identified in a number of disorders associated with 
keratinocyte fragility, such as keratins (KRT) 5 and 14 in epidermolysis bullosa 
simplex (EBS: Coulombe et ai, 1991; Lane et ai, 1992) and KRTs 1 and 10 in bullous 
ichthyosiform erthroderma (BCIE: McLean et ai, 1994). In those identified autosomal 
dominant keratin disorders, the majority of mutations have been found to be point 
mutations which tend to be clustered in the six domains critical for stable keratin 
filament heterodimerisation, particularly the lA rod domain (reviewed Lane, 1994). 
These keratin mutations are likely to reduce the resistance of the cytoskeleton to minor 
external trauma leading to collapse of the filament network in epidermal keratinocytes 
expressing those mutant keratins. 
6.3. Palmoplantar keratoderma 
The palmoplantar keratodermas (PPK) are a heterogeneous group of skin diseases 
characterised by hyperkeratosis ("thickening") of the skin of the palms and soles 
(reviewed Lucker et ai, 1994; Stevens et ai, 1996a). Autosomal dominant forms of the 
disease have been subclassified according to the presence or absence of epidermolysis 
("cell bursting"), the pattern of lesions within the palm and sole skin, associated 
histopathologies and, more recently, from the identification of the specific gene defect. 
Broadly, the PPKs fall into three classes based purely on the pattern of distribution of 
palmoplantar hyperkeratosis: diffuse, focal and punctate (Figure 6.1). 
There is only one identified keratin whose expression is specifically restricted to the 
palmoplantar epidermis, the type I keratin, KRT9 (Langbein et ai, 1993). Mutations in 
the lA region of the KRT9 rod domain have been identified in families with an 
epidermolytic form of diffuse palmoplantar keratoderma (EPPK; Reis et ai, 1994). 
However, of relevance to this study, a large pedigree has been described in which 
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EPPK occurs in association with an increased susceptibility to breast and/or ovarian 
cancer (Blanchet-Bardon et ai, 1987). A KRT9 mutation has been identified which 
segregates with EPPK (and breast/ovarian cancer) in this family (Torchard et ai, 
1994). The majority of type I keratins, including, KRT9, are clustered on 
chromosome 17q12-21 and map approximately 1 cM proximal to BRCAI (Albertsen 
et ai, 1995). Thus in this family, it was likely that the KRT9 mutation was segregating 
with a mutation in BRCAI. Subsequently, a nonsense mutation in exon 11 of BRCAI 
has been identified in affected individuals from this family (Friedman et ai, 1995). 
Non-epidermolytic forms of PPK (NEPPK) have been shown to be associated with 
malignancy. An extensive family from Liverpool, UK has been described in which 
focal NEPPK (previously termed "Tylosis") is associated with susceptibility to 
oesophageal carcinoma (Howell-Evans et ai, 1958; Ellis et ai, 1994). Families with 
punctate NEPPK have also been identified in which the disease is associated with 
internal neoplasia (Bennion and Patterson, 1984; Bianchi et ai, 1994; Stevens et ai, 
1996b). Genetic studies in these families may determine if the cancer susceptibility is 
due to mutations in the PPK disease gene(s) or in a closely linked locus. 
6.4. Aim of study 
Linkage analyses were performed on families with three autosomal dominant forms of 
non-epidermolytic palmoplantar keratoderma: diffuse, punctate and focal. For two of 
these forms, families were identified in which the NEPPK was associated with cancer 
susceptibility. The aim of the study was to determine the genetic basis of NEPPK 
predisposition and to assess the relationship between NEPPK and cancer 
susceptibility. 
As all the identified epithelial keratins have been localised to either of two keratin gene 
clusters: the acidic keratin cluster (type I) at 17q12-21 and the basic keratin gene 
cluster (type II) at 12q 11-13 (Lessin et ai, 1988; Rosenberg et ai, 1988), initial linkage 
studies were performed using microsatellite marker loci flanking these two keratin 
clusters (detected as described in section 2.7). Microsatellite marker loci were 
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identified from published genetic maps (Gyapay et ai, 1994: Dib et ai, 1996) unless 
otherwise stated. 
RESULTS 
6.5. Diffuse NEPPK 
Diffuse NEPPK presents with an even, thick, yellow hyperkeratosis over the whole of 
the palm and sole (Figure 6.1 (b». The disease manifests within the first year of life 
and is 1 00 % penetrant. DNA from informative individuals from two families with 
diffuse NEPPK (designated 2242 and 2244) were analysed with microsatellite marker 
loci spanning the two gene keratin clusters. No association between NEPPK and 
malignancy was observed in these pedigrees. 
Linkage analysis was performed in family 2244 (as described in section 2.13.2) and 
the computed LOD scores are shown in Table 6.1. Linkage was observed between the 
disease and microsatellite marker loci localised to chromosome 12q 11-13 with a 
maximum two-point LOD score of 3.11 at a recombination fraction of 0.00 for 
D12S368. 
Table 6.1. Linkage of diffuse NEPPK to the Type II keratin gene cluster at 12ql1-13 
Pedigree Locus Recombination Fraction Candidate genes 
0.0 om 0.05 0.1 0.2 0.3 0.4 
2244 KRT9 -8.94 -6.61 -4.11 -2.64 -1.24 -0.56 -0.18 Type I keratins 
2244 DI288S 2.53 2.47 2.24 1.93 1.31 0.70 0.19 Type II keratins 
2244 DI28368 3.11 3.06 2.87 2.61 2.07 1.46 0.78 
Haplotypes for microsatellite marker loci mapping to chromosome 12q 11-13 were 
constructed for this pedigree and for pedigree 2242. For meioses where phase was 
equivocal, haplotypes showing the minimum number of recombination events were 
formed. In both pedigrees studied, there was a haplotype that segregated with the 
disease (Figure 6.2 (a) and (b». 
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FiKure 6.1. Three patterns of non-epidermolytic palmoplantar 
keratoderma 
The soles of a representative affected individual from families with either of the three 
forms of non-epidermolytic palmoplantar keratoderma (NEPPK) analysed in this 
study. 
(a) Focal NEPPK 
Affected individual from family 2239 has large hard compact masses of keratin at 
pressure points and other sites of recurrent friction on the sole, in particular, the toes, 
ball and heel of the foot. 
(b) Diffuse NEPPK 
Affected individual from family 2242 has an even, thick hyperkeratosis over the whole 
of the sole. 
(c) Punctate NEPPK 
Affected individual from family 2039 has small punctate keratoses over the whole of 
the sole. 
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As gennline mutations in the type I keratin, KRT9, have been demonstrated in a 
number of diffuse epidennolytic PPK pedigrees (Reis et ai, 1994; Torchard et ai, 
1994), it has been proposed that all patterns of diffuse PPK are the result of KRT9 
mutations. However, this study shows that diffuse NEPPK is linked to the region 
12qll-ql3 where the type II keratins are located. As KRT9 maps to 17qI2-21, a 
mutation in KRT9 can be excluded as the inherited predisposition to diffuse NEPPK. 
This confirms genetically that diffuse NEPPK and EPPK are separate disease entities. 
Linkage to the same region on chromosome 12 with diffuse NEPPK was also 
observed in families from northern Sweden (Lind et ai, 1994). 
A proposed candidate gene for this disease is the type II keratin, KRTI (Kimonis et ai, 
1994), which maps centromeric to the microsatellite marker locus D12S96 and 
telomeric to D12S803 (Figure 6.2(c». No KRTI DNA sequence variants have been 
detected in DNA from affected family members when compared to that obtained from 
unaffected individuals (Prof. I. Leigh, personal communication). A crossover in one 
affected individual from family 2244 places the disease locus centromeric to the 
microsatellite marker locus Dl2S803 (arrowed in Figure 6.2(a». This recombination 
event excludes a number of keratins, including KRT I, as candidate genes for diffuse 
NEPPK on the basis of their physical location (Figure 6.2(c». KRT 7 could be 
regarded as a potential candidate gene as it maps proximal to D12S803 (Figure 6.2(c». 
However, this keratin is biologically unlikely to be the genetic basis of this disease as 
it is expressed in, for example, the mammary gland and bladder epithelial cells but not 
in the palmoplantar epidermis (Moll et ai, 1988). 
It is plausible that a mutation in a KRT 6 gene may be the genetic basis of NEPPK as 
it may map proximal to Dl2S803 (Figure 6.2(c), but its expression appears not to be 
limited to palmoplantar skin (Moll et ai, 1988). However, five KRT 6 sequences have 
been identified (two functional and three likely to be pseudogenes: Prof. I. Leigh and 
Dr. I. McLean, personal communications) and it is possible that one of these KRT6 
genes is expressed predominantly in the palmoplantar epidermis. The position of 
KRT6 genes in relation to D 12S803 and their DNA sequence analysis in diffuse 
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Fia:ure 6.2. Mappina: of diffuse NEPPK to the Type II keratin a:ene 
cluster 
Haplotype analysis of two pedigrees in which diffuse NEPPK is segregating with 
microsatellite marker loci spanning the type II epithelial keratin gene cluster on 
chromosome 12qll-13. (The allele numbering is not comparable between the two 
families). 
(a) Structure and haplotype analysis of pedia:ree 2244. 
The sex of each individual is as described in Figure 1.1. Affected status is indicated by 
a red-filled in box/circle. The haplotypes are shown under each individual. The 
microsatellite marker loci genotyped and their order are shown beneath the pedigree. A 
zero allele indicates individual not genotyped at that microsatellite marker locus. The 
haplotype segregating with the disease in each family is indicated in red text. The 
affected individual arrowed has inherited the disease haplotype centromeric to 
D12S803. 
(b) Structure and haplotype analysis of pedia:ree 2242 
The pedigree is constructed and labelled as in Figure 6.2(a). The haplotype segregating 
with the disease is indicated in red text. 
(c) Ora:anisation of the type II keratin cluster 
Schematic representation of the organisation of the keratin genes in relation to 
micro satellite marker loci mapping to chromosome 12qll-13 (adapted from Krauter et 
ai, 1995). Microsatellite marker loci are indicated above the bold line with the position 
of each keratin gene below the line. The orientation of the loci in relation to the 
position of the centromere (CEN) and telomere (TEL) is indicated. The arrow above 
the line indicates the diffuse NEPPK disease gene maps centromeric to D 12S803 
(from the cross-over detected in the affected individual arrowed in pedigree 2244 
(Figure 6.2(a)). 
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NEPPK affecteds may identify such a candidate. Alternatively, a mutation in a 
unidentified keratin (or a gene which effects keratin integrity) may underly diffuse 
NEPPK. Further studies are in progress to identify the genetic basis of this disease. 
6.6 Focal NEPPK without associated Oesophaa=eal Cancer 
Focal NEPPK presents as large hard compact masses of keratin particularly on the sole 
and also at other sites of recurrent friction (Figure 6.1 (a». The NEPPK in the pedigree 
studied, 2239 (see Figure 6.3), was inherited as an autosomal dominant trait and 
manifested at around 7 years of age. Intermittent subtle nail abnormalities and oral 
hyperkeratosis were also observed in affected individuals from the pedigree (Dr. H. 
Stevens, personal communication). Linkage analysis was performed as in section 
2.13.2. 
Linkage and haplotype analysis of the focal NEPPK pedigree provided evidence for 
the localisation of the disease gene to chromosome 17qI2-21, the location of the type I 
keratin gene cluster (fable 6.2; Figure 6.3.(a». A two-point LOD score of 2.49 was 
obtained with the disease and a microsatellite marker mapping within intron 4 of the 
KRT9 gene (Reis et ai, 1994) at a recombination fraction of 0.00. A three-point 
analysis (as described in section 2.13.2) with KRT9, D17S855 and the disease gave a 
LOD score of 3.25 at a recombination fraction of 0.0 (Table 6.2), providing stronger 
evidence for linkage of focal NEPPK to this region. There was clear evidence against 
linkage of the disease to the type II keratin gene cluster at 12ql1-13, with a negative 
LOD score of -2.22 with the marker locus D12S85 at a recombination fraction of 0.1 
(Table 6.2; Figure 6.3 (b». 
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Table 6.2. Linkage of focal NEPPK to the Type I keratin gene cluster at 17q12-21 
Pedigree Locus Recombination Fraction Candidate genes 
0,0 om 0.05 0.1 02 03 0.4 
2239 KRT9"CA" 2.49 2.44 2.27 2.04 1.56 1.06 0.54 1Ype I keradns 
2239 D17S855 2.25 2.20 1.98 1.71 1.17 0.65 0.20 
2239 KRT91D17S855 3.25 3.20 2.97 2.68 2.07 1.42 0.73 
2239 Dl2S85 -8.37 -5.68 -3.39 -2.22 -1.09 -0.50 -0.17 TyIX! II keratins 
2239 Dl2S368 -5.81 -2.76 -1.43 -0.90 -0.43 -0.20 -0.07 
A disease-causing mutation in the type I keratin KRT9 (genetic basis of EPPK: see 
section 6.3) is unlikely in this family, as this keratin is only expressed in palmoplantar 
skin and therefore would not explain the distribution of oral lesions plus the other 
observed secondary characteristics. The expression of KRT's 6 and 16 in the 
palmoplantar epidermis and oral mucosa (Moll et at, 1988) strongly correlates with the 
clinical lesions present in affected individuals from this pedigree. However as KRT6 is 
a type II keratin mapping to 12qll-13, this implicates KRTI6, which maps to 17q12-
21, as a strong candidate gene for focal NEPPK. Subsequent DNA sequence analysis 
revealed mutations in the lA domain of KRT16 in affected members of this and 
another focal NEPPK family (Shamsher et ai, 1995). This domain is critical for keratin 
filament formation and integrity (McLean and Lane, 1995). 
Mutations in the lA domain of KRT16 (and KRTI7) have also been demonstrated to 
occur in the clinically similar disease pachyonychia congenita (McLean et ai, 1995). A 
significant clinical difference between the two skin diseases is the gross thickening and 
curvature of the nails seen in pachyonychia congenita affected individuals which is 
absent in focal NEPPK. This may reflect a functional difference in the amino acids 
substituted in KRT 16 in each disease (Shamsher et ai, 1995). In addition to the site of 
mutation, severity of phenotype may be related to distinct "modifying" genetic factors 
or due to environmental effects such as physical trauma. 
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Fieure 6.3. Mappine of focal NEPPK (without associated Oesophaeeal 
Cancer) to the Type I keratin eene cluster 
Haplotype analysis of pedigree 2239 with microsatellite marker loci spanning the two 
epithelial keratin gene clusters. The segregation of a 17qI2-21 haplotype with focal 
NEPPK supports the localisation of the disease gene in this family to the chromosomal 
region harbouring the type I keratin genes. 
(a) Structure and haplotype analysis of 17g12-21 in pedieree 2239. 
The sex of each individual is as described in Figure 1.1. Affected status is indicated by 
a red-filled in box/circle. The haplotypes are shown under each individual. The 
microsatellite marker loci genotyped and their order are shown to the left of the 
affected typed individual in generation 4. The microsatellite marker locus, designated 
KRT9 'CA' maps within intron 4 of the KRT9 gene (Reis et ai, 1994). The haplotype 
which is segregating with the disease is indicated in red text. 
(b) Structure and haplotype analysis of 12g11-13 in pedieree 2239. 
Pedigree is constructed and labelled as in Figure 6.3(a). The physical mapping of these 
rnicrosatellite marker loci in relation to the type II keratin genes is shown in Figure 
6.2(c). 
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6.7. Focal NEPPK and Oesopba&eal Cancer 
A large pedigree. designated 2216. from the United States of America (USA) was 
studied in which focal NEPPK was segregating in association with susceptibility to 
squamous cell carcinoma (SeC) of the oesophagus. A number of the branches of this 
family are shown in Figure 6.4. Other malignancies were also present in certain family 
members presenting with the skin disease. The focal NEPPK disease phenotype 
segregated as an autosomal dominant trait with 100% penetrance. The pattern of focal 
NEPPK in this family is clinically similar to that for focal NEPPK affected individuals 
who carry a mutation in KRTI6 (described section 6.6). However, the normal 
appearance of the nails in affected individuals from this family is one noticeable clinical 
difference between the two pedigrees (not shown). The nails from KRTl6-focal 
NEPPK affected individuals have an obvious widening of the onychocorneal band and 
terminal splinter haemorrhages (Dr. H. Stevens, personal communication). From 
family 2216. 125 affected individuals in seven generations have been identified with 
17 affected individuals having associated cancer (the complete pedigree is described in 
Stevens el al. 1996a). Eight cases of SCC of the oesophagous were identified in 
individuals with focal NEPPK, of which seven occured in heavy tobacco smokers or 
chewers. An NEPPK affected individual from this family has a 40% chance of 
developing oesophageal cancer by age 70 (Prof. T. Bishop, personal communication). 
Other malignancies in NEPPK affected individuals from this family included two cases 
of malignant melanoma, two cases of carcinoma of the breast, two cases of lung 
carcinoma, two cases of colonic adenocarcinoma, one case of chronic lymphocytic 
leukaemia and one case of multiple adenomatous polyps of the colon; none of which 
sites were significantly increased in frequency (Prof. T. Bishop, personal 
communication). 
6.8 Linka&e analysis in pedi&ree 2216 
Blood samples were drawn and DNA extracted from affected and unaffected members 
of the focal NEPPK and oesophageal cancer family 2216 (ascertained and extracted as 
described in sections 2.1.2 and 2.3.2, respectively). DNA samples were genotyped by 
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peR amplification with microsatellite marker loci flanking the two keratin clusters at 
12q 11-13 and 17q 12-21 (same loci as described in sections 6.5 and 6.6). Alleles were 
detected as described in section 2.7.3. A number of cross-over events between 
NEPPK and these microsatellite marker loci in affected (and unaffected) individuals 
indicated that disease in this family was not due to an inherited mutation in the 
candidate genes KRT6 or 16 (or other genes) mapping in these two chromosomal 
regions (data not shown). 
A large extensive family from Liverpool, UK in which "Tylosis" (a form of NEPPK) 
is associated with a high risk of developing oesophageal cancer has been described 
(Howell-Evans et al. 1958). It has been calculated that a NEPPK affected individual in 
this family has a 92% probability of dying from oesophageal cancer by age 70 (Ellis et 
aI, 1994). In this family. genetic linkage was demonstrated with the disease and 
microsatellite marker loci mapping to 17q23-qter locus (Risk et ai, 1994). This was 
termed the Tylosis Oesophageal Cancer (TOe) locus. As this region maps 
approximately 45 cM telomeric to the keratin gene cluster on chromosome 17 (Dib et 
ai, 1996), a mutation in the type I keratins including KRT16 can be genetically 
excluded as the inherited basis of this pattern of keratoderma. Interestingly, a clinical 
reappraisal of the "tylotic" phenotype in affected members of this family indicated that 
it is best described as focal NEPPK similar to that seen in the focal NEPPKI 
oesophageal cancer pedigree 2216 (Prof. I. Leigh, personal communication). 
Lymphocyte DNA from 2216 family members was genotyped with microsatellite 
marker loci mapping to the 6-7 cM minimal region for the TOC locus defined from 
haplotype analysis of the UK pedigree (flanked by D 17S929 and D 17S937, Risk et ai, 
1994: Figures 6.4 and 6.5). Microsatellite marker loci were identified from published 
genetic maps (Gyapay et ai, 1994; Dib et ai, 1996) and linkage analysis was performed 
as described in section 2.13.2. A maximum two-point LOD score of 8.20 at a 
recombination fraction of 0.00 for the microsatellite marker locus D 17S 1603 and focal 
NEPPK was calculated. LOD scores obtained for D 17S 1603 and D 17S785 are shown 
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Fi&ure 6.4. Mappin& of focal NEPPKLoesopha&eal cancer in pedi&ree 
2216 to the TOe re&ion 
Haplotype analysis of pedigree 2216 with microsatellite marker loci mapping to the 
region harbouring the TOC locus. The pedigree is as described in the box in the left 
hand comer of the first page of the pedigree. The age of diagnosis of malignancy (if 
known) is shown to the right of the cancer type under (or to the right of) the affected 
individual. Microsatellite marker loci genotyped and their genetic map order is 
indicated to the left of the figure under the Key. Genotypes at these loci are shown 
under each typed individual (in the order defined at left of the figure). A zero allele 
indicates individual not genotyped at that microsatellite marker locus. The putative 
disease haplotype segregating through the pedigree is indicated in red text. 
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in Table 6.3. This result localises the disease gene segregating in family 2216 to the 
same region as that of the UK focal NEPPK ("Tylosis") pedigree (Stevens et aI, 
1996a). This suggests that mutations in the TOC gene underlie the genetic basis of 
focal NEPPK (and possibly oesophageal cancer predisposition) in these two pedigrees 
Table 6.3. Linkage analysis of focal NEPPK with microsatellite marker loci mapping 
in the region harbouring the TOC locus in pedigree 2216. 
Locus Recombination Fraction 
0.0 0.001 om 0.05 0.1 0.2 0.3 0.4 
D17S1603 8.20 8.19 8.02 7.29 6.36 4.51 2.75 1.21 
D17S785 6.67 6.65 6.51 5.89 5.11 3.56 2.11 0.87 
6.9 Fine mappine of the TOe locus 
Linkage analysis demonstrated that the skin disease in family 2216 is linked to 
microsatellite marker loci mapping in the TOC region. Towards refining the 
localisation of the TOe locus, haplotypes for individuals from the pedigree 2216 were 
constructed for microsatellite marker loci mapping in the previously defined minimal 
region for the TOC locus (Risk et aI, 1994). Additional family members not previously 
genotyped for the linkage study (section 6.8) were also analysed. Haplotypes were 
compared between affected and unaffected individuals, and, if phase was equivocal, 
they were constructed on the basis of a minimum number of recombination events at 
meiosis. 
Haplotype analysis of this family (and the UK family: Dr. J. Risk, personal 
communication) confirmed the order of microsatellite marker loci (Dib et aI, 1996) 
with the exception that D 17S80 1 was more likely to map between D 17S 1839 and 
D 17S 1603, rather than telomeric to D 17S785. An example showing the position of 
D17S801 centomeric to D17S785 can be seen from haplotype comparison of the 
offspring of 26152 and 26206 (Figure 6.4). Individual 26146 has inherited the 
paternal chromosome (3/4: 2: 0: 3: 3: 7). As 26146 has inherited the "7" allele rather 
than the "1" allele at D 17S785 from her father 26152, this suggests a cross-over 
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telomeric to D17S1603 and D17S801 had occurred. The position of D17S801 
centromeric to D17S1603 was obtained from haplotype analysis of the UK family (Dr. 
J. Risk, personal communication; Kelsell et ai, 1996b). 
A haplotype in pedigree 2216 was clearly demonstrated to segregate with the disease 
telomeric to the locus D 17S 1864 and proximal to the locus D17S785 (Figure 6.4). The 
genetic distance between these microsatellite marker loci is estimated to be 5 cM (Dib et 
ai, 1996). Examples of recombination events in affected and unaffected individuals 
supporting this refined genetic location for the TOC locus can be seen in Figure 6.4. 
An ideogram in Figure 6.5 summarises these cross-over events and the localisation of 
the disease gene in this family. 
The refinement of the TOC locus from analysis of the USA pedigree 2216 is in 
agreement with the localisation of the disease locus from haplotype analysis of affected 
and unaffected members of the UK family (Dr. J. Risk, personal communication; 
Kelsell et ai, 1996b). Further recombination events were identified in the UK family 
which placed the disease gene in a region estimated to be approximately 1 cM, flanked 
by D 17S 1839 and D 17S 1603 (Figure 6.5). Analysis of the UK family was conducted 
by Dr. J. Risk. 
In addition, a third, less extensively characterised pedigree with focal NEPPK (of 
which two PPK affecteds had developed oesophageal cancer) from Germany has been 
described. In this pedigree, PPK has also been demonstrated to be linked to 
microsatellite marker loci mapping to the TOC region (Hennies et ai, 1995a). 
Therefore, three families have been identified in which focal NEPPKloesophageal 
cancer is linked to microsatellite marker loci mapping to the chromosomal region 
17q24-2S; designated the Toe locus. 
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Fieure 6.S. Summary of recombination events at the 17q24-2S TOe 
locus identified in the American focal NEPPKloesophaeeal cancer 
pedieree 2216. 
(a) Diagramatic summary of the localisation of the TOC locus from haplotype analysis 
of family 2216 (and the UK pedigree; Dr. J. Risk, personal communication). The 
order of the rnicrosatellite marker loci are shown to the left in orientation with the 
centromere (CEN) and the telomere (TEL). The TOC locus was previously mapped to 
a 6-7 cM region flanked by D 17S929 and D 17S937 (Risk et ai, 1994). To the right of 
the map are arrows indicating the position of the TOC locus from specific 
recombination events identified in affected (A) and unaffected (U) members of the 
pedigree 2216 (see Figure 6.4). The individual identification numbers and affected 
status are shown above the arrows. For example, the cross-over identified in 
individual 26146 positions the TOC locus centromeric to D 17S785 (this individual 
shares the disea~ haplotype proximal to this locus; Figure 6.4). From the analysis of 
pedigree 2216. the TOC locus can be localised between D17S1864 and D17S785, 
indicated by the green bar to the right of the figure. The localisation of the TOC locus 
from the UK pedigree analysis (Dr. J. Risk, personal communication) between 
D 17S 1839 and D 17S 1603 is indicated by the red bar. This is estimated to be a genetic 
distance of I cM (Dib et al. 1996) and is shown to the right of the genetic map. 
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6.10. Ancestral roc mutation? 
Disease haplotypes were constructed for five gene carriers from each of the three 
identified TOC-Iinked focal NEPPK families (USA, UK and German pedigrees; 
section 6.9). Haplotypes were compared to determine whether the same disease 
haplotype was segregating in two or more of these families. The microsatellite marker 
loci analysed spanned the TOC locus between (and including) D17S1864 and 
D17S785 (Figure 6.5(a)). The allele sizes for the three disease haplotypes were 
estimated as described in section 2.7.3 and are shown in Table 6.4. 
Table 6.4. D~ease haplotype comparison of the three TOC·linked focal 
N EPPKJoesophageal cancer pedigrees 
Marker loci 
017S 1864 
017S 1839 
017S801 
017S 1603 
017S785 
USA 
120 
255 
278 
229 
209 
UK 
118 
247 
266 
235 
189 
Gennan 
122 
247 
266 
235 
191 
Allele sizes in base-pairs (bp). ABeles in common indicated 
in bold text. 
Interestingly. the disea~ haplotypes for the UK and German families are identical for 
the microsalellite marker loci mapping in the minimal region defined for the TOC locus 
from haplotype analysis: D 17S 1839. D 17S80 1 and 0 17S 1603 (Figure 6.5(a»). This 
would support the possihility that the same ancestral mutation is segregating through 
the two pedigrees. The alleles shared by these two families at the D17S1839 and 
D17S801loci are common (55 % and 30 %. respectively: Genome Database). This is 
in agreement with the ohservation of a number of homozygotes and spouses carrying 
these alleles from analysis of the extensive UK pedigree (Dr. J. Risk, personal 
communtcation). However. the sharing of a less frequently occurring allele at the 
o 17S 1603 locus (17~: 11166 chromosomes from a panel of 33 unrelated caucasions 
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a'i described in section 2.14: data not shown) supports the two families having 
inherited the same ancestral mutation. If this is so, it also confirms the localisation of 
the TOC gene to the minimal region defmed from haplotype analysis (flanked by 
017Sl839and 017S16(3)' 
The American pedigree (2216) ha'i a different disease haplotype compared to the UK 
and Gennan families. This suggests affected individuals from 2216 are unlikely to be 
carrying the same mutation as those from the other two pedigrees. The apparent 
genetic unrelatcdness of the American family with the German family is interesting as 
the lineage of the American family can be traced back to focal NEPPK affected 
individuals in CJCnnany (though not to members of the German family described in 
this study: Dr. H. Stevens. personal communication). No genealogical link has been 
demonstrated between the UK and German pedigree even though they appear to have 
inherited the same ancestral mutation. 
Two lines of evidence support the hypothesis that the same gene defect confers focal 
NEPPK and oesophageal cancer susceptibility in these pedigrees (compared to the 
possihility of two closely linked gene mutations segregating in the pedigrees): 
(i) the two phenotypes segregate together in all three pedigrees studied (two of which 
are ex.tensive (USA and UK families: 6-7 generations) 
Oi) two distinct haplotypes segregate with the disease gene 10 the three families 
studied. 
6,11 Does Toe act as a tumour suppressor eene? 
The question of why the elevated risk of oesophageal squamous cell carcinoma in 
individuals carrying a TOC mutation and not those who inherited a KRT16 mutation 
arises. One explanation could be that the TOC gene may function as a tumour 
suppressor gene. To ex.plore this possibility, paired oesophageal tumour/normal DNA 
samples from hoth the USA and UK TOC-linked pedigrees were genotyped with 
microsatellite marker loci spanning the TOC locus to assess the rate of allele loss as 
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described in section 2.8 ONA extraction and genotyping was as described in sections 
2.3.3 and 2.7.3. In order to detennine if the TOC locus has a role in sporadic as well 
a'i familial tumour progression. a panel of sporadic oesophageal tumours were also 
a'isessed for allele loss. 
(n TOC·lioked oesopbaeeal tumours 
11le initial focus wa'i the comparison of DNA extracted from archival oesophageal 
tumour sections with matched lymphocyte ONA of affected family members of the 
USA and UK families. This would provide the strongest evidence for the TOC gene 
functioning as a tumour suppressor (in an analogous fashion to BRCA1: see section 
5.1 ). 
However. reproducible results were only achieved from the ONA analysis of one 
familial oesophageal tumour/ blood DNA pair. This ONA was extracted from an 
oesophageal carcinoma from an affected member of the UK family (individual IV 58; 
pedigree not shown). No evidence of allele loss was detected in the oesophageal 
tumour DNA at four constitutively heterozygous microsatellite marker loci spanning 
the TOC locus: D17S929. D17S 1864, 017S801 and 017S785 (see map in Figure 
6.5). An example of retention of heterozygosity at the 0 17S929 locus in this tumour is 
shown in Figure 6.6(a). This result suggests that TOe may not act as a familial tumour 
suppressor gene. 
(ii) Sporadic oesopbaeeal tumours 
From the previous section, there is suggestive evidence that TOC does not function as 
a familial tumour suppressor gene. To determine whether this may also be the case in 
sporadic cancer, a panel of sixteen archival oesophageal tumour/ nonnal oesophageal 
DNA pairs were examined for allele loss. In addition to analysis of allele loss at the 
TOC locus (017S929. D17S1864 and 017S785), the microsatellite maker locus, 
D 17S579. was screened across the paired DNA samples to assess allele loss in the 
chromosomal region harbouring BRCA 1. 017S579 maps approximately 1-2 cM 
telomeric to BRCAI (see Figure 3.12; Albertsen etal, 1994). 
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Filure 6.6. Examples of allele status in the chromosomal re2ion 17g24-25 
(JOe locus) in oesophaaeal carcinomas 
Examples of the results from microsatellite marker loci analysis of oesophageal 
tumour DNA. Allele size (in bp) is shown underneath each allele peak (detected 
and sized as described in section 2.7.3). Allele profiles of PCR amplification 
products are shown to the right of tumour (T) and normal (N) DNA. Allele status 
was assessed as described in section 2.8. 
(a) No allele loss at DI7S929 in a TOe-linked oesophageal tumour 
The oesophageal tumour/lymphocyte DNA pair was analysed from an NEPPK 
affected individual (lV58) who had inherited the TOC haplotype which was 
segregating with the skin disease (and oesophageal cancer) in the UK family (Dr. J. 
Risk. personal communicaton). The allele segregating wth disease in the UK 
family at this locus is the 231 bp allele. Tumour DNA was extracted from archival 
pathological material (as described in section 2.3.3). No loss was apparent in the 
tumour DNA when its allele profile was compared to that obtained from the 
lymphocyte DNA of this individual at this locus. 
(b) Allele loss at D17S785 in the oesophageal tumour 8847 (see Table 6.5) 
Tumour and normal oesophageal DNA was extracted from archival pathological 
material (determined as described in section 2.2.5). A reduction of the 192 bp allele 
peak is clearly evident when compared to that obtained for the normal oesophageal 
DNA from this individual. 
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1be results are summarised in Table 6.5 with 14 of the 16 oesophageal tumours 
analysed displaying allele loss at both or one of the chromosomal regions investigated 
on the long ann of chromosome 17. This high percentage of tumours displaying allele 
loss (87 % of tumours assessed) does suggest that there is a major locus (or loci) on 
chromosome 17 implicated in the development of oesophageal carcinomas. An 
example of allele loss at 017S785 in tumour 8847 is shown in Figure 6.6(b). Three of 
the oesophageal tumours demonstrated allele loss in only one of the regions tested 
(Table 6.5). ONA from oesophageal tumours (7769, 9231) demonstrated allele loss 
specifically at 017S579; whilst tumour 1693 showed loss specifically at D17S 1864 
which maps telomeric to 017S929. However, the number of tumours studied here is 
too small to determine which region on chromosome 17 is the focus for allele loss in 
oesophageal tumours. Mori el aJ (1994) suggested the focal region for allele loss in 
oesophageal tumours is at a locus mapping adjacent to BRCA 1. 
In summary, there is no strong evidence for or against TOC acting as a tumour 
suppressor gene. However the high frequency of 17q allele loss detected in sporadic 
oesophageal tumours supports the presence of a tumour suppressor gene(s) which has 
a key role in oesophageal tumorigenesis. Once TOC has been identified, its possible 
involvement in oesophageal cancer predisposition and/or progression may be 
determined. 
6.12 Candidate aenes for TOe? 
A number of biologically plausible genes localised to the long arm of chromosome 17 
can be excluded as candidates for TOC, including KRT16 and the other type I 
keratins, as they map approximately 45 cM centromeric to the TOC locus (Dib et ai, 
1996). Other possible candidate genes excluded on the basis of their localisation 
include plakoglobin and two members of the Discs-Large gene family, DLG2 and 
DLG3 (Aberle et ai, 1995; Mazoyer et ai, 1995; Smith et ai, 1996). Plakoglobin is a 
desmosome-associated protein with homology to the catenin family implicated in cell-
cell adhesion modulation (reviewed Garrod, 1995). DLG2 and DLG3 are also thought 
to have a role in cell-cell adhesion and cell membrane organisation. Mutations in the 
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Drosophila homologue of DLG2 have been shown to impair cell-cell adhesion and 
result in proliferation of the imaginal disc epithelium (Woods and Bryant, 1989). 
6.12(i) Somatic cell hybrid characterisation of the chromosomal reaion 
174124-25 
DNA from a series of human/rodent somatic cell hybrids containing fragments of 
chromosome 17 (Black et ai, 1993) were characterised with microsatellite marker loci 
mapping around the TOC locus. The aim of this approach was to determine if these 
hybrids may be useful in localising candidate genes to the region harbouring the 
disease locus. These hybrids have been well characterised with DNA marker loci 
mapping in the 17q12-21 region, but only poorly characterised for more telomeric 
DNA marker loci (Black et ai, 1993; Prof. E. Solomon, personal communication). 
Three hybrids were chosen which had maintained fragments of the human complement 
of chromosome 17 telomeric to 17qI2-21: PLT8, TLT8 and TLTIO (gift from Prof. E. 
Solomon). DNA extracted from these hybrid DNA samples were peR amplified with 
microsatellite marker loci localised in the chromosomal region harbouring TOC (as 
described in section 2.6.1). An ideogram summarising the presence/absence of a 
locus-specific peR product in each hybrid is shown in Figure 6.7 (a). Examples of 
ethidium bromide stained 2 % agarose gels of peR fragments derived from the hybrid 
DNA screen are shown in Figure 6.7 (b). The results generated are consistent with the 
genetic order of the microsatellite marker loci (see section 6.9). 
The microsatellite marker loci fall into three groups based on the 17 q hybrid DNA 
content: 
(i) the most centromeric microsatellite marker locus, D 17S 1826, is absent in all three 
hybrids tested (gel data not shown) 
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Fi&ure 6.7. 17'124-25 characterisation of somatic cell hybrid DNA 
Analysis of DNA extracted from somatic cell hybrids which contain specific fragments 
of chromosome 17 (Black et al, 1993). These were screened for presence or absence 
of microsatellite marker loci which span the TOC locus by PCR amplification (as 
described in section 2.6.1). 
(a) Graphic representation of results from PCR amplification of the 
hybrid DNA panel 
1be order of microsatellite marker loci are shown positioned along the single line, 
including their orientation with respect to the chromosome 17 centromere (CEN) and 
telomere (TEL). The minimal region harbouring the TOC locus is shown to the left of 
the marker loci. The somatic cell hybrids are indicated at the top of the figure. Arrowed 
lines underneath each hybrid indicate the presence of specific marker loci in each 
hybrid. PCfBA I.S is a monochromosomal hybrid and contains the whole of 
chromosome 17 (Kelsell et al , 1995a). 
(bl Examples of PCR amplification of the hybrid DNA panel. 
Photographs of 2 % agarose gels showing DNA products from the peR amplification 
of DNA extracted from somatic cell hybrids and species-specific DNA templates. The 
arrow to the left of each gel indicates the human-specific peR amplification product 
(sized previously as described in section 2.7.3). The lane order is indicated above each 
gel and the loading order is the same for each gel. The DNA template added to the 
PCR reaction loaded in each lane is as follows: Lane 1: PL TS, lane 2: TLTS, lane 3: 
TLTlO, lane 4: human, lane 5: mouse, lane 6: water, lane 7: PCTBA1.8. 
(i) D 17S IS39 specific-PCR amplification products are present in lanes: 1, 2, 3, 4 and 
7. The smaller sized DNA fragment is mouse-specific as it is present in lanes: 1, 2, 3, 
5, 7. It is clearly distinguishable from the human D 17S 1839 peR product. 
(ii) D 17S929 specific-peR amplification products are present in lanes: 1, 4 and 7. 
(iii) D 17S 1864 specific-peR amplification products are present in lanes: 1, 4 and 7. 
The larger sized DNA fragment is mouse-specific as it is present in lanes: 1,2,3,5, 7. 
It is clearly distinguishable from the human D 17S 1864 PCR product. 
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(ii) the most telomeric group of microsatellite marker loci: D 17S 1839 (Figure 
6.7.b.(i)). D17S801 (Figure 6.8 (bn. D17S 1603 (Figure 6.8 (a». D17S785 (gel data 
not shown) and 017S802 (gel data not shown) are present in all three hybrids 
(iii) microsatellite marker loci mapping between D 17S 1826 and D 17S 1839: D 17S929 
and 01751864 are only present in hybrid PLT8 (Figure 6.7.b.(ii) and (iii» 
This mapping data suggests the hybrid panel has limited use in assigning transcribed 
sequenccs to the TOC minimal region. Its main limitation is the inability to localise loci 
centromcnc to D 175 160~ or indeed. 0175802 (which is a genetic distance of 4 eM 
tclomeril" to D 17S80 1: Dih rt ell. 1996). Therefore. the characterisation of a physical 
contig of the n:gion IS a priority for the localisation of candidate genes for TOC 
(described In the nc;(t section). 
6.1200 Towards a lAC (aod RAe) cootie of the TOe reeioo 
Haplotype analysis of focal NEPPKloesophageal families has defined an 
approximately I cM minimal interval in which the TOC gene is located (section 6.9: 
Kelsell ~t al. I 996b). This genomic region is of a small enough size to suggest the 
construction of a physical map. using Y ACs situated between the flanking marker loci 
o 17S 1839 and D 17S 1603. is feasible (compared to 6 cM for BRCA2: see section 
4.3 ). 
Three YACs wcn: idcntified on the basis of their STS content from a published 
integratcd physical and genetic map of chromosome 17 (Chumakov et al. 1995: as 
described in section 2.11.1). Two YAC clones were selected which contain the 
microsatellite marker locus. D 17S80 I: Y ACs 786_C 7 and 868~ 7. One Y AC clone 
was selected which contains the microsatellite marker locus, 017S1603: YAC 
644_b_1O (Figure 6.8 (a) lane 7). However. two lines of investigation demonstrated 
that allthrce of the Y ACs were chimeric and contained co-ligated human DNA inserts 
mapping to distinct regions of the genome: 
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(i) fluorescent in situ hybridisation of total Y AC DNA to human lymphocyte 
metaphase ~preads revealed hybridisation signals on other chromosomal regions 
including 17q2~-25 for all three Y ACs (S. Ford. personal communication). 
(ii) AlII fingerprint D~A profiles of human DNA inserts from the Y ACs 786_C 7, 
868 J.-7 and ~ _ h _10 mdlCated "shared fragments" with human DNA inserts from 
YACs whICh contam lOCI mapping to other regions of the genome (as described in 
section 2.11.1). YAC 786_C 7 shares A/" DNA fragments with. for example, the non-
chimenc Y A('s DO_a_ ~ and 786_C 12 which contain the microsatellite marker loci 
08S 1077 and 0 12S353. respectively (data not shown). The high degree of chimerism 
demonstrated hy these Y ACs makes them unsuitable as a starting material for the 
construction of a physical (ontig of the TOC region. No Y AC clones were identified 
for the mlcrmatelhte marker loci 0 17S 1864 and 0 17S 1839 (as described in section 
2.11.2 ). 
Microsatellite marker loci spanning the TOC locus were then used to screen a Bacterial 
Artificial Clone (SAC) Iihrary (as described in section 2.12). Bacterial Artificial 
Chromosomes (BACs) are vectors based on the low-copy number replicon found in 
the F-factor system of E.coli which can harbour cloned DNA fragments of around 300 
kb (Shizuya n a/. 1992: StrdChan and Read. 1996). Three BAC clones (149.14.1, 
88.6.13. and 149.14.3) were identified which contain the telomeric flanking 
microsatellite marker locus for TOC. 017S1603 (Figure 6.8 (a». DNA extracted from 
these BAC clones (as described in section 2.3.5) were screened by PCR amplification 
for presence or absence of the nearest centromeric microsatellite marker locus to 
DI7SI603. 017S801 (as described in section 2.6.1). The absence of D17S801 PCR 
amplification products in these BAC clones (Figure 6.8 (b» indicated that these two 
microsatellite marker loci were not present in the same BAC clone. Fluorescent in situ 
hybridisation of total BAC DNA to human lymphocyte metaphase spreads revealed 
hybridisation signals only at 17q24-25 (S.Ford. personal communication). This 
indicates that these BACS are unlikely to be chimeric and provide a starting point for 
the construction of a physical map of the TOC region. This work is ongoing. 
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Fi&VR 6.8. Somatic cell hybrid. YAC and HAC characterisation with 
017S1603 and 017S801. 
This figure .. how .. the analysis of D!'A extracted from somatic cell hybrids which 
contain .. peclfic fragments of chromosome 17 (Black et aI. 1993); the YAC 644_b_lO 
and three BACc10nes (149.14.1. 88.6.13 and 149.14.3). These were screened for 
pre'iCl1Ce or ab'iCnce of the microsatellite marker loci. D17S1603 and 017S801 by 
PCR amphficauon (a.'\ dcscrihcd in section 2.6.1). (An ideogram showing the 17q24-
25 Ol'iA content of the somatic ceIl hyhrids is shown in Figure 6.7(a)). 
(at 017S1603 
2 ~ agaro'iC gel ,howmg products from the PCR amplification of DNA extracted from 
'\OmatlC cell hyhrlds. a Y Ac' three BAC clones and species-specific ONA templates 
WIth DI7S160.~. The arrow to the left of each gel indicates the 017S1603 PCR 
amphtkallon prodoct (Sil.ed previously as described in section 2.7.3). The lane order 
is mdicatcd ahove the gel image. lbe DNA template added to each PCR amplification 
reaction loaded in each lane is as follows: Lane I: BAC 149.14.1, lane 2: BAC 
88.6.13. lane 3: BAC 149.14.3. lane 4: hybrid PLT8. lane 5: hybrid TLT8, lane 6: 
hyhnd PLTIO. lane 7: YAC 644_b_IO. lane 8: human, lane 9: mouse. 017S1603 
PeR amplificatIOn products are present in lanes: I. 2, 3, 4, 5, 6, 7, and 8. 
(b) 017S801 
2 ~ agarose gcl showing products from the PeR amplification of DNA extracted from 
somatic cell hyhrids. a Y AC, three BAC clones and species-specific DNA templates 
with D17S801. The figure is as described above for Figure 6.8(a). The ONA template 
added (0 the PCR amplification reaction loaded in each lane is as follows: Lane I: BAC 
149.14.1. lane 2: BAC 88.6.13. lane 3: BAC 149.14.3. lane 4: YAC 644_b_IO, lane 
5: hybrid PLT8.lane 6: hybrid TLT8. lane 7: PLTIO, lane 8: human, lane 9: mouse, 
lane 10: no DNA. 017S801 PeR amplification products are present in lanes: 5, 6, 7 
and 8. lbe differences in product sizes are due to variations in the number of (CA) 
repeat hlocks. 
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6.12Uij) Enyoiliakio. a candidate ,ene (or TOe 
A 210 k.D protem. enyoplakin (EVPU. which demonstrates significant homology to 
the intennedJate filament-binding proteins desmoplakin and plectin, has been localised 
to 17q25 Ie. Ruhmerg. ICRF Keratinocyte laboratory, Lincoln's Inn Fields, London: 
personal communication). Lik.e desmoplakin and plectin. a series of heptad repeats are 
found in the central domain of EVLP suggesting it may exist as a coiled-coil dimer. 
EVLP 1\ e~prc .. sed in stratified squamous epithelium from the oral mucosa and the 
oesophagus: but lis expression in palmoplantar epidermis has yet to be examined (c. 
Ruhrhcrg. pcr .. onal communication). The EVLP protein shows partial cellular 
locah..ation to the desmo .. omes and may link keratin filaments to the desmosomes 
whICh arc hound 10 the cornified enyelope (Figure 6.9a). If EVLP specifically binds to 
KRTI6 (or its type II keratin partner). a mutated copy of EVLP could feasibly cause a 
,imilar phenotypic disruption to epidermal cells as KRTI6 affected individuals with 
focal NEPPK. 'Therefore. EVLP could be regarded as a candidate gene for TOC on the 
ba\ls of lis chromosomal location. pattern of tissue expression and its putative 
function. 
l! .. ing gene specific oligonucleotide primers for EVLP, the YAC 644_b_lO was 
identified from a PCR amplification screen of the CEPH YAC library (c. Ruhrberg, 
personal communic<llion). This Y AC also contains the telomeric flanking rnicrosatellite 
marker locus for TOC. D 17S 1603 (discussed in previous section). FISH localisation 
of a cosmid clone containing EVLP to 17q25 (c. Ruhrberg, personal communication) 
suppons EVLP mapping adjacent to D 17S 1603. 
EVLP-spccific oligonucleotide primers (ao; described in section 2.6.7) were used to 
screen DNA extracted from the panel of chromosome 17 hybrids, the Y AC 644-b_lO 
(extracted as described in section 2.3.4) and the three HACs identified with 
D 17S 1603. EVLP-specific PCR products were detected in the same hybrids as for 
DI7S 1603 (sec ideogram of hyhrid content. Figure 6.7 (a)) supporting the localisation 
of EVLP to the TOC region (Figure 6.9 (h)). However, no EVLP PCR products were 
amplified when the DNA template was from the three BACs containing DI7S1603. 
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Fieure 6.9. Envoplakin (EVLP), a candidate for the TOe eene? 
(a) Putative role or EVLP in cornified envelope formation. 
Simplified model for a proposed role for EVLP in linking keratin filaments to the 
desmosomaJ junctions (adapted from C. Ruhrberg and Dr. F. Watt, personal 
communication ). 
(bl Confirmation or the assienment of EVLP to the TOe reeion 
2 9C agarose gel showing products from the PCR amplification of DNA extracted from 
somatic cell hybrids. a Y AC, three BAC clones, human and rodents with human 
EVLP oligonucleotide primers. The arrow to the left of the gel indicates the EVLP 
PCR amplification product. The lane order is indicated above the gel image. Lane 1 
~x 174 DNA digested with Haem molecular weight marker (Boehringer Mannheim). 
The DNA template added to each PCR amplification reaction loaded in each lane is as 
follows: Lane 2: SAC 149.14.1. lane 3: BAC 88.6.13, lane 4: BAC 149.14.3, lane 5: 
hybrid PLT8, lane 6: hybrid TLT8, lane 7: hybrid PLTIO, lane 8: YAC 644_b_1O, 
lane 9: mouse. EVLP PCR amplification products are present in lanes: 5,6, 7, and 8. 
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Further work is in progress to detennine the orientation of EVLP to D 17 S 1603. If 
EVLP maps centromeric to DI7S1603. it can be regarded as a strong candidate for the 
focal NEPPK/oesophageal cancer gene. TOe. 
6.13 Summary or Toe analysis 
The TOC locus has been mapped to a 1 cM regIon flanked by D17S1839 and 
D 17S 1603 (KelseH el al. 1996b). From the haplotype comparison study described in 
section 6. 10. two disea'\e haplotypes were identified in the three families analysed. 
The two largest families. UK and American. have different haplotypes segregating 
with the disease suggesting two distinct mutations in the same gene. This may explain 
the difference in oesophageal cancer risk between the two families, with the UK 
mutation conferring an elevated risk of cancer in TOC gene carriers. 
The high incidence of oesophageal cancer observed in the TOC-PPK affecteds 
compared to the KRTI6-PPK affecteds is interesting as they present with similar 
patterns of keratoderma. This may be due to differences in the function of the proteins 
encoded by the two distinct genetic susceptibility loci in cytoskeletal organisation. It is 
possible that the TOC gene may anchorthe KRT16 filaments to the cornified envelope 
and therefore. if mutated. may increase the permeability of the cell to environmental 
carcinogens. A gene. envoplakin (EVLP), which may possibly link keratins to the 
cornified envelope and maps in the region harbouring the TOC gene, is currently under 
investigation as a strong candidate for the genetic basis of this disease. This is 
discussed further in Chapter 7. 
6.14 Punctate NEPPK 
Punctate NEPPK presents with punctate keratoses over the surface of the palm and 
sole (Figure 6.1 (c). A four generation family, 2039, with punctate NEPPK has been 
identified (Figure 6.10; Stevens et ai, 1996b). The disease appears to be inherited as 
an autosomal dominant trait presenting with phenotypically identical multiple keratoses 
in affected family members. All keratoses developed from the age of puberty, though 
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the age of onset varied from 13 to 40 years of age. In addition, the number and size of 
keratoses varied between family members, some only noticeable after immersion in 
water (Dr. H. Stevens, personal communication). A possible association between 
PPK and cancer was noted in the family, with a number of tumours developing before 
the age of 50 (Stevens et al. 1996b). DNA extracted from the lymphocytes of affected 
and unaffected family members was genotyped with rnicrosatellite marker loci 
spanning the two keratin clusters and other candidate gene regions (as described in 
section 2.7). Linkage analysis was performed as described in section 2.13.2. 
Close linkage to the disease was excluded with rnicrosatellite marker loci mapping near 
to the epithelial keratin gene clusters on 12qll-13 and 17qI2-21. A LOD score of -2.3 
at a recombination fraction of 0.1 was obtained with the marker D17S855 and -3.04 at 
a recombination fraction of 0.00 with the marker 012S368 (Table 6.6). The lack of a 
17qI2-21(or 12qll-13; data not shown) haplotype in common between affected 
family members further supports the exclusion of a type I (or type II) keratin as the 
genetic basis of this disease (Figure 6.10). Evidence against linkage of the disease to 
other regions of the genome implicated in hereditary skin diseases was also 
demonstrated including: D 12S330 (Darier's disease: Parfitt et ai, 1994), D 17S80 1 
(TOC: this study) and D3S 1292 (Hailey-Hailey disease: Ikeda et ai, 1994) (Table 6.6). 
The genetic basis of punctate NEPPK and possibly cancer susceptibility requires 
further studies. 
Table 6.6. Loci scores obtained for pedigree 2039: evidence against linkage with 
punctate PPK and candidate chromosomal regions 
0.0 0.01 0.05 0.1 0.2 0.3 0.4 
D17S85S -5.05 -4.02 -2.9\ -2.30 -1.75 -1.16 .0.47 lYpe I keratins 
D12S368 -3.04 -1.57 -0.34 0.06 0.24 0.17 0.05 lYpe II keratins 
DI2S330 -5.48 -4.05 -2.39 -1.48 -0.62 -0.23 .0.05 Dariers disease 
D17S801 -3.21 -3.16 -2.33 -1.44 -0.58 -0.20 .0.04 17q24-25 (TOC) 
D3S1292 -3.72 -3.09 -1.78 -1.13 -0.49 -0.19 .0.04 Hailey-Hailey disease 
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Fi&ure 6.10. Genetic exclusion of the type I keratins with punctate 
palmoplantar keratoderma se&re&atin& in pedi&ree 2039. 
The sex of each individual is as described in Figure 1.1, the identification number is 
shown underneath each individual. The type of malignancy with age of diagnosis is 
given beneath the affected individual. PPK affected status is as indicated from the key 
in the lower right hand comer of the figure. The order of microsatellite marker loci is 
also shown to the bottom right of the figure (see also Figure 3.10). Detection of alleles 
for each microsatellite marker locus is as described in section 2.7.1. Haplotypes are 
displayed under each individual typed. No specific 17 q 12-21 haplotype is segregating 
with punctate PPK in this pedigree. 
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Fieure 6.10 Genetic exclusion of the type I keratins with Punctate palmoplantar keratoderma seereeatine in pedieree 2039 
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6.1S Summary of Cbapter 6 
In this chapter. the genetic analysis of families with three forms of non-epidermolytic 
palmoplantar keratoderma (NEPPK): focal, diffuse and punctate; was performed. In 
some of the pedigrees, a striking association of focal NEPPK with oesophageal cancer 
susceptibility was observed. This study demonstrated genetic heterogeneity between 
the three fonns of N"EPPK (Kelsell et ai, 1995b). 
Genetic heterogeneity was also established between families presenting with clinically 
similar fonns of focal NEPPK. Mutations in the type I keratin, KRT16, were 
identified as the genetic basis of focal NEPPK in a pedigree without associated 
susceptibility to oesophageal cancer (Shamsher et ai, 1995). Haplotyping of three 
families with focal NEPPK associated with elevated susceptibility to oesophageal 
cancer has excluded mutations in KRT16 as the genetic basis of disease in these 
families. Disease in these families is genetically linked to a 1 cM region on 
chromosome 17q24-25: the TOC locus (KelseH et aI, 1996b). 
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CHAPTER 7. DISCUSSION 
7.1. Introduction 
This study focussed on two areas in the field of cancer susceptibility. The initial focus 
was the genetic analysis of a recently mapped breast cancer susceptibility locus, 
BRCA1, in a number of breast and breast-ovarian cancer families (Chapters 3, 4 and 
5). During the course of this investigation, there have been dramatic developments in 
breast cancer genetics culminating in the identification of two major breast cancer 
susceptibility genes, BRCAI and BRCA2 (Miki et ai, 1994; Wooster et ai, 1995; 
Tavtigan et ai, 1996). The other area of study has been the genetic analysis of a group 
of autosomal dominant skin diseases, tenned the non-epidennolytic palmoplantar 
keratodennas (NEPPK: Chapter 6). Although the skin disorders themselves are only 
mildly debilitating, there is an association of the skin disease with the development of 
malignancy in a number of pedigrees. Indeed in one family, the risk of dying from 
oesophageal cancer for an individual affected with NEPPK has been calculated to be 
92 % by age 70 years (Ellis et ai, 1994). 
7.2. Breast-ovarian cancer 
7.2.1. Linka&e study 
The large breast-ovarian cancer family, BOV3, provided the majority of evidence for 
linkage of cancer susceptibility to the locus BRCAI (Chapter 3). Initial linkage studies 
of the other 15 families gave little information towards confirming BRCAI association 
and narrowing the genetic region harbouring this locus. This was because of problems 
often encountered in mapping common disease genes ie. heterogeneity, a partially 
penetrant gene, phenocopies, small pedigrees and limited DNA material, particularly 
from affected individuals. For example, an individual with ovarian cancer, which did 
not share the putative disease haplotype segregating with the disease in the rest of the 
BOV3 family, suggested disease in this family may not be linked to BRCAI. 
However, analysis of further genetic maker loci and additional affected individuals in 
this family clarified the situation and demonstrated this individual was likely to be a 
case of "sporadic" disease (Chapter 3: Section 3.5 (a)). All linkage data generated from 
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families genotyped worldwide was analysed by the Breast Cancer Linkage 
Consortium. This collaborative study demonstrated the power of analysing a large data 
set for such a complex disease (Easton et ai, 1993b). Analysis of 57 breast-ovarian 
cancer families suggested that disease in the majority was likely to be due to an 
inherited mutation in BRCAI. Subsequent to this analysis, individual families could be 
reassessed as to their likelihood of disease being linked to BRCAI and contradictory 
locations for BRCA1 (from individual recombination events) could be interpreted with 
greater clarity. 
Analysis of the BOV3 family was the main focus for this part of the study resulting in 
a number of findings, including the identification of a recombination event which 
significantly reduced the BRCAI minimal region to an interval of 1-1.5 Mb (Chapter 
3; Section 3.5; KelseH et ai, 1993). After the cloning of BRCA1 (Miki et aI, 1994), a 
185deiAG BRCA 1 mutation in this family was identified (Shattuck -Eidens et ai, 1995; 
Xu et ai, in press).The same mutation was also identified in two other ICRF families, 
ICRF178 and ICRF546 (Neuhausen et ai, 1996a; Xu et ai, in press). Haplotype 
analysis revealed that gene carriers from these two families had inherited the same 
ancestral mutation as the BOV3 family (Chapter 5: Section 5.3(iv)). These three 
families were all ascertained in the north of England. Disease haplotypes in gene 
carriers from these families were extended by genotyping an additional 12 
microsatellite marker loci spanning a genetic distance of, approximately, 47 cM on the 
long arm of chromosome 17. As approximately 23 cM of the putative ancestral disease 
haplotype was in common, this would suggest the three families are closely related, 
separated by only a few generations, even though family members have no knowledge 
of any genetic links between the three families. Further studies are in progress to 
determine the relationship between these three families. Founder mutations have been 
identified which frequently occur in two "isolated" populations: in Iceland 
(BRCA2:Thorlacious et ai, 1996) and in the Ashkenazi Jewish population (BRCA 1 
and BRCA2: Struewing et ai, 1995a; Neuhausen et ai, 1996b). Interestingly, these 
latter two founder mutations (one in BRCAl, the other in BRCA2) are likely to 
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account for a quarter of all early-onset breast cancer cases in the Ashkenazi population 
(Neuhausen et ai, 1996b). 
Compelling evidence from the analysis of allele status in DNA extracted from breast 
tumours of the BOV3 family implicated BRCAI as a tumour suppressor gene (Chapter 
5: Section 5.2). Breast tumour DNA samples from nine gene carriers in this family 
were hemizygous for the mutated BRCAI allele. Further support came from the BCLC 
study in which 86 % of breast and ovarian tumours from putative BRCAI gene 
carriers also demonstrated loss of the wildtype BRCAI allele (Comelis et ai, 1995). 
On the strength of these observations, allele loss data was incorporated into the linkage 
analysis of disease association with BRCAI in 63 breast and breast-ovarian cancer 
families (Chapter 5: Section 5.3). This was found to be extremely helpful in analysing 
pedigrees of small size and/or limited sample availability to improve LOD scores and 
assess whether disease in these families was likely to be due to a germline BRCA 1 
mutation. 
The same set of families genotyped with microsatellite marker loci flanking BRCAI 
(Chapter 5: Section 5.3) were also assessed for linkage of the disease to BRCA2 (E. 
Mavraki, personal communication). This was to estimate, by multipoint lod score 
analysis, the proportion of families in which disease was likely to be due to BRCA 1 or 
BRCA2 and to assess if there is evidence for a presently unidentified third locus for 
breast-ovarian cancer susceptibility, BRCA3 (Prof. T. Bishop and G. Crockford, 
personal communication). From this data set, statistical analysis suggests that disease 
in the majority of families is likely to be due to either a mutation in BRCA 1 or BRCA2 
in approximately equal proportions. However, this analysis does not preclude the 
possibility of the existence of BRCA3 or further breast cancer susceptibility loci. This 
is due to the fact that some familes studied added only a limited amount of information 
(that is, LOD scores close to zero for each locus) to the analysis due to their small size 
(in terms of structure and sample availability). Therefore, it is possible that BRCA3 (or 
BRCA4 etc) could account for disease susceptibility in a proportion of these pedigrees. 
It is also likely that cases of sporadic disease in these families, particularly those of 
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limited sample availability, may be affecting the interpretation of the linkage and 
haplotype analysis in these pedigrees. For example, a negative lod score at BRCAI (or 
BRCA2) with the disease in a family does not exclude the possibility that disease, in a 
proportion of cases in that family, is in fact due to a BRCAI (or BRCA2) germline 
mutation (for example, Friedman et ai, 1995; Phelan et ai, 1996). A more accurate 
assessment of the proportion of families due to BRCA 1 and BRCA2 would require the 
combination of linkage analysis with DNA mutation analyses of both susceptibilty 
genes in lymphocyte DNA extracted from a number of affected family members. 
Mutation analyses are currently being performed in the 63 ICRF families which had 
been previously assessed for linkage with the disease to BRCA1 or BRCA2 (BRCA1: 
Prof. E.Solomon, personal communication; BRCA2: Elena Mavraki, personal 
communication-see next section). 
Putative gene carriers from six ICRF breast cancer families (out of the 63 familes 
analysed) showing supportive evidence of linkage of the disease to BRCA2 (Prof. T. 
Bishop, personal communication) have been screened for mutations in BRCA2 (E. 
Mavraki, personal communication). After screening the whole of the coding region of 
BRCA2, a germline BRCA2 mutation has been identified in one of the six families. A 
recent report identified germline BRCA2 mutations in 8 of 49 site-specific breast 
cancer families (Phelan et ai, 1996). These two studies would suggest that BRCA2 
does not account for such a high proportion of familial breast cancer cases as 
previously estimated from linkage studies. The relatively low proportion of familes 
with identified BRCA2 mutations is in contrast to the much higher proportion of breast 
and breast-ovarian cancer families with identified BRCA1 mutations. For example, 
BRCA1 mutations were identified in 26 of 37 families analysed (Friedman et ai, 1995) 
and 22 of 32 from another study (Gayther et ai, 1995). 
7.2.2. Role of BRCAI and BRCA2 in sporadic breast cancer 
The roles of BRCA I and BRCA2 as classical tumour suppressor genes in sporadic 
breast cancer is at present unclear. The relatively high number of sporadic breast 
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tumours displaying allele loss at BRCAI (47 %: Chapter 5: Section 5.4) and BRCA2 
(45 %: Chapter 5: Section 5.5) suggests a role for these genes in sporadic disease. 
However, no somatic BRCAI or BRCA2 mutations have yet been identified in 
sporadic breast carcinomas (for example, Futreal et ai, 1994; Lancaster et ai, 1996). 
(No somatic BRCAI or BRCA2 mutation analyses have been performed in the 
sporadic breast tumours assessed for allele loss in this study). A clue may lie in the 
observations that breast tumours from BRCAI gene carriers often have the histology 
of grade 3 infiltrating ductal carcinomas (for example, Eisinger et ai, 1996). This 
tentatively suggests a role for BRCAI in sporadic disease with this histology. 
However, allele loss at BRCAI in sporadic breast carcinomas demonstrated no 
correlation with histological grade (statistical analysis performed by Dr. D. Barnes and 
colleagues: data not shown). 
From the analysis of somatic events occurring in grade 3 infiltrating ductal carcinomas 
from BRCAI gene carriers of the BOV3 family, allele loss at both BRCAI and 
BRCA2 was unequivocal in five of the seven tumours analysed (Chapter 5: Section 
5.6). Interestingly, re-examination of the allele loss patterns at these two loci in the 
sporadic breast tumours revealed a similar pattern of combined loss (or retention) of 
BRCAI and BRCA2 in those classified as grade 3 infiltrating ductal carcinomas 
(Kelsell et ai, 1996a). It is possible that the apparently "sporadic" grade 3 infiltrating 
ductal carcinomas may be carrying a germline mutation in the retained allele of 
BRCAI. Alternatively, this may suggest a key role for BRCAI (and BRCA2) in the 
development of sporadic tumours of this histology and possibly a compensatory effect 
between different pathways involving BRCAI and BRCA2 in breast epithelial cells. 
However, as somatic BRCAI or BRCA2 mutations are extremely rare in breast 
tumours with (or without) allele loss, distinct mechanisms of gene inactivation may be 
occurring in sporadic tumours compared to the familial breast tumours. It is possible 
that loss of one copy of both genes is sufficient for the development of these sporadic 
breast tumours: a dosage effect. Alternatively, the retained wildtype copies of BRCAI 
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and BRCA2 may be transcribed at low levels or even silenced. This could be due to 
methylation of the retained copy of both BRCA 1 and BRCA2. Alternatively, somatic 
mutations may be present in a gene(s) which affects the transcriptional or translational 
regulation of BRCA1 and BRCA2. It has been demonstrated that BRCAI mRNA 
levels are reduced in sporadic breast tumours (Thompson et ai, 1995). BRCAI 
expression also appears to be hormonally regulated by oestrogens and is at its highest 
level during pregnancy (Marquis et ai, 1995; Gudas et ai, 1995). The inhibition of 
breast epithelial cell growth by hormonally-regulated BRCA1 supports the suggestion, 
from epidemiological studies, of a protective effect of women having an early 
pregnancy from breast cancer. A hypothetical model of the role of BRCA1 (and 
BRCA2) in sporadic versus familial grade 3 infiltrating ductal carcinomas is shown in 
Figure 7.1. 
Focussing on the sporadic grade 3 breast tumours, recent analysis (statistical analysis 
performed by Dr. D. Barnes and colleagues: data not shown) suggests patients with 
breast tumours displaying combined loss (or retention) of BRCA1 and BRCA2 
(chromosomes 17q and 13q, respectively) have a greatly improved prognosis to those 
with tumours displaying loss of BRCA1 (l7q) and not BRCA2 (l3q). A possible 
explanation of this result is that tumours displaying loss at 17 q and not 13q may 
harbour a p53 mutation in the retained allele (as whole chromosome 17 deletions are 
common: data not shown) and have developed by a distinct tumorigenic pathway. This 
would result in cells with no functional copy of p53. Indeed, a number of studies have 
associated somatic p53 mutations in breast tumours with poor prognosis in patients 
(for example, Borresen et ai, 1995; Kovach et ai, 1996). Further studies (by 
colleagues) of "sporadic" grade 3 infiltrating breast tumours are in progress to explore 
these preliminary findings. These include: 
1) BRCA1, BRCA2 and p53 mutation analyses in germline and tumour DNA 
2) allele loss status at BRCA1 and BRCA2 in a larger group of breast tumours of this 
grade 
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FiKUre 7.1. Hypothetical model for a hormonally reKUlated dosa2e effect of BRCAI (and BRCA2l in sporadic breast cancer 
This model is based on the observation of a combined role for BRCA I and BRCA2 in grade 3 infiltrating ductal carcinomas. It proposes that BRCA I and 
BRCA2 either interact directly or along the same pathway in the control of breast epithelial cell proliferation. It also includes the possibility that BRCAI (and 
possibly BRCA2) are under hormonal (estrogen) regulation. The levels of estrogen in the model do not account for fluctuations in levels due to menstruation 
or pregnancy. BRCA 1 expression levels are shown as a black bar, estrogen levels as a hatched bar. 
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7.2.3. Function of BRCAI 
Allele loss studies in tumours from disease gene carriers have implicated BRCA1 as a 
tumour suppressor gene (for example; Kelsell et ai, 1993a (Chapter 5); Comelis et ai, 
1995). A function of normal BRCA1 may be the inhibition of proliferation in 
mammary epithelial cells (Thompson et ai, 1995). In support of this, transfection of 
the wildtype BRCA 1 gene inhibited tumour growth and improved the prognosis of 
MCF-7 derived breast tumours in nude mice (Holt et ai, 1996). The same study found 
that near full-length truncated BRCA1 protein inhibited ovarian cancer cell growth but 
not that of breast cancer cells. This is in agreement with the genotype-phenotype 
correlations observed previously (Gayther et ai, 1995). This suggests that the first 
two-thirds of the BRCA1 protein are functionally important in suppression of ovarian 
cell proliferation. 
Mice deficient in two functional copies of BRCAI die as early embryos, displaying 
defects of the neural tube (Gowen et ai, 1996). This suggests murine BRCA 1 protein 
may be important as a developmental switch for the differentiation of neuroepithelial 
cells, as well as, later in development, having a role in mammary cell differentiation 
(Marquis et ai, 1995). However, in humans, BRCA 1 appears to be much more tissue-
specific, possibly being activated at puberty to control the differentiation of breast 
epithelial cells. This is based on the observation of two women who survived to 
adulthood without a normal copy of BRCAI; in contrast with the BRCAI-deficient 
mice which died before birth (Boyd et ai, 1995; Dr. M. Boyd and Dr. D. Black, 
personal communication: discussed in Chapter 5: Section 5.3 (ii)). These two women, 
deficient in two functional copies of BRCA I, appeared phenotypically normal and 
developed breast cancer at comparable ages to female BRCA 1 heterozygotes. 
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The identification of a RING finger (zinc-binding) domain near the amino terminal end 
of the protein suggests BRCAI may playa role as a transcription regulator (Miki et ai, 
1994). Recently, it has been proposed that BRCAI and possibly, BRCA2, may be 
members of the granin family, suggesting they may encode hormonally-regulated 
secretory proteins involved in cell membrane signal transduction pathways (Jensen et 
ai, 1996). The size of these proteins suggests that BRCAI and BRCA2 may be multi-
functional and could be involved in a number of regulatory pathways in the nucleus, 
cytoplasm and extra-cellular matrix of breast (and ovarian) epithelial cells. 
7.3 Non-epidermolytic palmoplantar keratoderma (NEPPK) and cancer 
susceptibility 
7.3.1. Genetic hetero2eneity 
The main aim of this investigation was to determine the genetic basis of NEPPK in a 
number of pedigrees. This study has demonstrated genetic heterogeneity between 
variant forms of this disease; that is, mutations in different genes can cause similar 
phenotypes. For example, families with focal NEPPK but no associated increase in 
cancer risk have a heritable defect in the type I epidermal cytoskeletal intermediate 
filament protein, keratin 16 (KRTI6: Chapter 6: Section 6.6; Shamsher et ai, 1995). It 
is also possible that a type n keratin may underlie the genetic basis of diffuse NEPPK 
(Chapter 6: Section 6.5; Kelsell et ai, 1995b). Further studies are in progress to 
identify the specific gene defect for this disease. These findings were not wholly 
unexpected as keratin mutations have been demonstrated as the genetic basis for a 
number of disorders displaying epidermal fragility (reviewed Lane, 1994; McLean and 
Lane, 1995). However, three families with a similar phenotypic form of focal NEPPK 
to that associated with KRT16 mutations which segregates with squamous cell 
carcinoma of the oesophagous are not due to a inherited mutation in KRT 16, or indeed 
any of the known epidermal keratin genes. Disease in these three families is linked to 
the chromosomal region l7q24-25, designated the TOC locus (Chapter 6: Section 6.7 
and subsequent sections). 
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A number of other skin diseases have also been implicated by linkage analyses to be 
due to genes other than keratins (Darier's disease: Parfitt et ai, 1994; Hailey-Hailey 
disease: Ikeda et ai, 1994; Clouston hidrotic ectodermal dysplasia: Kibar et ai, 1996). 
A striated form of PPK is linked to microsatellite marker loci mapping adjacent to the 
desmosomal cadherin gene cluster on chromosome 18q 12 in two families (Hennies et 
ai, 1995b; D. P. Kelsell and S. P. Bryant: data not shown). Recently, a mutation in 
loricrin, a component of the conified cell envelope, has been demonstrated to be the 
genetic basis of Vohwinkel's syndrome, a mutilating form of PPK (Maestrini et ai, 
1996). Curiously, this mutation predominantly causes symptoms in the palmoplantar 
epidermis even though loricrin is expressed in all epidermal cells. A model showing 
how some of these proteins may interact in forming the cornified cell envelope is 
shown in Chapter 6: Figure 6.9 (a). 
7.3.2. Focal NEPPK and Cancer susceptibility 
The genetic basis of focal NEPPK and oesophageal cancer susceptibility has been 
localised to an approximate 1 cM interval on chromosome 17q24-25; the TOC locus 
(Chapter 6: Section 6.7 and subsequent sections; Kelsell et ai, 1996b). Genetic 
analysis of the three TOC-linked pedigrees suggests that both the skin disease and the 
cancer susceptibility are likely to be caused by mutations in the same gene from two 
lines of evidence: 
I) the two phenotypes segregate together in all three pedigrees, and 
2) the same ancestral TOC mutation appears to be segregating in two of the pedigrees. 
This is in contrast to the epidermolytic PPK pedigree associated with breast-ovarian 
cancer (Blanchet-Bardon et ai, 1987; Torchard et ai, 1994; Friedman et ai, 1995) in 
which mutations in two tightly -linked gene loci (KRT9: EPPK and BRCAl: breast-
ovarian cancer) are segregating with the two disorders. Although the KRT 16 and 
TOC form of focal NEPPK cause almost identical hyperkeratotic lesions in the mouth 
and oesophagous (Dr. H. Stevens and Prof. I. Leigh, personal communication), only 
TOC gene carriers have a high risk of developing oesophageal cancer. No keratin 
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mutations to date have been associated with cancer susceptibility. This is probably 
because they are structural intra-cellular proteins which are indirectly attached to the 
nuclear and cell membrane. A candidate gene for TOC, envoplakin (EVLP), is a 
desmosomal-associated protein that putatively links keratin filaments to the cornified 
cell envelope (C. Ruhrberg and Dr. F. Watt, personal communication). As it may 
attach to the keratin filaments, a heterozygous mutation in EVLP could confer a similar 
level of epidermal fragility as a keratin mutation, for example, a mutation in KR T 16. 
EVLP may associate with transmembrane proteins of the desmosome, for example, 
plakoglobin and cadherins, which appear to be involved in the intra-cellular cascade of 
response to extra-cellular positional information. Though EVLP is unlikely to have a 
direct role in the cell cycle or proliferation, a mutation in this gene could plausibly 
increase the risk of oesophageal cancer in a TOC-gene carrier. For example, when an 
oesophageal cell carrying a defective copy of envoplakin is physically stressed, this 
could affect the integrity of the desmosomes leading to a: 
1) pertubation of the oral and oesophageal cornified envelope lining causing an 
ineffective barrier to carcinogen damage, for example, that caused by tobacco smoke, 
and/or 
2) an alteration in desmosomal cell binding affinity may lead to cell isolation as 
desmosomes are intercellular couplings and mediate cell adhesion. An accumulation of 
somatic mutations in other genes in such a cell may lead to invasion or metastasis. 
These hypothetical models are shown in Figure 7.2. 
Envoplakin mutation analyses of gene carriers from these three families are currently in 
progress (Dr. 1. Risk, C. Ruhrberg and Dr. A. Reis; personal communications). If 
mutations are identified, Envoplakin can be added to the growing list of cytoskeletall 
cell adhesion genes implicated in cancer predisposition or progression. These include 
the Neurofibromatosis 2 gene (NF2; Trofatter et ai, 1993), Deleted in Colorectal 
Cancer gene (OCC: Fearon et ai, 1990), and the Adenomatous Polyposis Coli gene 
(APC: Groden et ai, 1991). 
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7.3.3. Punctate PPK and Cancer 
Genetic analysis of a family with punctate PPK associated with the development of a 
range of malignancies including breast cancer was performed (Chapter 6: Section 
6.14). A number of candidate gene regions have been excluded as the genetic basis of 
the skin disease (and cancer susceptibility). An autosomal genome search is currently 
in progress in this family and others with punctate PPK (Dr. A. Reis, personal 
communication). Recently, the gene for Cowden disease (or multiple hamartoma 
syndrome) has been localised to chromosome 10q22-23 (Nelen et al, 1996). This is an 
autosomal dominant disease in which 30 % of affected female individuals develop 
breast cancer. As one of the phenotypes of Cowden disease is palmoplantar 
keratoderma, the skin disease and cancer susceptibility in Cowden disease and 
punctate PPK may have a similar genetic basis. 
7.4. Concludine remarks 
This study has encompassed a number of the complexities of autosomal dominant gene 
mapping. For BRCAl, there are the problems associated with mapping a commonly 
occurring disease such as heterogeneity (the complications caused by BRCA2 and, 
possibly, an unidentified locus, BRCA3), phenocopies (sporadic cases of breast 
cancer arising in BRCA1-linked pedigrees) and variable penetrance. Contrastingly, for 
NEPPK, the disease is much rarer in the population so the problem of phenocopies is 
minimal. In addition, the disease gene is fully penetrant so gene carriers are easily 
identifiable. In the cancer associated-forms of NEPPK, an objective was to determine 
whether the cancer susceptibility was due to a distinct tightly linked locus or if the 
NEPPK disease gene itself also predisposes individuals to malignancy. For focal 
NEPPK and associated oesophageal cancer susceptibility (TOC locus), genetic studies 
support the latter scenario. 
Additionally, it is evident that other gene mutations (of low penetrance) and 
environmental effects may modify the risk and type of cancer in disease gene carriers 
carrying the same BRCAI or BRCA2 or TOC mutation. This is apparent from the 
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study of Icelanders all of whom have inherited the same founder BRCA2 mutation 
though its penetrance appears extremely variable (Thorlacious et ai, 1996). By 
studying these founder popUlations, it may be possible to identify genes and/or 
environmental factors that modify cancer susceptibility in BRCA 1 or BRCA2 gene 
carners. 
Finally, from the genetic analysis of rare and often only mildly debilitating inheritable 
skin diseases, for example, palmoplantar keratoderma, specific proteins that form the 
complex intra- and inter- cellular interactions of cells can be identified. These proteins 
may also have a role in sporadic cancers. This will aid in the understanding of cell 
adhesion defects that underlie a cell's ability to isolate itself and then accrue the genetic 
alterations required for it to become cancerous. 
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